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ABSTRACT 
Oncogene-induced senescence (OIS) is classically described as a potent anti-
tumourigenic barrier that restrains the proliferation of pre-malignant cells. Senescent 
cells can also promote immune clearance by secreting a plethora of chemokines and 
inflammatory factors, collectively known as the Senescence-Associated Secretory 
Phenotype (SASP). However, the SASP can also promote tumourigenesis 
paracrinally. In this study, OIS and the SASP were studied in mouse models for 
adamantinomatous craniopharyngioma (ACP), which express oncogenic β-catenin in 
pituitary progenitors/stem cells. Surprisingly, oncogenic β-catenin-targeted cells did 
not give rise to the tumour mass in the majority of cases and stopped dividing after a 
short burst of proliferation to form β-catenin-accumulating cell clusters. Here it is 
demonstrated that β-catenin clusters undergo OIS as determined by a lack of 
proliferation markers, activation of the p53/p21 and p16/Rb pathways, induction of 
the DNA damage response (DDR) and activation of the NF-κB pathway. Additionally, 
unbiased mRNA expression analysis shows enrichment of OIS and SASP genes in 
β-catenin clusters, while SASP gene expression is corroborated by qRT-PCR and 
ELISA assays. Of translational significance, these results are recapitulated in the β-
catenin clusters of human ACP. Furthermore, evidence is presented indicating that 
the paracrine signals secreted by the β-catenin clusters are involved in non-cell 
autonomous tumourigenesis through modification of their microenvironment and the 
recruitment of endothelial progenitors displaying aberrant SOX9 expression. A 
genetic strategy demonstrated that induction of OIS and the SASP in the clusters is 
p53-independent, but that p53 is required to prevent a full bias for cell-autonomous 
tumourigenesis. Finally, a mouse line that also develops β-catenin clusters, albeit with 
a dampened SASP is described. These clusters do not appear to modify their 
microenvironment and tumours do not develop. Together, the mouse and human data 
suggest that senescence and SASP are likely to modify the tumour microenvironment 
resulting in cell transformation, tumour growth and survival. 
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ACC  Agenesis of corpus callosum 
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CSC  Cancer stem cell 
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Hesx1  Homeobox expressed in ES cells 1  
HPA  Hypothalamic-pituitary axis 
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IL  Intermediate lobe of the pituitary 
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SDF-1  Stromal cell-derived factor 1 
SHH  Sonic hedgehog 
SIPS  Stress-induced premature senescence 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SOX  Sry-related box 
TP53  Tumour suppressor p53  
TSH  Thyroid-stimulating hormone  
VD  Ventral diencephalon  
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1.1 The pituitary gland 
1.1.1 Function and components of the pituitary gland 
The pituitary gland, or hypophysis, is a crucial component of the mammalian 
endocrine system. It relays signals emitted from the hypothalamus, the brain’s 
homeostatic control centre, by secreting various hormones that regulate functions of 
great importance for the organism such as: growth, metabolism, stress-response, 
sexual maturation and reproduction (Shlomo Melmed 2011). The hypothalamus is 
responsible for processing and balancing the demands of these ever-changing 
biological processes, which lead to the controlled release of hypothalamic factors into 
the hypophyseal portal blood vessel system. These vessels carry the hypothalamic 
factors into the pituitary gland where they regulate the release of the pituitary 
hormones into the systemic circulation. The pituitary hormones can act then either 
systemically or on specific target organs (adrenals, thyroid gland and gonads), which 
provide regulatory feedback directly to the pituitary or indirectly into the hypothalamus 
(Perez-Castro et al. 2012). This complex, yet finely tuned system is called the 
hypothalamic-pituitary axis (HPA) and is of mayor relevance for medical research as 
congenital defects or disease affecting any point of the axis will often result in 
pleiotropic detrimental effects (Denef 2008; Ward et al. 2006).   
 Anatomically, the pituitary gland is comprised by three distinct structures 
(Figure 1.1):  
1) The anterior lobe (AL) or adenohypophysis, which contains most of the 
endocrine cells. The pituitary hormones produced in this structure are: growth 
hormone (GH), prolactin (PRL), adrenocorticotropic hormone (ACTH), thyroid-
stimulating hormone (TSH), follicle-stimulating hormone (FSH) and luteinizing 
hormone (LH) and they are produced by somatotrophs, lactotrophs, corticotrophs, 
thyrotrophs and gonadotrophs, respectively. 
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2) The intermediate lobe (IL), which separates the anterior and posterior 
pituitary lobes. This structure is poorly developed and rudimentary in humans but in 
mice and other vertebrates it contains a subpopulation of melanotrophs, which 
produce melanocyte-stimulating hormone (MSH) (Saland 2001).  
3) The posterior lobe (PL) or neurohypophysis, which contains axons originated 
in the hypothalamus that deliver the neurohormones vasopressin (VPN) and oxytocin 
(OXT) directly into the pituitary circulation (Markakis 2002). The posterior lobe also 
contains glial cells known as pituicytes. 
 
Figure 1.1 Components of the murine pituitary gland.  
(a) Representation of the murine pituitary gland and surrounding structures as seen 
from a sagittal plane (antero-posterior axis). The mature gland lies on top of the 
basisphenoid bone (BB), below the third ventricle (3V) and the ventral diencephalon 
(which comprises the hypothalamus). Axons from the hypothalamus directly innervate 
the posterior lobe (PL). The glandular portion of the pituitary is comprised of the 
intermediate lobe (IL), which is directly in contact with the PL; and the anterior lobe 
(AL), which lies on top the BB. (b) Coronal representation of the pituitary gland 
showing the location of different neuroendocrine populations. The PL contains axons 
derived directly from arginine-vasopressin (AVP) and oxytocin (OXT) producing 
neurons in the hypothalamus. The IL contains a subpopulation of melanotrophs. The 
AL contains most of the endocrine cells, namely: somatotrophs, lactotrophs, 
corticotrophs, thyrotrophs and gonadotrophs. The region of cells lining the lumen of 
the AL and IL is known as the marginal zone (MZ) and is rich in progenitor cells 
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expressing stem cell markers such as SOX2 and SOX9. 3V: third ventricle; VD: 
ventral diencephalon; PL: posterior lobe; IL: intermediate lobe; AL: anterior lobe; BB: 
basisphenoid bone; AVP: arginine-vasopressin; OXT: oxytocin; ACTH: 
adrenocorticotropic hormone; MSH: melanocyte-stimulating hormone; GH: growth 
hormone; PRL: prolactin; TSH: thyroid-stimulating hormone; LH: luteinizing-hormone; 
FSH: follicle-stimulating hormone; MZ: marginal zone.  
 
1.1.2 Development of the pituitary gland and its components 
Morphogenesis of the pituitary gland  
Figure 1.2 describes the process of pituitary organogenesis, which begins in 
mice around 8.5 dpc (days post coitum), as a thickened patch of oral ectoderm, which 
invaginates towards the brain above it, the future ventral diencephalon (VD) 
(Castinetti et al. 2011). By 10.5 dpc, the pituitary primordium displays a distinctive 
lumen and is therefore called Rathke’s Pouch (RP). In the following days, this 
structure migrates passively in close contact with a region of the future ventral 
diencephalon which thickens and forms the PL primordium, known as the 
infundibulum (IF). By 12.5 dpc, RP has separated completely from the oral ectoderm 
and its ends have fused creating a closed pouch with clear separation between its 
dorsal (future IL) and ventral (future AL) regions. The closed lumen is then called the 
pituitary cleft, and in mice is delimited dorsally by the IL and ventrally by the AL 
(Hashimoto et al. 1998). For both the IL and the AL, cells directly facing the pituitary 
lumen are referred to as the marginal zone (MZ) or periluminal region. The MZ 
contains progenitor cells that will divide continuously in the following days of 
development, giving rise to committed precursor cells that migrate (ventrally in the 
case of the AL) and will eventually differentiate between 13.5 and 16.5 dpc into the 
hormone-producing populations (Garcia-Lavandeira et al. 2009; Florio 2011). Finally, 
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by 18.5 dpc, the pituitary gland contains all hormone-producing cell types (Bilodeau 
et al. 2009).  
Morphogenic ligands directing pituitary organogenesis  
Proper patterning and specification of the pituitary has been shown to depend 
on signalling cues provided by neighbouring structures such as the VD, the 
surrounding mesenchyme and the oral ectoderm. These tissues provide crucial 
factors known as morphogens, which exhibit specific spatio-temporal expression 
patterns. These factors can then either act directly on the pituitary lineage, by 
controlling the timely expression of transcription factors responsible for maintaining 
pools of progenitors/stem cells or controlling their commitment and differentiation into 
distinct endocrine populations (Kelberman et al. 2009); or they can act indirectly by 
restricting the expression domains of other morphogenic ligands (Zhu et al. 2007). 
Examples of these morphogens are Sonic Hedgehog (SHH), Bone Morphogenic 
Proteins (BMPs), Fibroblast Growth Factors (FGFs) and Wingless-related Integration 
site proteins (WNTs) (Takuma et al. 1998; Treier et al. 1998; Treier et al. 2001; Potok 
et al. 2008).  
 
 
Figure 1.2 Development and components of the pituitary gland.  
Sagittal representation of the developing pituitary gland at different embryonic stages. 
At 9.0 dpc a portion of oral ectoderm (OE) diverges in fate after establishing close 
contact with the future ventral diencephalon (VD).  At 10.5 dpc, the pituitary anlage, 
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Rathke’s Pouch (RP), has begun evaginating from the OE and migrates towards the 
brain. At the same time, the region of the VD in contact with RP has invaginated in 
order to form the infundibulum (INF). By 12.5 dpc, the future components of the 
mature gland can be discerned. RP has separated from the OE and formed a definite 
pouch displaying a lumen. The dorsal region in contact with the INF will become the 
IL while the ventral region will become the AL. By 18.5 dpc, the mature components 
of the pituitary gland have been established. Image adapted from (Kelberman et al., 
2009). 3V: third ventricle; VD: ventral diencephalon; RP: Rathke’s pouch; OE: oral 
ectoderm; INF: infundibulum; PL: posterior lobe; IL: intermediate lobe; AL: anterior 
lobe; BB: basisphenoid bone. 
 
1.1.3 Pituitary embryonic progenitors and stem cells 
The pituitary gland is responsible for the maintenance of the organism’s 
endocrine homeostasis as it is challenged by ever-changing physiological demands. 
Therefore, the mammalian pituitary has evolved mechanisms for outstanding 
adaptability and plasticity. In the pituitary and other organs, it is now well established 
that the maintenance of homeostatic cell turnover is highly dependent on a particular 
cell population with special characteristics, referred to as stem cells.  
The most accepted definition for stem cells establishes they are un-
differentiated, possess the ability to self-renew (i.e. divide indefinitely) and can give 
rise to the differentiated cell types of their respective organ or tissue (i.e. they are 
multipotent). The latter occurs by asymmetric division, which gives rise to one 
identical stem cell and a progenitor daughter cell with restricted potential (i.e. short or 
absent self-renewal) but capable of differentiating into committed cell lineages 
(Vankelecom 2010; Seaberg & Van Der Kooy 2003). Therefore, their multipotentiality 
and self-renewal characteristics promote replenishment the organ’s functional 
populations according to physiological demands and also allow the maintenance of a 
tissue’s stem cell pool. 
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 Tissue-specific stem cells have been shown to often share the expression of 
defined transcription factors and markers with the embryonic progenitors that gave 
rise to the organ during development (Slack 2008). However, if long-term self-renewal 
has not been demonstrated convincingly, the terms “progenitor” or “progenitor/stem 
cell” are to be used to define such populations (Vankelecom & Gremeaux 2010). 
HESX1+ embryonic progenitors of the pituitary gland 
A number of transcription factors have been demonstrated to define the identity 
of pituitary embryonic progenitor/stem cells (Florio 2011; Vankelecom 2010; Rizzoti 
2015). Such is the case of the homeo-box transcription factor Hesx1 (homeobox 
expressed in ES cells 1), a gene mostly known for its role in proper forebrain 
patterning (Andoniadou et al. 2011). However, HESX1 has been shown to be crucial 
for proper pituitary development in both mice and humans, where mutations in this 
gene leads to syndromes characterised by hypopituitarism (Dattani et al. 1998; 
Kelberman et al. 2006; Jayakody et al. 2012; Sajedi et al. 2013; Gaston-Massuet et 
al. 2011). Although initially expressed in the anterior-visceral endoderm (AVE) at 6.5 
dpc, Hesx1 is later detected in the anterior neural ectoderm (prospective forebrain) 
from 7-8.5 dpc, while from 8.5 dpc it is also expressed in the oral ectoderm. 
Importantly, Hesx1 is expressed in RP progenitor cells from 8.5 to 13.5 dpc (Thomas 
et al. 1996; Hermesz et al. 1996). Furthermore, lineage-tracing experiments 
demonstrated that most cells in the mature pituitary gland (by 18.5 dpc) were derived 
from the Hesx1 lineage (Gaston-Massuet et al. 2011; Jayakody et al. 2012). 
Therefore, Hesx1 is expressed in embryonic pituitary progenitors, which give rise to 
all pituitary cells.  
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SOX2 and SOX9 in pituitary embryonic progenitors and adult stem cells 
Other transcription factors of crucial importance for pituitary development are 
the members of the SOX-family of proteins (SRY-region), specifically members of the 
SOXB1 group: SOX1, SOX2 and SOX3. SOXB1 factors are known for their 
importance for the early embryonic development and pluripotency in embryonic stem 
cells (ESC). Importantly, SOXB1 proteins play important roles during organogenesis 
by maintaining an undifferentiated phenotype, multipotency and proliferation in 
progenitor/stem cells in various organs, particularly in the central nervous system 
(CNS) (K. Liu et al. 2013; Zhang & Cui 2014).  
SOX2 is the only SOXB1 member expressed early in pituitary development, 
and its expression can be observed from 9.5 dpc in pituitary embryonic progenitors 
(Rizzoti 2015). However, SOX2 is downregulated in differentiating cells that commit 
to different endocrine lineages. As lineage commitment proceeds, SOX2 expression 
becomes restricted until the majority of SOX2+ cells become restricted to the 
periluminal region (or MZ), an expression pattern that is conserved postnatal life. 
Importantly, absence of SOX2 in Hesx1+ embryonic progenitors leads to aberrant 
pituitary development due to depletion of the pool of progenitor cells (Jayakody et al. 
2012).  
There is a considerable amount of evidence showing that the adult pituitary 
gland contains cells that fulfil the definition of stem cells. Although these populations 
have been isolated and identified by different methods, they share characteristics like 
the capacity to grow in culture and be passaged multiple times, as well as the ability 
to differentiate into all or several hormone-producing cell populations (Florio 2011; 
Vankelecom 2010). Moreover, these pituitary stem cells also share the expression of 
certain markers, such as SOX2 (Gleiberman et al. 2008; Fauquier et al. 2008; Garcia-
Lavandeira et al. 2009; Chen et al. 2009). This SOX2+ population was shown to 
expand and replenish the organ’s cells after pituitary injury (Fu et al. 2012) or in 
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response to physiological demand (Rizzoti et al. 2013). Additionally, in vivo long-term 
lineage tracing revealed that SOX2+ cells are able to self-renew and differentiate into 
all hormone-expressing cell populations in the adult pituitary gland (Andoniadou et al. 
2013).  
Another SOX transcription factor of importance for pituitary development is 
SOX9, a member of the SOXE group. SOX9 is a transcription factor known to regulate 
cell fate and differentiation in several organs during embryogenesis, such as the male 
gonads, the skeleton, cardiac-valves and intestine (Sun et al. 2013; Huang et al. 
1999; Ikeda et al. 2004; Hattori et al. 2010; Akiyama et al. 2004; Moniot et al. 2004). 
SOX9 has been shown to play context-dependent roles within progenitor/stem cell 
populations (Joa et al. 2012). In the hair-follicle, SOX9 was demonstrated to be 
indispensable for the formation and maintenance of the follicle’s stem cell niche 
(Adam et al. 2015); and a similar role for SOX9 was found in the maintenance of 
pancreatic progenitor cells (Seymour et al. 2007). Conversely, in the developing CNS 
it has been shown that SOX9 regulates neural progenitor cell fate and guides 
differentiation towards gliogenesis (Stolt et al. 2003; Kang et al. 2012). Additionally, 
upregulation of SOX9 expression in neural crest (NC) cells after delamination has 
been revealed to be necessary for their epithelial-mesenchymal transition (EMT) and 
subsequent migration (Cheung & Briscoe 2003; Theveneau & Mayor 2012).  
In the developing pituitary gland, SOX9 is coexpressed with SOX2 from 14.5 
dpc. Its expression is thought to coincide with switch from embryonic progenitor cell 
proliferation towards a more quiescent state (Castinetti et al. 2011). Postnatally, 
SOX2 expression mostly colocalises with SOX9, including in MZ cells. Additionally, 
long-term lineage tracing of adult SOX9 cells showed they also differentiate into 
hormone producing cells throughout life (Rizzoti et al. 2013). Finally, SOX2+/SOX9+ 
cells have been shown to possess in vitro clonogenic potential and the capacity to 
differentiate into all hormone-producing cell types both in vivo and in vitro (Fauquier 
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et al. 2008; Rizzoti et al. 2013; Andoniadou et al. 2013), further suggesting that the 
SOX2+/SOX9+ population represents bona fide adult pituitary stem cells.  
1.1.4 Pituitary disease and tumours  
Proper pituitary development depends on correct patterning, cell lineage 
commitment and maintenance of pituitary progenitor/stem cells, all which are 
determined by interactions between developmental transcription factors (e.g. HESX1, 
LHX3/4, PITX1/2, PROP1) and signalling pathways (e.g. SHH, WNT, BMP and FGF). 
Mutations or dysregulation in these genes and/or pathways have been shown to be 
the cause of pituitary-related conditions of great relevance for paediatric clinical 
research (described in Table 1), such as: congenital hypopituitarism, septo-optic 
dysplasia and pituitary tumours (Davis et al. 2009). This knowledge derives in part 
from expression and sequencing studies in human biopsies or functional experiments 
in human pituitary cell lines. However, a detailed understanding of the role that these 
genes and pathways play in vivo during pituitary development and the underlying 
biological mechanisms, could not have been achieved without the use of animal 
models, particularly genetically engineered mice (Kelberman et al. 2009; Zhu et al. 
2007).  
The field of pituitary oncology has particularly benefited from the use of 
genetically modified mouse models. A considerable number of strains has been 
demonstrated to be useful for the study of pituitary tumours, mostly pituitary 
adenomas, and this has led to the identification of genes and pathways involved in 
pituitary adenoma pathogenesis (Cano et al. 2014; Lines et al. 2016), as well as the 
identification of cancer stem cells (CSCs) in pituitary tumours (Martinez-Barbera & 
Andoniadou 2016). Table 2 summarises both the syndromic effects of pituitary 
hormone dysfunction as well as the types of pituitary adenomas arising from each cell 
type.   
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Table 1. Genes involved in pituitary developmental syndromes in mice and 
humans 
Adapted from Kelbermann 2009. 
Gene Protein Murine loss LOF 
phenotype
Human phenotype Inheritance 
murine/human
HESX1 HESX1 Anopthalmia or 
microopthalmia, Agenesis  
of corpus callosum (ACC), 
abscence of septum 
pellucidum, pituitary 
dysgenesis or aplasia
Variable. Septo-Optic 
dysplasia , Combined 
Pituitary Hormone 
Deficiency (CPHD), 
Isoleted Growth Hormone 
Deficiency (IGHD) with 
Ectopic Posterior Pituitary 
(EPP)
Dominant or recessive 
un humans, recessive 
in mouse
OTX2 OTX2 Forebrain or midbrain 
abscence, malformation of 
optic placode
Anopthalmia, Anterior 
Pituitary Hypoplasia (APH), 
EPP, Absent Infundibulum
Heterozygous: 
haploinsifficiency/domi
nant negative
SOX2 SOX2 Homozygous null: emyronic 
lethal
Heterozygous or 
hemizygous: poor growth, 
reduced fertility, CNS 
abnormalities, anopthalmia, 
pituitary hypoplasia with all 
cell types affected
Hypogonadotrophic 
Hypogonadism, APH, 
Abnormal hippocampus, 
bilateral 
anophtlamia/micropthalmia, 
abnormal corpus callosum, 
learning difficulties, 
esophageal atresia, hearing 
loss, hypothalamic 
hamartoma
De novo 
haploinssuficiency in 
humans, heterozygous 
mutation associated 
with haploinssuficiency 
in mouse
SOX3 SOX3 Poor growth, craniofacial 
abnormalities, hypothalamic 
and infundibular 
abnormalities
IGHD and mental 
retardation, hypopituitarism, 
aph, Infundibular 
hypoplasia, EPP, midline 
abnormalities
X-linked recessive in 
both mice and humans
GLI2 GLI2 Pituitary hypoplasia Holoprosencephaly, 
hypopituitarism, craniofacial 
abnormalities, polydactily, 
partial ACC
Haploinssuficiency
LHX3 LHX3 Hypoplasia of Rathke´s 
Pouch
Pituitary hypoplasia with 
GH, TSH and gonadotropin 
deficiency. Variable ACTH 
inssuficiency. Hearing loss. 
Short, rigid cervical spine.
Recessive in both
LHX4 LHX4 Mild hypoplasia of anterior 
pituitary lobe
GH, TSH and cortisol 
deficiency, Persistent 
cranioharyngeal canal and 
abnormal cerebellar tonsils, 
APH, ectopic posterior 
pituitary, absent 
infundibulum
Recessive in mouse, 
dominant in human
PROP1 PROP1 Hypoplasia of anterior 
pituitary lobe. Affected cell 
types: GH, PRL, TSH, 
ACTH, LH and FSH
GH, TSH, PRL, and 
gonadotropin deficiency. 
Evolving ACTH deficiency. 
Enlarged pituitary with later 
involution
Recessive in both
POU1F1 PIT1 Hypoplasia of anterior 
pituitary lobe. Affected cell 
types: GH, PRL, and TSH
Variable posterior pituitary 
hypoplasia with GH, TSH 
and PRL deficiency
Recessive in mouse, 
dominant/recessive in 
humans
Table 1. Genes involved in pituitary developmental syndromes in mice and humans 
Adapted from Kelbermann 2009.
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Table 2. Pituitary cell types, their biological functions and pathological 
phenotypes. 
Adapted from Watkins-Chow and Camper, 1999 and Melmed 2011. 
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1.2 Adamantinomatous craniopharyngioma (ACP) and 
mouse models of ACP 
1.2.1 Pathophysiology of human ACP 
In addition to pituitary adenomas, there are other two classes of pituitary 
tumours: Rathke´s cleft cysts and craniopharyngiomas, while the latter can be further 
divided into papillary and adamantinomatous subtypes. Similar to pituitary adenomas, 
Adamantinomatous Craniopharyngiomas (ACPs) are non-malignant epithelial 
tumours, but do not express any pituitary hormones or differentiation markers such 
as PIT1 and synaptophysin. Despite their low incidence (1.6 cases/million per year 
for all ages and 2.14 for children), ACPs are the most common non-neuroepithelial 
intracranial neoplasm in children and represent up to 11.5% of all paediatric CNS 
tumours (Bunin et al. 1998; Müller 2014). The mean age at diagnosis displays a 
bimodal distribution, being around 10 years of age for childhood-onset ACP and 74 
years for adult-onset ACP (Nielsen et al. 2011). The paediatric and adult 
manifestations of the disease are not yet considered to differ in terms of treatment of 
choice, post-treatment survival rates, post-surgical effect on quality of life or 
recurrence (Nielsen et al. 2011; Dekkers et al. 2006; Zoicas & Schöfl 2012). Despite 
high survival rates (up to 95% in 5 years), ACPs are considered to be aggressive 
tumours with high morbidity potential due to the invasion of surrounding brain 
structures such as the optic tract and hypothalamus (Müller 2013). Additionally, 
detrimental post-operative effects are frequent and can lead to clinical complications 
such as onset of hypothalamic obesity (Müller et al. 2004). Therefore, ACP represents 
a chronic and clinically-challenging disease for which no targeted molecular therapies 
are currently available (Lughetti & Bruzzi 2011; Müller 2013). 
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1.2.2 Aetiology and histopathology of human ACP 
The aetiology of craniopharyngiomas is an ongoing research subject and the 
cell-of-origin giving rise to human ACP is currently not known. A longstanding 
hypothesis is that ACPs are tumours derived from embryonic remnants of Rathke’s 
pouch, a proposition derived from the common expression of certain cytokeratins 
between the oral epithelium and ACP specimens (Kato et al. 2004; Buslei et al. 2007; 
Tateyama et al. 2001). The pathogenesis of childhood-onset ACP results particularly 
interesting as they represent 50% of all ACP cases and scrutiny of clinical data 
revealed that paediatric ACP patients suffer significantly from height deficit around 12 
months of age, well before ACP diagnosis (Müller et al. 2004; Qi et al. 2013). 
Therefore, childhood-onset ACP is potentially a developmental tumour originating 
from Rathke’s pouch. Further supporting this notion, the occurrence of foetal 
craniopharyngiomas has been reported in several occasions (Jurkiewicz et al. 2010; 
Joo et al. 2009; Scagliotti et al. 2015; Kostadinov et al. 2014) and a review of 154 
cases of foetal CNS tumours found that 11% were diagnosed as craniopharyngiomas 
(Isaacs 2009).  
 ACPs have very distinctive histological features, which differentiate them from 
other pituitary neoplasms, including the papillary craniopharyngiomas subtype (PCP). 
ACPs are composed of squamous, epithelial non-differentiated cells that display a 
variety of histomorphological features: 1) an outer “palisaded epithelium” formed by 
tightly-packed columnar cells; 2) loosely connected cells in areas with microcystic 
changes, known as “stellate reticulum”; 3) areas formed by anucleated cell remnants 
(or “ghost cells”) displaying eosinophilic keratinous bodies and occasional 
calcifications, collectively known as “wet keratin” (Figure 1.3).  
The most notable histological feature of human ACP is the presence of nucleo-
cytoplasmic β-catenin accumulating cells which form dense nodular structures  known 
as “clusters” (Sekine et al. 2002; Kato et al. 2004; Gaston-Massuet et al. 2011) 
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(Figure 1.4a). This feature is a hallmark of the disease, as it is not present in PCPs 
nor in any other type of pituitary tumour and has been observed even in ACPs 
diagnosed in utero (Kostadinov et al. 2014; Scagliotti et al. 2015). Therefore, definitive 
diagnosis of ACP requires the immunohistochemical observation of nucleo-
cytoplasmic accumulation of β-catenin, commonly found as tightly packed “clusters”. 
It must be noted that these cell clusters comprise a very small proportion of the total 
tumour mass. Importantly, it is now widely accepted that activating mutations in the 
β-catenin gene (CTNNB1) are present in the vast majority of human ACP cases (up 
to 100% in some cohorts) (Sekine et al. 2002; Kato et al. 2004; Buslei et al. 2005; 
Brastianos et al. 2014; Oikonomou et al. 2005). These are somatic mutations located 
in exon 3, resulting in proteosomal degradation resistance that leads to β-catenin 
accumulation and consequent WNT pathway activation. 
 
Figure 1.3 Histopathological features of human adamantinomatous 
craniopharyngioma (ACP).  
Haematoxylin & eosin staining in a human ACP section showing distinctive features 
such as palisaded epithelium (PE) which separates the tumour tissue from the 
reactive glial tissue (GT) or cystic components. Within the tumour, other features are 
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observed such as a loosely connected stellate reticulum (SR) and anucleated ghost 
cells also referred to as wet keratin (WK). The presence of “whorls” or cell clusters 
(arrows) often close to the invasive front is also a hallmark characteristic of human 
ACP. 
 
1.2.3 Malignant transformation of human ACP 
The malignant transformation of ACP is extremely rare with only 23 cases 
reported in the literature (Rodriguez et al. 2007; Sofela et al. 2014; Negoto et al. 
2015). While the acquisition of the malignant phenotype is based on histopathologic 
observations, there is a clear difference in the behaviour of these tumours, as median 
survival after transformation is around 6 months. Non-malignant ACPs are defined as 
slow growing tumours with a low content of proliferation markers such as Ki67 
(Martinez-Barbera 2015; Buslei et al. 2007). Conversely, malignant ACPs display a 
drastic increase in Ki67 expression (50 to 70% of total cells) (Rodriguez et al. 2007; 
Sofela et al. 2014), while nucleo-cytoplasmic β-catenin immunoreactivity is observed 
throughout these tumours instead of being restricted to nodular cell clusters 
(Rodriguez et al. 2007). Interestingly, malignant ACPs also display increased 
expression of p53 protein, suggesting the presence of p53 mutations in these tumours 
(Kristopaitis et al. 2000; Rodriguez et al. 2007; Negoto et al. 2015). On the other side, 
non-malignant ACPs have been reported to contain a low proportion of p53+ cells 
while no mutations in the p53 gene (TP53) were found in some cohorts (Nozaki et al. 
1998; Brastianos et al. 2014). Because it has been suggested that radiotherapy is a 
factor promoting the malignant transformation of ACP (Kristopaitis et al. 2000; Gao 
et al. 2011; Aquilina et al. 2010; Negoto et al. 2015), a better understanding of the 
molecular pathogenesis of ACP will prove crucial in the improvement of current 
treatment and development of safer therapeutic approaches.  
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1.2.5 Mouse models for ACP 
An embryonic mouse model for ACP: Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice 
Previously, it was reported that deletion of the exon 3 in the β-catenin gene 
(Ctnnb1 in mice) produces a degradation-resistant form of β-catenin (also referred to 
as oncogenic β-catenin), which is able to accumulate and overactivate the WNT 
pathway (Harada et al. 1999). This genetic alteration is therefore functionally 
equivalent to the mutations found in human ACP. Importantly, conditional expression 
of this degradation-resistant form of β-catenin in pituitary embryonic progenitors 
(Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice) lead to WNT pathway overactivation and the 
formation of pituitary tumours (Gaston-Massuet et al. 2011). Conversely, expression 
of oncogenic β-catenin in committed pituitary progenitors or terminally differentiated 
hormone-producing populations did not lead to tumour formation, supporting a role 
for pituitary embryonic progenitors in WNT-driven pituitary tumourigenesis. 
 Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours partially resemble human ACP in their 
histology, as they possessed microcystic changes (stellate reticulum) and nodular, 
“whorl-like” cell formations. The murine tumour histology differs from their human 
counterparts in some features as they lack an overall epithelial morphology, the 
presence of a palisaded epithelium, wet keratin or calcifications. However, molecular 
characterisation of these tumours concluded that they most closely resemble human 
ACP, as judged the lack of pituitary hormone expression, presence of β-catenin 
accumulating clusters and absence of synaptophysin+ cells, a diagnostic marker of 
neuroepithelial tumours and pituitary adenomas (Gaston-Massuet et al. 2011).  
However, the most interesting finding from this study was that 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries contain the hallmark feature of ACP: the presence 
of nucleo-cytoplasmic β-catenin accumulating clusters (Figure 1.4b). These clusters 
can be observed in RP as early as 9.5 dpc, are present throughout pituitary 
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development and remain postnatally, before tumour formation. Another interesting 
finding from this study is that the β-catenin clusters from both Hesx1Cre/+;Ctnnb1lox(ex3)/+  
pituitaries and human ACP are in a non-proliferative state as indicated by the absence 
of the proliferation marker Ki67. Additionally, murine clusters show absence of bromo-
deoxy-uridine (BrdU) uptake and express cell cycle inhibiting proteins such as p27Kip1 
and p57Kip2 at 18.5 dpc (Gaston-Massuet et al. 2011). This observation, together with 
the expression of the pituitary stem cell marker SOX2, initially led to the conclusion 
that the murine β-catenin clusters display a progenitor/stem cell phenotype 
characterised by a slow-dividing, quiescent state. Similar conclusions were derived 
from studies in which accumulation of the cell cycle inhibitor p21Cip1 was observed in 
human ACP β-catenin clusters (Buslei et al. 2007; Stache, Hölsken, Fahlbusch, et al. 
2014), while Ki67+ cells were only observed in proximity to the clusters (Gaston-
Massuet et al. 2011; Stache, Hölsken, Schlaffer, et al. 2014). Again, differences 
between mouse and humans exist as murine ACP clusters express SOX2, while their 
human counterparts do not. 
Subsequently, microarray expression analysis comparing β-catenin-
accumulating cells and non-cluster tissue was conducted after flow-sorting of 
dissociated Hesx1Cre/+;Ctnnb1lox(ex3)/+;BAT-gal pituitaries (Andoniadou et al. 2012). In 
this model, activation of the WNT signalling pathway in cluster cells leads to 
expression of bacterial β-galactosidase, which can then be detected by the addition 
of X-gal. Interestingly, the β-catenin cluster fraction showed a significant upregulation 
of members of several signalling pathways with important roles in carcinogenesis 
such as WNT, SHH, BMP, FGF and TGFβ (Labeur et al. 2010; Wesche et al. 2011; 
Yauch et al. 2008). These observations were corroborated by in situ hybridisation 
(ISH) and recapitulated in human ACP samples, suggesting the clusters act as a 
source of secreted pro-oncogenic factors that feed tumour growth in a paracrine 
manner. Additionally, this study also reported upregulation of the chemokine receptor 
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CXCR4 and several chemokines of the CXC- family in the β-catenin clusters (section 
1.4). 
An inducible model for ACP: Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice 
The finding that oncogenic β-catenin leads to cluster formation and consequent 
induction of pituitary tumours only when expressed in embryonic pituitary progenitors 
(e.g.not in committed cell types), suggested that cell “stemness” may be involved in 
the development of WNT-driven pituitary tumours. Tamoxifen-inducible expression of 
oncogenic β-catenin in SOX2+ stem cells (Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice) 
at embryonic and adult stages led to the formation of nucleo-cytoplasmic β-catenin 
clusters (Figure 1.4c) and the induction of pituitary tumours (Andoniadou et al. 2013). 
These tumours also resembled human ACP by the lack of pituitary hormone and 
synaptophysin expression, while the resulting β-catenin clusters were also negative 
for proliferation markers and overexpressed pro-oncogenic factors belonging to the 
SHH, WNT, BMP and FGF pathways. Importantly, this study also defined that the cell 
giving rise to β-catenin clusters in mice is a SOX2+/S100B+ stem cell. 
Intriguingly, lineage tracing analysis revealed that the tumours were not derived 
from oncogenic β-catenin-targeted cells (labelled by YFP expression). While all 
tumours were negative for the reporter protein (YFP-), β-catenin accumulating 
clusters that were YFP+ could be observed in their vicinity. This unexpected result 
was corroborated by PCR analysis of laser-capture microdissected (LCM) tumour 
tissue, which revealed the absence of recombination in either the reporter (ROSA26) 
or the Ctnnb1 loci, demonstrating that Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice 
develop tumours that are not derived from the originally mutated cells. Therefore, 
these tumours develop non-cell autonomously, possibly due to the paracrine activities 
of the β-catenin clusters. The identity of the cell-of-origin giving rise to tumours in both 
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the Hesx1Cre/+;Ctnnb1lox(ex3)/+  and Sox2CreERT2/+;Ctnnb1lox(ex3)/+ models is currently not 
known. 
 
 
Figure 1.4 Nucleo-cytoplasmic accumulating β-catenin clusters are found in 
human adamantinomatous craniopharyngioma (ACP) and murine models for 
ACP. 
(a) Immunofluorescence in human ACP showing the nucleo-cytoplasmic 
accumulation of β-catenin in cell groups known as “clusters” (arrows), a defining 
characteristic of these tumours. (b) Expression of oncogenic β-catenin in embryonic 
pituitary progenitors also leads to the formation of clusters in Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries. An 18.5 dpc specimen is shown. (c) Inducible expression of oncogenic β-
catenin in adult pituitary stem cells also leads to cluster formation in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ pituitaries. 16-week post-tamoxifen induction shown. 
Scale bars: 100 μm. 
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1.2.6 Mouse ACP carcinogenesis does not follow the cancer 
stem cell model  
The cancer stem cell (CSC) model 
The cancer stem cell (CSC) model establishes that tumours/cancers contain a 
small group of cells capable of self-renewal and give rise to most of the tumour cells. 
CSCs recapitulate most characteristics of normal stem cells: they are multipotential 
and also possess self-renewal capacity (Clarke & Fuller 2006; Nguyen et al. 2012; 
Beck & Blanpain 2013). Therefore, CSCs divide asymmetrically and give rise to the 
tumour bulk-mass (Fig 1.5a). These characteristics together with their resistance to 
chemotherapeutics make CSCs ideal targets in cancer therapy and great effort has 
been directed to understand their biology, in order to improve their identification and 
therapeutic targeting. Importantly, a CSC should not be confused with the cell that 
receives the first oncogenic hit(s), as it may not be directly related to the CSC 
population giving rise to the tumour mass at a certain point (Visvader et al. 2012; 
Kreso & Dick 2014).  
Lineage tracing studies in mice have been crucial in demonstrating that normal 
tissue-specific SCs are able to give rise to tumours cell-autonomously when targeted 
with oncogenic mutations and/or inactivation of tumour-suppressor genes (Schepers 
et al. 2012; Nakanishi et al. 2013; Zomer et al. 2013). However, this is not always the 
case and it has been shown that CSCs can arise from committed progenitor cells or 
differentiated cell types (Clevers 2011; Valent et al. 2012). Still, the cell-autonomous 
tumour formation from a single originally mutated cell is the predominating 
mechanism described in the literature and forms the basis for most models of 
carcinogenesis to date. Importantly, the universal application of this model has 
recently been challenged by studies showing that cancer cells can arise non-cell 
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autonomously (i.e. from a cell not carrying the original hit) (Lujambio et al. 2013; Kode 
et al. 2014; Andoniadou et al. 2013). 
A model for the non-cell autonomous origin of mouse ACP tumours 
The demonstration of a non-cell autonomous origin for pituitary tumours in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice is in direct contrast with the established CSC 
paradigm and suggests that a very different mechanism of tumourigenesis is involved 
in murine models for ACP. 
 The model for paracrine tumourigenesis proposed by Andoniadou et al. 
suggests that SOX2+ cells targeted with oncogenic β-catenin undergo a short burst 
of proliferation and form nucleo-cytoplasmic β-catenin clusters. The plethora of pro-
oncogenic factors secreted by the clusters eventually cause the paracrine 
transformation of a neighbouring cell, which then propagates and generates a tumour 
in cell-autonomous fashion (Figure 1.5b).     
It has been shown that excessive production of growth factors, such as those 
produced by the β-catenin clusters, can lead to paracrine cell transformation (Oshima 
et al. 2014; Martin et al. 2014; Rogelj et al. 1988). These inductive signals can 
promote the overactivation of oncogenic pathways that induce hyperproliferation and 
DNA replicative stress, leading to DNA damage and the acquisition of novel mutations 
which could confer tumourigenic capacity (Zheng et al. 2015; Aaronson 1991; Löbrich 
& Jeggo 2007; Gaillard et al. 2015). Furthermore, the occurrence of non-cell 
autonomous tumourigenesis in different contexts is increasingly being supported 
(Deschene et al. 2014; Nicolas et al. 2003; Arwert et al. 2010; Fomchenko et al. 2011; 
Lujambio et al. 2013; Kode et al. 2014) (all studies further discussed in the discussion 
chapter). Therefore, there is considerable evidence supporting the validity of the 
paracrine model of tumourigenesis proposed by Andoniadou et al. However, the 
extent of tumour/cancer types that apply to this model remains to be addressed.  
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Figure 1.5 Comparison of different models of tumourigenesis. 
 (a) The cancer stem cell (CSC) model establishes that an original cell, being either 
a progenitor, committed or differentiated cell type, is initially transformed by an 
oncogenic stimulus. This cell’s lineage can be traced using a genetic reporter strategy 
(fluorescent YFP labelling in this example, depicted in green). All the descendants 
from the original cell carry the oncogenic mutation and express YFP. At some point a 
YFP+ descendant cell acquires a CSC phenotype (green/red cell) which allows it to 
self-renew and divide asymmetrically giving rise to differentiated tumour cells 
(green/purple cell), which form the bulk mass of a YFP+ tumour. (b) The paracrine 
model of tumourigenesis proposed by Adoniadou et al. states that expression of 
oncogenic β-catenin in SOX2+ adult pituitary stem cells leads to non-cell autonomous 
tumour formation. After a burst of proliferation, targeted cells (also labelled by YFP) 
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form nucleo-cytoplasmic accumulating β-catenin clusters. These clusters do not 
proliferate nor form tumours, therefore they must enter a senescent arrest and 
acquire a Senescence-Associated Secretory Phenotype (SASP) composed of 
several pro-oncogenic secretory factors. The SASP acts on non-targeted cells (YFP-
) and induces the paracrine transformation of the cell-of-origin, which will give rise to 
a YFP- tumour. Further maintenance or progression of YFP- tumours might also be 
aided by continuous SASP signalling from the β-catenin clusters. 
 
Therefore, findings derived from both mouse ACP models indicate that 
overactivation of the WNT pathway in a subset of β-catenin clusters underlies ACP 
pathogenesis. Intriguingly, these clusters do not proliferate nor form tumours, yet they 
persist during the early stages of tumourigenesis, suggesting their survival and 
paracrine actions are of importance for tumour formation/progression. The following 
sections will introduce three features of the β-catenin clusters’ biology of relevance 
for this thesis: 1) Overactivation of WNT/β-catenin pathway as the initiating oncogenic 
step; 2) CXCR4/SDF-1 signalling as a candidate pathway promoting β-catenin cluster 
survival and mediating their interaction with the microenvironment; 3) Cellular 
senescence and the SASP as biological mechanisms underlying the non-cell 
autonomous origin of pituitary tumours.  
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1.3 The β-catenin/WNT signalling pathway  
1.3.1 Overview of β-catenin/WNT signalling  
WNTs are a group of secreted glycoproteins with crucial roles in embryonic 
development, stem cell biology, disease and cancer. Since the discovery of the first 
WNT member, WNT1, 19 different WNT genes have been discovered in humans, 
with both overlapping and distinct functions depending on the biological context 
(Mikels & Nusse 2006). WNT genes have been mainly studied for their essential roles 
in embryonic development, where they act as morphogens (i.e. signalling molecules 
that act on cell fate determination according to concentration gradients) (Hüsken & 
Carl 2012); and for their function in regulating stem cells and their niches (Clevers et 
al. 2014). Moreover, aberrant cell-to cell WNT signalling occurs in disease and 
cancer. Because WNTs and their overall mechanisms and biological roles have been 
highly conserved throughout evolution (Klaus & Birchmeier 2008), their study in 
animal models has proven to be of great value for the understanding and treatment 
of disease in humans.  
WNT signalling can occur through both β-catenin-dependent and independent 
mechanisms. However, this introduction will focus on signalling mediated by β-
catenin, also known as the canonical WNT pathway. 
In the absence of WTN ligands, β-catenin is continuously targeted for 
proteasomal degradation, which prevents its accumulation and translocation to the 
nucleus. This regulation is achieved by the β-catenin destruction complex, which is 
composed by a variety of proteins including: glycogen synthase kinase 3 (GSK3β), 
casein kinase 1 (CK1), adenomatous polyposis coli (APC) and Axin proteins (a 
constitutively active Axin1 and an induced Axin2 as regulatory feedback). Axins and 
APC act as scaffold proteins that promote N-terminal phosphorylation of β-catenin by 
GSK3β and CK1. This phosphorylation allows polyubiquitination of β-catenin by the 
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E3-ubiquitin ligase βTRCP, which allows proteasomal recognition and degradation. 
Binding of WNT ligands to a Frizzled receptor (Fzd) and coreceptors Lrp5/6, induces 
translocation of Dishevelled (Dvl) protein to the plasma membrane. The interaction of 
Dvl with Fzd and Lpr5/6 then induces sequestration and inactivation of the destruction 
complex, preventing further degradation of β-catenin protein. When stabilised, β-
catenin can translocate to the cell nucleus and displace TLE repressing factors, which 
normally inhibit TCF/LEF-mediated transcription. β-catenin further promotes 
transcription by recruiting coactivators such as BCL9 and CBP/p300. The resulting β-
catenin-TCF transcription complex ultimately activates genes involved in cell survival, 
proliferation and differentiation. Importantly, some target genes, such as Axin2, 
function as a negative-regulatory feedback to the pathway in order to prevent its 
overactivation (Stamos & Weis 2013).  
1.3.2 β-catenin/WNT signalling in cancer  
WNT proteins were discovered as a result of a screening for genes activated 
by viruses that induce mammary tumours in mice (Nusse & Varmus 1982). One such 
proto-oncogene was named Int1 (Integration 1) and it was later found that the 
Wingless (Wg) gene in Drosophila melanogaster was its homolog. This realization led 
to the amalgamation of Wg and Int1 into Wnt (Klaus & Birchmeier 2008). It took almost 
a decade in order to establish a link between human cancer and WNT signalling when 
it was reported that the tumour suppressor APC directly interacted with β-catenin 
(Rubinfeld et al. 1993; Su et al. 1993).  
Mutations in the APC gene had already been associated with familial 
adenomatous polyposis, which involves the formation of thousands of polyps in the 
colon and their eventual progression to malignant carcinomas (Bodmer et al. 1987; 
Leppert et al. 1987). Analysis of APC mutations revealed they were present in up to 
85% of sporadic colorectal cancers (Kinzler & Vogelstein 1996), and it was reported 
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that nuclear accumulation of β-catenin was a defining histological feature of this 
cancers (Inomata et al. 1996). More recently, whole exome sequencing studies have 
determined that APC loss-of-function mutations represent driver mutations in 
colorectal cancers (Wood et al. 2007; The Cancer Genome Atlas Network 2012). 
Further evidence of their causative nature in human colorectal cancer can be derived 
from the fact that these tumours display the same frequency of APC mutations 
independently of their progression stage (early vs. late), and that they have been 
found even in the earliest lesions (microscopic adenomas) (Fearon 2011).    
 Both loss-of-function mutations in APC and stabilizing gain-of-function 
mutations in β-catenin (encoded by the CTNNB1 gene) are known to directly affect 
the ability of the APC protein to bind β-catenin and facilitate its proteasomal 
degradation (Korinek et al. 1997; Morin et al. 1997; Rubinfeld et al. 1997). Importantly, 
mice carrying a truncated form of APC (known as Min for Multiple Intestinal 
Neoplasia) were found to also develop intestinal polyposis (Su et al. 1992). Later, a 
conditional gain-of-function mutation of β-catenin (exon 3) was shown to lead to 
intestinal tumourigenesis (Harada et al. 1999). Together, these findings paved the 
way for further research using genetically engineered mice as models for studying 
the relationship between aberrant WNT signalling and carcinogenesis. In general, it 
is now understood that mutations in ACP, β-catenin or other components of the 
canonical WNT-pathway promote nucleocytoplasmic accumulation of β-catenin 
which then leads to hyper-activation of target genes involved in cancer cell survival 
and proliferation (Polaskis 2012).  
Despite the existence of a wealth of evidence demonstrating the role of aberrant 
β-catenin/WNT signalling in the development of colorectal cancer, its role in other 
types of cancer is less clear. Gain-of-function mutations in CTNNB1 have been 
reported in a wide number of cancers (Polaskis 2012) and increased levels of nuclear 
β-catenin are known to often correlate with poor prognosis (Anastas & Moon 2013). 
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However, the biological relation between CTNNB1 gain-of-function mutations and 
carcinogenesis has only been addressed in a number of paediatric cancers including: 
adamantinomatous craniopharyngioma (ACP), WNT-driven medulloblastoma, 
hepatoblastoma and Wilms’ tumours (Gaston-Massuet et al. 2011; Brastianos et al. 
2014; Polakis 2007; Austinat et al. 2008; Koesters et al. 1999; Huff 2011). Therefore, 
the discovery of novel mechanisms of WNT-directed carcinogenesis can provide 
fresh insight into the pathogenesis of other types of cancer.    
 
1.4 The CXCR4/SDF-1 signalling pathway  
1.4.1 Overview of CXCR4/SDF-1 signalling  
Chemokines are a family of low-molecular weight secreted proteins whose main 
function is to direct cell migration (chemotaxis). Chemokines normally act by binding 
to G-protein Coupled Receptors (GPCRs) present in the cell’s membrane, which then 
activate signal transduction cascades through secondary messengers such as G 
proteins (Holland et al. 2006). Depending on the distance between their first two 
cysteine residues, chemokines are grouped as: C-, CC-, CXC- and CX3C- type 
chemokines, of which CC- and CXC- families contain the vast majority of known 
chemokines. Accordingly, chemokine receptors are named after the family of 
chemokines they bind to (Nomiyama et al. 2013). The most ancient of the CXC- 
chemokines is SDF-1 (Stromal-Derived Factor 1, also known as CXCL12), being 
highly conserved in sequence and function throughout evolution and prompting the 
suggestion that it might represent the original chemokine. Its receptor CXCR4 also 
appeared earlier in evolution than other chemokine receptors and displays the highest 
level of conservation among them (Bajoghli 2013; Mithal et al. 2012).  
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As a chemokine receptor, the main function of CXCR4 in the cell is to direct its 
migration towards tissues secreting SDF-1. Being a GPCR, it acts mainly through the 
G-proteins Gαi and the dimer Gβ/Gγ (Massa et al. 2006) which, upon SDF-1 binding, 
activate multiple signalling pathways including: NF-κB (nuclear factor kappa-light-
chain-enhancer of activated B cells), p38/MAPK (Mitogen-activated protein kinases), 
ERK1/2 and intracellular Ca2+ signalling through PLC/IP3/DAG. The signalling 
cascades initiated by CXCR4/SDF-1 activation then culminate in the transcription of 
genes related to cell migration, survival and proliferation (Teicher & Fricker 2010).  
1.4.2 CXCR4 in development and homeostasis  
 The CXCR4/SDF-1 signalling axis has been implicated in the development of 
the nervous, immune and cardiovascular systems. In the developing nervous system, 
CXCR4 has been shown to be crucial for the proper migration and arrangement of 
neuron progenitors of the cortex, hippocampus, cerebellum and spinal cord (Stumm 
et al. 2003; Lu et al. 2002; Zou et al. 1998; Deaconess et al. 1998; Luo et al. 2005). 
CXCR4/SDF-1 signalling is also required for the proper migration of cranial neural 
crest cells involved in the formation of the pharyngeal arches, peripheral ganglia and 
cardiac structures (Theveneau et al. 2010; Kasemeier-Kulesa et al. 2010; Escot et al. 
2013). CXCR4-guided migration of endothelial progenitors has been demonstrated to 
be crucial during embryonic angiogenesis and blood-vessel patterning in several 
contexts (Virgintino et al. 2013; Bussmann et al. 2011; Li et al. 2013). During pancreas 
development, SDF-1 is secreted by the endodermal pancreatic progenitors, which 
then guides CXCR4-expressing angioblasts in order to form the pancreatic 
vasculature (Katsumoto & Kume 2011). CXCR4/SDF-1 also plays important roles in 
homeostasis as it is responsible for the retention and homing of haematopoietic stem 
cells of the bone marrow and for the migration and maturation of immune cell 
progenitors (Balabanian et al. 2012; Nie et al. 2004). Additionally, CXCR4 is essential 
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for the migration of endothelial progenitors to sites of ischemic injury, where it 
promotes wound repair (Tu et al. 2016). 
CXCR4/SDF-1 signalling in pituitary development  
Expression of both Cxcr4 and Sdf-1 mRNA in the developing pituitary gland has 
been previously reported (McGrath et al. 1999). Other groups have also observed 
their expression in normal and tumourigenic pituitary tissue. However, a 
comprehensive description of both CXCR4 mRNA and protein expression patterns 
throughout pituitary development has not been reported yet and the question of its 
function in vivo remains to be addressed (Rostène et al. 2011).  
1.4.3 CXCR4/SDF-1 signalling in cancer  
CXCR4 and SDF-1 have gained considerable attention in the area of cancer 
research because of their involvement in different aspects of tumour progression and 
malignancy. Both CXCR4 and SDF-1 are overexpressed in a wide array of human 
cancers, often correlating positively with tumour malignancy (Burger & Kipps 2006; 
Fischer et al. 2008; Lippitz 2013). CXCR4 mediates cancer cell metastasis towards 
sites of high SDF-1 secretion, promotes cancer cell chemoresistance and 
proliferation, as well as tumour angiogenesis (Liang et al. 2007; Sun et al. 2010; Drury 
et al. 2011). Importantly, CXCR4/SDF-1 expression can be controlled by signalling 
pathways like SHH and WNT, often reinforcing proliferative cues and tumour growth 
(Mo et al. 2013; Sengupta et al. 2012; Singh et al. 2012). Finally, in some 
tumours/cancers the expression of CXCR4 has been used as a marker to identify and 
isolate cancer stem cell (CSCs) (Trautmann et al. 2014; Hermann et al. 2007; Würth 
et al. 2014; Fujita et al. 2015; Jung et al. 2013). 
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CXCR4/SDF-1 signalling in pituitary adenomas  
In the context of pituitary-derived tumours, the study of CXCR4/SDF-1 
signalling has been mostly restricted to pituitary adenomas. Overexpression of these 
genes has been reported mainly in growth hormone-secreting adenoma (GHomas) 
tissue and GHoma cell lines. Interestingly, the majority of GHomas so far studied 
overexpressed CXCR4/SDF-1 (Barbieri et al. 2008; Lee et al. 2010; Nomura et al. 
2009; Barbieri et al. 2014), while in vitro studies found that activation of this pathway 
induces GHoma cell proliferation and growth hormone production (Kim et al. 2011; 
Lee et al. 2008; Massa et al. 2006; Yoshida et al. 2010).  
Recently, a study reported the identification of CSCs in a large cohort of human 
pituitary adenomas (Mertens et al. 2015). These CSCs were characterised by the 
expression of CXCR4, expressed the stem cell markers SOX2 and NESTIN, could 
be grown and serially passaged in culture and gave rise to hormone expressing cells 
corresponding to the adenoma type they were isolated from. When the purified 
CXCR4+ CSCs were injected into SCID mice, they demonstrated increased 
tumorigenic capacity in comparison to the main population. Importantly, chemical 
inhibition of CXCR4 lead to a decrease in tumour cell proliferation/viability and a 
significant reduction in xenograft tumour growth. Therefore, pituitary adenomas 
contain CXCR4+ CSCs which represent a promising therapeutic target for the 
treatment of these tumours. 
CXCR4/SDF-1 signalling in human and mouse ACP 
A possible role for the CXCR4/SDF-1 axis in ACP pathogenesis was previously 
suggested by Andoniadou et al. Expression analysis of the β-catenin-accumulating 
clusters from Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries showed that Cxcr4 expression was 
significantly upregulated in the clusters (2.62-fold change in expression), while its 
ligand Sdf-1 was significantly upregulated in the non-cluster fraction (4.91-fold 
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change in expression). In situ hybridisation (ISH) in both Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries and human ACP samples demonstrated increased CXCR4 expression in 
structures that matched β-catenin cluster location in consecutive histological sections 
(Andoniadou et al. 2012). Subsequently, a significant correlation was found between 
poor recurrence-free survival and higher expression of CXCR4 and SDF-1 in patients 
with paediatric form of ACP (Gong et al. 2014), suggesting this pathway represents a 
prognostic factor during ACP tumourigenesis. 
1.4.4 Other CXC receptors  
CXCR7  
CXCR7 is the only other receptor known to bind SDF-1. Initially it was 
considered to act only as a scavenger receptor, as it does not signal through G 
proteins (Rajagopal et al. 2010). In the developing brain, CXCR7 is necessary for 
correct CXCR4-mediated cell migration by creating SDF-1 gradients (Wang et al. 
2011). However, it has also been shown that it mediates a cell-autonomous regulation 
of cell migration by forming heterodimers with CXCR4 and thereby affecting receptor 
sensitisation (Décaillot et al. 2011; Levoye et al. 2009). In vivo studies have found 
CXCR7-mediated regulation of CXCR4 to be crucial for the correct development of 
the brain, heart  and kidney (Sánchez-Alcañiz et al. 2011; Mellado et al. 2007; Haege 
et al. 2012). Importantly, this complementation of CXCR4 function by CXCR7 has 
also been found to be involved in a variety of cancers, where CXCR7 can display pro-
oncogenic or tumour suppressive functions depending on the context (Grymula et al. 
2010; Heckmann et al. 2013; Hernandez et al. 2011).  
CXCR2  
Angiogenesis and inflammation are well known mechanisms involved in tumour 
progression (Acosta & Gil 2009). CXCR2 is another receptor that has been shown to 
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be relevant for regulating CXCR4 function, particularly in inflammation and cancer. It 
has been investigated mainly for being the receptor for interleukin 8 (IL-8), which is 
of great importance for neutrophil inflammatory responses in tumours (Wu et al. 
2012), including in models were neutrophil invasion has been shown to result pro-
tumourigenic (Jamieson et al. 2012). The mechanism by which CXCR2 guides cell 
migration and invasion often involves antagonising CXCR4 signalling in a cell-
autonomous fashion (Eash et al. 2010; Martin et al. 2003). In the mouse, this effect 
is mainly mediated by the IL-8 analogue chemokines CXCL1, CXCL2 and CXCL3 
(Luan et al. 2001). Importantly, the genes encoding these chemokines were 
overexpressed (2.15, 30 and 29-fold, respectively) by the β-catenin-accumulating cell 
clusters of the embryonic mouse model for ACP (Andoniadou et al. 2012).  
 
1.5 Cellular Senescence 
1.5.1 Definition and role of cellular senescence 
Cellular senescence is defined as an irreversible loss of proliferative capacity, 
while the cell still retains normal metabolic activity and viability. It is now established 
that senescence occurs as a response to different stress stimuli and reflects 
abnormalities in the cell’s homoeostatic machinery. In contrast, cellular quiescence is 
also characterised by a long-term cell cycle arrest, but is reversible upon specific 
mitotic signals. Cellular quiescence occurs normally in some types of differentiated 
cells (e.g. fibroblasts) and especially in stem cells (Campisi 2013).  
The first description of senescence was derived from observing the behaviour 
of human cells in culture, which showed a gradual decay and eventually permanent 
arrest in their proliferative capacity, although they remained viable and metabolically 
active (Hayflick & Moorhead 1961; Hayflick 1965). It is now known that, under normal 
conditions, cells can only divide a finite number of times (their “Hayflick limit”). This 
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phenomenon is now known as replicative senescence and it occurs due to gradual 
telomere erosion (Bodnar et al. 1998).  
Further research unveiled other stress-inducing stimuli able to trigger 
senescence: accumulation of unresolved DNA damage, reactive-oxygen species 
(ROS), ionizing radiation, cytotoxic chemical agents, the endoplasmic reticulum (ER) 
stress response or loss of a tumour suppressor such as PTEN (Fitzgerald et al. 2015; 
Colavitti & Finkel 2005; Le et al. 2010; Liao et al. 2014; Ewald et al. 2010; Matos et 
al. 2015; Pluquet et al. 2015; Thomas Kuilman et al. 2010; Dörr et al. 2013). 
Senescence occurring through these mechanisms does not depend on the cell’s 
telomere status and is referred to as Stress-Induced Premature Senescence (SIPS).  
A different type of telomere-independent senescence occurs upon the 
activation of oncogenes such as mutant β-catenin, HRASV12, BRAFV600E and 
KRASG12D (Serrano et al. 1997; Gu et al. 2014; Xu et al. 2008; Wajapeyee et al. 2008; 
Collado et al. 2005; Collado & Serrano 2010) and is referred to as Oncogene-Induced 
Senescence (OIS). Importantly, OIS has been demonstrated to represent a potent 
anti-tumourigenic barrier in several contexts by preventing the overproliferation of 
oncogene-carrying cells. The finding that tumours contain larger numbers of 
senescent cells in pre-malignant stages compared to malignant ones, lead to the 
hypothesis that senescence is the rate-limiting step in tumour progression in both 
mice and humans (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; 
Michaloglou et al. 2005).  
The Senescence Associated Secretory Phenotype (SASP) 
Another feature of senescent cells is that they can promote directly their own 
clearance and induce tissue repair by means of the Senescence-Associated 
Secretory Phenotype (SASP). The SASP involves the secretion of a wide variety of 
soluble and insoluble factors including: interleukins, chemokines, growth factors and 
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extracellular matrix (ECM) components (Shelton et al. 1999; Coppé et al. 2008; 
Coppé, Patil, et al. 2010). The SASP signature appears to vary depending on the 
nature of the senescence-inducing stimuli (Coppé, Patil, et al. 2010; Maciel-Barón et 
al. 2016). However, some secreted factors appear to be more prevalent among 
reported SASP signatures. Examples include: the interleukins IL1A, IL1B and IL6; the 
chemokines IL8 (CXCL1-3 in mice), CCL2, CCL5 and CCL20; growth factors: bFGF, 
HGF, VEGF and inflammatory cytokines: TGFβ, TNFα and MIF, among others 
(Coppé, Desprez, et al. 2010; Tchkonia et al. 2013).  
In general, the SASP is known to mediate two main effects: 1) the recruitment 
of the immune system, which then removes senescent cells from the environment 
(Xue et al. 2007; Kang et al. 2011; Iannello et al. 2013; Chien et al. 2011; 
Krizhanovsky et al. 2008; Sagiv et al. 2013); and 2) reinforcing the overall senescent 
response by both autocrine and paracrine signalling (Acosta et al. 2008; Acosta et al. 
2013; Hubackova et al. 2012).  
Until recently, the prevailing view was that replicative senescence, SIPS and 
OIS were uniquely beneficial mechanisms preventing the propagation of abnormally 
stressed cells carrying irreparable damage in their DNA or metabolic machinery 
(Sharpless & Sherr 2015), while the SASP aided in their immune clearance. However, 
novel roles have been uncovered for senescent cells, as they are involved in 
appropriate wound repair and even in tissue remodelling during embryonic 
development (Krizhanovsky et al. 2008; Demaria et al. 2014; Storer et al. 2013; 
Muñoz-Espín et al. 2013; Yun et al. 2015). Importantly, these functions also rely 
greatly on their interaction with the microenvironment and the immune system 
through the SASP.  
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1.5.2 Detrimental effects of senescence and the SASP 
Senescence and the SASP in ageing 
The deleterious consequences of the ineffective clearance of senescent cells 
and their over-accumulation in tissues have mainly been studied in relation to age-
related diseases, which also include an exponential increase in the development of 
cancer (Krtolica et al. 2001; Campisi 2013). Aged tissues of mice, primates and 
humans contain larger numbers of senescent cells, particularly in the lungs, skin and 
spleen (White et al. 2015; Dimri et al. 1995; Herbig et al. 2006; Wang et al. 2009), 
while the number of senescent cells in the liver and intestine was shown to be an 
accurate life-span predictor in mice (Jurk et al. 2014). Importantly, genetic or chemical 
ablation of senescent cells delayed the onset of age-related disorders, leading to 
increased life-spans and also promoting tissue rejuvenation in late life (Chang et al. 
2016; Baker et al. 2011; Baker et al. 2016). 
 The exact mechanisms connecting senescence and age-related pathologies 
are still under debate. One hypothesis is that the onset of senescence in stem cells 
leads to the depletion of a tissue’s regenerative potential (Flores et al. 2006; Castilho 
et al. 2009; Pollina & Brunet 2011). Another emerging possibility is that the 
accumulation of senescent cells during ageing leads to persistent SASP signalling 
and the development of chronic inflammation, which leads to overall deterioration of 
a tissue’s homeostatic environment (i.e. “inflammaging”) (Franceschi & Campisi 
2014; Salminen et al. 2008; Shaw et al. 2010; Hall et al. 2016). 
The pro-tumourigenic activities of the SASP  
There is increasing evidence indicating that senescence and its SASP can act 
as a double edged-sword in cancer development. The discovery that SASP factors 
from senescent fibroblasts are able to promote growth and enhance tumourigenesis 
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in premalignant epithelial cells, but not normal ones, gave way to research revealing 
the pro-tumourigenic properties of the SASP (Krtolica et al. 2001; Coppé, Patil, et al. 
2010).      
Senescent cells and the SASP has been shown to promote carcinogenesis by 
different mechanisms, which can be categorised as: 1) Direct signalling on pre-
malignant or malignant cells; and 2) Indirect signalling by modification of the 
microenvironment, which then becomes permissive for cancer progression. 
 The most reported direct effect of the SASP is to induce proliferation in 
neighbouring non-senescent cells, enhancing their tumourigenic properties (Coppé, 
Patil, et al. 2010; Laberge et al. 2015; Nakamura et al. 2014; Kuilman et al. 2008; 
Bavik et al. 2006). Pro-tumourigenic phenotypes characterised by chemoresistance 
and epithelial-to-mesenchymal transition (EMT) are also enhanced by the SASP 
(Canino et al. 2012). Importantly, the SASP is also able to induce dedifferentiation 
and reprogramming of naïve cells, leading to the emergence of CSCs (Parrinello et 
al. 2005; Cahu et al. 2012; Ohanna et al. 2013).  
The SASP has also been shown to promote tumourigenesis indirectly by 
signalling on the microenvironment. Notably, a large number of proangiogenic factors 
are known to be secreted by senescent cells, while no angiostatic molecules have 
been found (Campisi 2013). Indeed, the SASP has been reported to promote tumour-
supportive angiogenesis and endothelial cell invasiveness (Yu et al. 2013; Vital et al. 
2014; Ancrile et al. 2007). In addition, the SASP displays important modulatory 
activities on the immune system such as: promoting macrophage polarization towards 
tumour-promoting phenotypes (Lujambio et al. 2013) and generating 
immunosuppressive niches permissive for tumour growth or cancer cell metastasis 
(Ruhland et al. 2016; Luo et al. 2016).    
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1.5.2 Pathways and mechanisms underlying senescence  
Senescent cells have traditionally been identified by the activity of the 
Senescence-Associated β-Galactosidase (SA-β-Gal). However, the prevailing view 
is that cellular senescence is a complex state that can only be accurately determined 
by the use of several molecular markers (Sharpless & Sherr 2015; Campisi 2013; 
Collado & Serrano 2010). These markers are associated with numerous stress-
related biological processes shared by senescent cells such as: loss of proliferative 
capacity, absence of apoptosis, increased lysosomal activity, acquisition of a DNA-
damage-response (DDR) and activation of the SASP. 
Cell cycle control and senescence 
As previously mentioned, the defining aspect of a senescent cell is that it enters 
a permanent arrest in the cell cycle. Therefore, a good preliminarily indicator relies 
on the use of proliferation markers such as the cell-cycle indicator Ki-67, the mitosis 
marker phosphorylated Histone H3 (Davalos et al. 2010) and the uptake of thymidine 
analogues (EdU/BrdU) during S-phase DNA synthesis. However, quiescent cells that 
can resume the cell cycle also lack these markers and this should be taken in 
consideration. 
It is now well established that the senescent cell cycle arrest is mostly mediated 
by the p53/p21 and the p16/Rb pathways (although some exceptions have been 
reported). In some cases, either of these pathways is indispensable for senescence 
onset, while they mostly cooperate and reinforce senescence together (Kamijo et al. 
1997; Zhu et al. 2015). 
The main effector of the p53/p21 pathway is the tumour suppressor protein p53 
(encoded by TP53 in humans and Trp53 in mice). p53 is crucial for proper regulation 
of cell survival. Its function is to mediate the cellular response to multiple stress 
signals, which include: DNA damage, replicative stress, oncogenic hyper proliferative 
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signals, hypoxia, oxidative stress and nutrient deprivation (Vousden & Ryan 2009; 
Bieging et al. 2014). Upon induction, p53 activates multiple responses, mainly 
through its key effector protein p21 (encoded by CDKN1A), including: inducing the 
cell cycle arrest or slowing cell cycle progression, promotion of DNA repair, 
senescence, autophagy or apoptosis (Menendez et al. 2009; Meek 2009). 
Additionally, recent evidence indicates that p53 also has roles in regulating the stem 
cell phenotype and their differentiation (Spike & Wahl 2011). Importantly, many of 
these functions are deeply involved in cancer pathogenesis. 
It is known that p53 is the gene most frequently found to be mutated in cancer. 
Around half of all sporadic cancers carry inactivating TP53 mutations (Olivier et al. 
2010), while germ-line mutations lead to high predisposition to multiple cancer types, 
known as Li-Fraumeni syndrome (Nochols et al. 2001). The study of mouse p53 
knockout models has provided considerable insight into the mechanisms of p53-
mediated tumour suppression and established the unequivocal importance of 
p53/p21 signalling in preventing cancer development (Donehower 2009). Importantly, 
many anti-cancer therapies (such as radiotherapy) rely on the induction of DNA-
damage, which leads to p53-dependent apoptosis (Norbury & Zhivotovsky 2004). 
The role of p53 in the anti-tumourigenic senescent response was initially 
demonstrated in vitro (Sugrue et al. 1997; Fang et al. 1999) and posteriorly in vivo, 
by revealing that premalignant tumours undergo p53-dependent senescence, while 
full malignant tumours progressed in the absence of p53 and other senescence 
markers (Dankort et al. 2007; Collado et al. 2005). Furthermore, it has been shown 
that restoration of p53 function in vivo leads to cancer cell senescence and eventual 
tumour regression (Ventura et al. 2007; Xue et al. 2007; Feldser et al. 2010).  
A second pathway responsible for mediating the cell cycle control is 
the Rb/p16INK4a pathway. Retinoblastoma protein (Rb) is normally associated to E2F 
transcription factors, preventing the transcription of cell cycle promoting genes. 
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During the G1 to S transition, the repressing activity of Rb is relieved by the activity 
of cyclin dependent kinases (CDK4/6).  Upon stress stimuli such as DNA damage, 
there is an increase in the expression of p16 (also known as IKN4A and encoded by 
the CDKN2A locus), which binds and inhibits the activity of CDK4/6, therefore 
stabilising Rb (Serrano et al. 1993). The activity of p16 has been shown to 
be crucial for the induction and maintenance of senescence (Dai & Enders 2000; 
Ohtani & Hara 2013; Baker et al. 2011; Demaria et al. 2014; Burd et al. 2013), 
including senescence induced by increased WNT signalling (Sato et al. 2015). 
Therefore, upregulation of p16 has been referred as a reliable functional marker of 
senescence in different contexts (Salama et al. 2014), even in those where 
senescence is independent from p53/p21 (Jacobs et al. 2004). Importantly, p16/Rb 
signalling has also been shown to play a significant role in vivo in the context of 
oncogene-induced senescence (OIS) (Michaloglou et al. 2005; Serrano et al. 1996; 
Serrano et al. 1997; Sarkisian et al. 2007). 
The lysosomal compartment in senescent cells 
As previously mentioned, the SA-β-gal assay at pH 6.0 (Dimri et al. 1995; 
Debacq-Chainiaux et al. 2009) is the gold-standard for the identification of senescent 
cells and it has been shown that the enzyme’s increased activity during senescence 
reflects an overall expansion of the cell’s lysosomal compartment (Kurz et al. 2000; 
Ivanov et al. 2013). The enzyme responsible for the SA-β-gal activity is encoded by 
the GLB1 gene (Lee et al. 2006) and it has been shown that its overexpression can 
be detected using anti-GLB1 antibodies and used as a senescence marker (Wagner 
et al. 2015). This expansion of the lysosomal compartment is thought to be a 
consequence of maintaining the highly demanding secretory machinery of senescent 
cells which leads to endoplasmic reticulum stress, an unfolded-protein response and 
proteotoxicity (Dörr et al. 2013). 
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DNA-damage and the DNA-damage response 
Compelling evidence indicates that oncogene-induced DNA damage is required 
in order to establish and perpetuate the OIS phenotype (Bartkova et al. 2006; Mallette 
et al. 2007). More importantly, DNA damage has been shown to be essential for the 
activation of the SASP (Rodier et al. 2009; Kang et al. 2015). 
 The exact mechanisms linking oncogene signalling and DDR induction are 
complex and not fully understood. However, it has been shown that oncogene 
expression can force the cell through hyper-replication, leading to sustained DNA 
replicative stress, which can result in the accumulation of DNA damage (e.g. double 
strand breaks, DSBs) (Di Micco et al. 2006; Prieur et al. 2011; Halazonetis et al. 
2008). Right after DSB formation, proteins recognising DSBs like PARP-1 help the 
recruitment of kinases like ATM/ATR and DNA-PKcs, which phosphorylate histone 
H2AX (γH2AX), leading to its rapid accumulation at DSB sites (Weaver & Yang 2013). 
γH2AX provides a positive feedback loop that amplifies overall protein recruitment, 
including ATM/ATR, which then initiate a signalling cascade culminating with the 
activation of DNA-checkpoint pathways, including p53/p21signalling (Gaillard et al. 
2015; Bonner et al. 2008). The collection of signalling pathways activated in this 
manner is known as the DNA-Damage response (DDR). 
The mTOR and autophagy pathways 
The mechanistic target of rapamycin (mTOR) is a serine/threonine kinase that 
forms part of a highly-conserved signalling complex (mTORC1), which is crucial for 
mediating cell growth and proliferation in response to environmental cues such as 
nutrient availability. The main function of mTOR is to induce the protein synthesis 
machinery. Upon activation, mTORC1 phosphorylates p70 ribosomal protein S6 
kinase 1 (S6K1), which in turn phosphorylates ribosomal protein S6 and activates 
protein translation; and the eukaryotic initiation factor 4E-binding protein (4E-BP1), 
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which induces mRNA synthesis, ribosome biogenesis and overall protein translation. 
Importantly, mTOR signalling has been shown to be involved in the establishment of 
cellular senescence (Vousden & Ryan 2009; Castilho et al. 2009; Hasty et al. 2013) 
and activation of the SASP (Laberge et al. 2015; Herranz et al. 2015). 
The second function of mTOR is to inhibit autophagy. Autophagy is a process 
in which cellular components, such as organelles and protein complexes, are 
sequestrated within vesicles known as autophagosomes, and then degraded within 
lysosomes (Wirawan et al. 2012). Although the effects of autophagy are many, its 
main function is to provide the cell with an alternative source of energy upon scarce 
nutrient availability, which then can be used to maintain the cell’s essential anabolic 
processes. Additionally, autophagy is also involved in the clearance of misfolded 
proteins, which can result toxic to intracellular homeostasis (Filomeni et al. 2015). 
The p62/SQTSM protein plays a crucial role during autophagy by functioning as a 
scavenger able to sequestrate large groups of proteins and facilitate their integration 
into the autophagosomes (Pankiv et al. 2007). Because p62 is also a target of 
autophagy, its accumulation can be observed in cells that are autophagy-deficient 
(Rusten & Stenmark 2010).  
The role of autophagy in the induction and maintenance of senescence is 
controversial as its pro-senescence or anti-senescence activities appear to be 
context-dependent (White 2012; Kang & Elledge 2016). Some studies have shown 
that autophagy is required for senescence (Zhang et al. 2014; Young et al. 2009), 
while others concluded it is necessary to prevent its onset (García-Prat et al. 2016). 
Additionally, the impairment of autophagic degradation of specific proteins (i.e. 
selective autophagy) was shown to be required for SASP induction (Kang et al. 2015). 
In contrast, others have shown that autophagy allows cells to cope with the mass 
synthesis of proteins required for the SASP (Dörr et al. 2013; Narita et al. 2011).  
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The Nf-κB pathway  
The nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) is a 
conserved complex of transcription factors that are mayor regulators of inflammation 
and stress signals, with important roles in cancer and disease (Hayden et al. 2006; 
Lawrence 2009). Stimuli leading to NF-kB activation include: inflammatory signalling 
through TGF-β, TNFα, and Il1B; oxidative stress through p38MAPK and DNA-
damage through PARP-1-mediated activation of NEMO/ATM (Weaver & Yang 2013). 
 The NF-κB complex is formed by heterodimers of class I (NFKB1 and NFKB2) 
and class II (RELA, RELB, REL) subfamilies. In the canonical NF-κB pathway, the 
NF-κB complex is normally held in the cytoplasm by inhibitor proteins belonging to 
the IκB family. Activation of the pathway initiates when a complex of IκB kinases (IKK) 
(including the master regulatory kinase NEMO/IKKγ) phosphorylate IκB proteins, 
leading to their proteasomal degradation and allowing translocation of NF-κB to the 
cell nucleus where it initiates transcription (Hayden & Ghosh 2012). Target genes of 
NF-κB include a wide array of cytokines and chemokines, immunoreceptors, stress 
response genes, growth factors and genes involved in cell survival (Perkins 2007; 
Lawrence 2009).  
Importantly, the process of oncogene-induced senescence culminates with the 
activation of the SASP by means of the NF-κB pathway. Besides being a requirement 
for initiating and maintaining the SASP (Crescenzi et al. 2011; Ohanna et al. 2011; 
Freund et al. 2011; Salminen et al. 2012), NF-κB signalling is also involved in 
reinforcing senescence in cell-autonomous and non-cell autonomous fashions 
(Acosta et al. 2008; Rovillain et al. 2011; Chien et al. 2011). 
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1.6 Rationale and aims of the thesis  
Tumours are no longer regarded as simple masses of uncontrolled proliferating 
cells. They are intricate and continuously-changing entities in which the interactions 
between the cancer cell and its microenvironment are crucial in determining the 
outcome of oncogenesis. Therefore, the biological processes guiding their origin must 
be equally complex. In several cancer models, the role of driver mutations is thought 
to comply with the CSC paradigm, indicating that the initial hit allows the targeted cell, 
and its progeny, to gain the advantages required to overcome the organism’s anti-
cancer mechanisms to eventually form a tumour. In this context, OIS and the SASP 
were initially proposed to represent one such protective mechanism. However, most 
of this knowledge has been derived from the study of tumours at later stages of 
progression. Thus, the study of OIS and the SASP during the earliest steps of tumour 
formation is imperative if critical advances in cancer prevention are to be achieved. 
The work of Andoniadou et al. brought forward outstanding questions regarding 
tumourigenesis in models of ACP such as: 
1) Does this mechanism also apply to tumourigenesis in the embryonic ACP model? 
Are there similarities with human ACP? 
2)  Why do β-catenin clusters stop dividing and do not form tumours?  
3) What is the mechanism underlying their secretory phenotype?  
4) What is the effect of these secreted factors in the microenvironment? 
5) What is the actual cell of origin of the tumours?  
 To answer these questions, the following hypothesis was formulated and forms 
the core of this work: nucleo-cytoplasmic β-catenin clusters undergo cellular 
senescence, preventing them from proliferating further, and this endows them with a 
Senescence-Associated Secretory Phenotype (SASP) capable of signalling to their 
surroundings and transforming a nearby naïve cell.  
. 
 65 
 
 
 
 
 
 
 
2. MATERIALS AND METHODS 
 
 66 
2.1 Mice 
2.1.1 Maintenance of mouse colonies 
All animal procedures were performed under compliance of the Animals 
(Scientific Procedures) Act 1986 and current Home Office legislation. Mice were bred 
and housed under conditions complying with the Home Office code of practice for the 
housing and care of animals bred, supplied or used for scientific purposes. 
2.1.2 Description of genetic targeting and lineage tracing 
strategies 
Mouse lines expressing Cre recombinase under the control a specific promoter 
can be bred with lines bearing insertion of LoxP sites in genes of interest. The 
presence of Cre will result in the excision of DNA flanked by LoxP in cells in which 
the chosen promoter is active (Sauer & Henderson 1988). If the flanked sequence is 
essential for protein function, then a conditional knockout can be achieved in tissues 
in which the chosen promoter is expressed, as well as of the descendants (i.e. the 
entire cell lineage). Inducible Cre driver lines have also been developed to allow 
temporal control in the induction of Cre expression. One such system is the 
CreERT2/LoxP system. This altered form of Cre contains a mutant oestrogen 
receptor domain, which retains Cre in the cell cytoplasm and is not responsive to 
endogenous oestrogen. Upon tamoxifen administration, CreER will translocate into 
the nucleus and excise LoxP-flanked DNA (Jaisser 2000; Glaser et al. 2005).  
R26YFP/+ mice contain the Yellow Fluorescent Protein (YFP) gene inserted into 
the ubiquitously active ROSA26 locus. Expression of YFP is normally inhibited 
through the presence of an upstream STOP polyadenylation sequence, which is 
flanked by two LoxP sites (Robertson & Soriano 1999). Crossing R26YFP/+ mice with 
a Cre driver line will allow the expression of Cre in a specific cell type, leading to 
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excision of the STOP sequence, and therefore constitutive expression of YFP in the 
targeted cell and all its descendants. This strategy is known as lineage tracing. 
2.1.3 Mouse strains and genetic crosses 
The following lines have been previously described and maintained by the host 
lab for over 50 generations in a C57BL/6 background: Hesx1Cre/+, Hesx1Cre/+R26YFP/+; 
Hesx1Cre/+;Ctnnb1lox(ex3)/+, Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+, 
Sox2CreERT2/+;Ctnnb1lox(ex3/+);R26YFP/+ (Andoniadou et al. 2011; Gaston-Massuet et al. 
2011; Andoniadou et al. 2013). Ctnnb1lox(ex3)/+ mice (Harada et al. 1999) contain LoxP 
sites flanking exon 3 of the β-catenin gene. Cre expression leads to exons 2 and 4 
connected in frame producing a degradation resistant and transcriptionally functional 
β-catenin protein. 
Cxcr4fl/fl mice (Cxcr4tm2Yzo) have been previously described and contain loxP 
sequences flanking exon 2, which represents 98% of the CXCR4 molecule (Nie et al. 
2004).  Hesx1Cre/+ and Cxcr4fl/fl mice were bred in order to obtain Hesx1Cre/+;Cxcr4fl/+ 
mice, which were then back-crossed with Cxcr4fl/fl animals to generate 
Hesx1Cre/+;Cxcr4fl/+ controls and Hesx1Cre/+;Cxcr4fl/fl mutants. Additionally, Cxcr4fl/fl and 
Ctnnb1lox(ex3)/lox(ex3) lines were crossed and their progeny was backcrossed order to 
obtain Cxcr4fl/+;Ctnnb1lox(ex3)/lox(ex3) mice. These were then crossed with 
Hesx1Cre/+;Cxcr4fl/fl mice in order to obtain Hesx1Cre/+; Ctnnb1lox(ex3)/+;Cxcr4fl/+ controls 
and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl mutants. CXCR7-GFP embryos were kindly 
donated by Dr. Ralf Stumm. Cxcr4-/- embryos were generated by crossing Cxcr4fl/fl 
with β-actinCre/+ mice. Cxcr7-/- (Cxcr7tm1Litt), and Cxcl12-/- (Ara et al. 2003) embryos 
were kindly donated by Dr. Sarah Ivins and Prof. Peter Scambler. 
Trp53fl/fl mice (Trp53tm1Brn) have also been previously described (Marino et al. 
2000) and contain LoxP sequences flanking exons 2 and 10, which effectively 
produces a null mutation upon Cre expression. Trp53fl/fl mice were crossed with 
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Hesx1Cre/+ and Ctnnb1lox(ex3)/lox(ex3);R26YFP/YFP mice to produce Hesx1Cre/+;Trp53fl/fl and 
Trp53fl/+;Ctnnb1lox(ex3)/ lox(ex3);R26YFP/YFP mice. These latter strains were bred to obtain 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ controls and Hesx1Cre/+;Ctnnb1lox(ex3)/ 
+;Trp53fl/fl;R26YFP/+ mutants.  
A similar approach was conducted for generating 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ and 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice, which were induced once by 
intraperitoneal injection of 0.15 mg of tamoxifen per gram of weight at 4 to 6 weeks 
of age.  
DNA uptake experiments at different embryonic stages were conducted using 
5-ethynyl-2’-deoxyuridine (EdU) according to manufacturer’s instructions (Thermo). 
Pregnant females were injected the day of the desired embryonic stage with a 
10mg/ml solution of EdU for a total dose of 100 mg of EdU per kg of weight. After 90 
minutes, embryos were dissected and processed as described below. 
2.1.4 Sample collection and processing 
For embryological studies, female mice were inspected for vaginal plugs the 
morning after mating set-up. Noon of the day a plug was observed was determined 
as 0.5 days post coitum (dpc) and pregnant females were sacrificed at the appropriate 
embryological age. For survival studies involving Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl, 
Hesx1Cre/+l;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ and Sox2CreERT2/+;Ctnnb1lox(ex3)/+; 
Trp53fl/fl;R26YFP/+ mice, the experimental end-point was determined as the onset of 
health deterioration symptoms such as: hunched posture, intracranial haemorrhage 
or more than 20% weight-loss, all in line within license established thresholds.  
All murine samples including embryos, pituitaries and end-point tumours were 
collected and further dissected in ice-cold Dulbecco’s Modified Eagle’s Medium 
supplemented with 10% Foetal Calf Serum (FCS). Tumours were imaged in 
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brightfield and under fluorescence for endogenous YFP expression under a 
stereomicroscope (Leica) using 0.8X magnification and a constant exposure of 3.7 
seconds. 
Samples to be used for immunohistochemistry or in situ hybridisation were 
washed in phosphate-buffered saline (PBS) and immediately placed in ice-cold 
freshly made 4% paraformaldehyde (PFA), fixed over-night and posteriorly 
dehydrated using ethanol (EtOH) gradients. Dehydrated samples were then paraffin-
embedded and cut into 6 μm-thick sections using a rotary microtome (Leica) and 
mounted in Superfrost Plus slides (Thermo). Serial sections were produced in series 
of 5 for embryos and in series of 8 for tumours and postnatal pituitaries. For embryos, 
up to 14.5 dpc, sectioning was conducted in a sagittal plane, while for older embryos 
and postnatal pituitaries sectioning was conducted in the coronal plane. 
Samples to be used for RNA extraction were also dissected in ice-cold medium, 
washed briefly in PBS, placed immediately in 350 μl of buffer RLT and dissociated 
completely by pipetting to ensure RNA stabilisation. Samples were then stored at -
80ºC until further use. Samples for protein extraction were immediately snap-frozen 
and stored at -80ºC until further use. In the case of embryonic and adult pituitaries 
the posterior lobe was manually dissected before addition of RLT buffer or snap-
freezing. 
Unless specified, all experiments performed on mouse embryos and pituitaries 
were performed with a minimum of three biological replicates at least from 2 different 
litters.  
2.2. Human samples 
Use of human samples was either carried out under ethical approval 14 LO 
2265 or under the ethical approval of specific tissue banks. Human ACP samples 
were kindly provided by the GOSH Histopathology Department. For each marker, a 
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minimum of three independent ACP samples were analysed. Additionally, the 
expression of each marker was also analysed in tissue microarrays containing a total 
of 23 different ACP cases and normal brain tissue as a control. Human embryonic 
samples were provided by the Joint MRC/Wellcome Trust (grant # 099175/Z/12/Z) 
Human Developmental Biology Resource. 
2.3 DNA methods 
2.3.1 Genotyping of mice and embryos by PCR of genomic 
DNA 
Genomic DNA was extracted from ear biopsies using DNAreleasy (Anachem) 
at a 1:5 dilution in a final volume of 25 µl for 30 minutes at 65oC. A negative control 
without tissue biopsy was included during the extraction step. Polymerase chain 
reaction (PCR) amplification of target DNA was conducted using 1 µl of sample and 
reaction conditions optimised for each primer set (Table 1). Depending on the 
protocol, the reaction used 10X Taq Polymerase Buffer (Bioline) or JD buffer (3x JD 
Buffer: 60 mM K-glutamate, 24 mM Hepes, 90 mM Tris, 15 mM MgCl2, 6 mM DTT, 
180 mM NH4Ac, 3% DMSO, 24% glycerol 3x JD Buffer: 60 mM K-glutamate, 24 mM 
Hepes, 90 mM Tris, 15 mM MgCl2, 6 mM DTT, 180 mM NH4Ac, 3% DMSO, 24% 
glycerol). The final components of the reaction mix are described in Table 2. As 
controls, a positive control of template DNA and a negative control without DNA were 
included. Initial strand denaturation was performed at 94oC for 2 minutes. Further 
denaturation steps were conducted at 94oC for 30 seconds followed by a primer-
dependent annealing step and polymerization extension at 72oC for 1 minute. The 
final extension step was conducted at 72oC for 5 minutes.  
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Component DNA Mix (μl) Enzyme Mix (μl) 
 Taq Buffer JD Buffer Taq Buffer JD Buffer 
H20 7.08 1.7 6.4 1.55 
Taq Pol Buffer (x10) 1.2 - 0.8 - 
MgCl2 (25mM) 0.72 - 0.48 - 
JD Buffer (x3) - 2.5 - 0.83 
Primer 1 1 (25 µM) 
0.5 (10 
µM) - - 
Primer 2 1 (25 µM) 
0.5 (10 
µM) - - 
dNTPs (25mM) - 0.3 0.16 - 
Taq Pol (5U/ul) - - 0.16 0.12 
Table 3. Reaction mix for PCR genotyping. 
 
Line Primer sequences Annealing Conditions Products 
Hesx1Cre 
OL89: 
GGAGACAATTCTTTTGTGAAACCCTG 
OL91: CCAGAGTGTCTGGCTTCTGTC 
CreT: CAGAAGCATTTTCCAGGTATGCTC 
OL39:TCAGCAAAGCTACAAGGTGAACTG 
58 for 30 
sec 
35 cycles 
JD 
WT: 500 
bp 
MUT: 
300 bp 
Sox2CreERT2/+ Fwd: GATGCAACGAGTGATGAGGTTCGC Rev: ACCCTGATCCTGGCAATTTCGGC 
63 for 30 
sec 
30 cycles 
Taq Pol. 
Buffer 
MUT: 
500bp 
Ctnnb1lox(ex3)/+ 
Fwd: AGAATCACGGTGACCTGGGTTAAA 
Rev: 
CATTCATAAAGGACTTGGGAGGTGT 
62 for 20 
sec 
40 cycles 
Taq Pol. 
Buffer 
WT: 600 
bp 
MUT: 
700bp 
Cxcr4fl/fl 
Fwd: 
CCACCCAGGACGACAGTGTGACTCTAA 
Rev: 
GATGGGATTTCTGTATGAGGATTAGC 
65 for 30 
sec 
30 cycles 
Taq Pol. 
Buffer 
WT: 481 
bp 
MUT: 
550 bp 
Trp53fl/fl Fwd: AAGGGGTATGAGGGACAAGG Rev: GAAGACAGAAAAGGGGAGGG 
60 for 30 
sec 
30 cycles 
Taq Pol. 
Buffer 
WT: 270 
bp MUT:  
390 bp 
R26YFP/+ 
R26R1: AAAGTCGCTCTGAGTTGTTAT 
R26R2: GCGAAGAGTTTGTCCTCAACC 
R26R3: GGAGCGGGAGAAATGGATATG 
60 for 1 
min 
35 cycles 
Taq Pol. 
Buffer 
WT: 
250bp 
MUT: 
600bp 
Table 4. Primers used for PCR genotyping of mice and embryos. 
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2.3.2 Cloning of the CXCR2 CDS 
In order to produce antisense riboprobes for in situ hybridisation, the protein 
coding DNA sequences (CDS) of the murine and human CXCR2 genes were first 
amplified and cloned. Because the CDS in both human and mouse CXCR2 do not 
contain any introns, amplification was conducted from genomic DNA. Specific primers 
were designed and adapted with restriction sites: 5’-XhoI for forward primers and 5’-
EcoRI for reverse primers. A 2-3 bp cap was added for improving enzymatic activity 
(Table 3). PCR amplification was conducted as described earlier using a normal Taq 
Buffer protocol. 
Target Primer sequences Insert size 
Mouse Cxcr2 
Fwd: 
GCCTCGAGTACTGCGTATCCTGCCTCAG 610 bp Rev: 
GCGAATTCTCTGCTAAGAACGTGACCTCT 
Human Cxcr2 
Fwd: 
GCCTCGAGATAGTGGCATCCTGCTACTG 633 bp Rev: 
GCGAATTCCTGATCAAGCCATGTATAGC 
Table 5. Primer sequences targeting the CDS of the murine and human 
CXCR2 genes. 
 
The PCR products were resolved by electrophoresis in a 1% agarose gel. 
Bands of the appropriate size were excised under a trans illuminator and purified 
using a Gel Extraction Kit (Qiagen) according to manufacturer’s instructions. The 
inserts were then digested with XhoI and EcoRI for 3 hours at 37oC, after which 
enzymes were inactivated by a 10-minute incubation at 65 oC and purified using a 
QIAquick PCR Purification Kit (Qiagen). The PBlueScriptSK vector was linearized 
also with XhoI and EcoRI for 2 hours at 37oC, incubated with 1 µl of alkaline 
phosphatase (20 U/µl, Roche) for 1 hour at 37oC to prevent self-ligation and 
purified in a column kit. Efficient digestion was confirmed by electrophoresis in 1% 
agarose gels.  Ligation of the insert and vector was conducted in a 3:1 insert to 
vector molar ratio and a total of 50 ng of vector DNA in a 15 µl reaction including 
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1 µl of T4 DNA ligase, 1.5 µl of 10X T4 reaction buffer (Roche) and incubated for 2 
hours at room temperature. A negative control reaction without DNA insert (self-
ligated vector only) was included.    
The ligation product was then used to transform competent DH5α E. coli cells 
(Thermo) by heat-shock. The cells were plated in agar plates containing ampicillin 
and grown overnight at 37oC. Resistant colonies were picked and grown in 1.5 ml 
L-Broth supplemented with ampicillin. DNA was isolated using a QIAprep Miniprep 
Kit (Qiagen) according to manufacturer’s instructions. Positive clones were 
evaluated for successful insertion by XhoI and EcoRI restriction enzyme digestion 
and gel electrophoresis. Positive clones were grown further overnight in 100 mL 
of ampicillin-supplemented L-Broth. Plasmid DNA was extracted using a Qiaprep 
Maxiprep Kit (Qiagen) according to manufacturer’s instructions. DNA quality and 
quantity were measured using a Nanodrop N-1000 spectrophotometer (NanoDrop 
Technologies). Verification of the insert was confirmed by Sanger sequencing in 
Source BioScience (Cambridge).  
2.4 RNA methods 
2.4.1 RNA isolation, cDNA preparation and quantitative real-
time PCR (qRT-PCR) 
 Total RNA extraction from pituitaries was conducted using the RNeasy 
microkit (Qiagen), including on-column digestion with DNase I (Qiagen cat. 79254). 
Quantity and quality of RNA were also measured using a NanoDrop. cDNA 
transcription was performed on 1 µg of total RNA in a 20µl reaction volume using the 
iScript™ cDNA synthesis kit and according to manufacturer’s instruction. 50ng of 
cDNA were used for each qRT-PCR reaction. Reactions were performed in triplicates 
in 96 well-plates on a CFX96 Touch™ Real-Time PCR Detection System using 
iTaq™ Universal SYBR® Green Supermix (BioRad). Verification of a single product 
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of the appropriate size was conducted by melting curve analysis and electrophoresis 
in 1% agarose gels. The expression of Glyceraldehyde 3-phospate dehydrogenase 
(GAPDH) was used as an expression normaliser. Analysis of expression between 
mutant and wild type expression was conducted by the comparative CT (ΔΔCT) 
method (Livak, 2001). Fold changes were calculated as 2 –ΔΔCt for each sample. qRT-
PCR experiments presented in Chapter 7 were conducted with the help of Dr. Sara 
Pozzi. 
 
Gene Forward (5’-3’) Reverse (5’-3’) 
Cdkn1a CAGATCCACAGCGATATCCA ACGGGACCGAAGAGACAAC 
Cdkn2a CGTGAACATGTTGTTGAGGC GCAGAAGAGCTGCTACGTGA 
Trp53 GCGTAAACGCTTCGAGATGTT TTTTTATGGCGGGAAGTAGACTG 
Il1α CGCTTGAGTCGGCAAAGAAAT TGGCAGAACTGTAGTCTTCGT 
Il1β TGCCACCTTTTGACAGTGATG TGATGTGCTGCTGCGAGATT 
Il6 CAAGAAAGACAAAGCCAGAGTC GAAATTGGGGTAGGAAGGAC 
Ccl20 AGCAACTACGACTGTTGCCT TGACTCTTAGGCTGAGGAGGT 
Cxcl1 CTGGGATTCACCTCAAGAACATC CAGGGTCAAGGCAAGCCTC 
Cxcl2 CCAACCACCAGGCTACAGG GCGTCACACTCAAGCTCTG 
Gapdh ATGACATCAAGAAGGTGGTG CATACCAGGAAATGAGCTTG 
Table 6. List of primers used for quantitative RT-PCR. 
 
2.4.2 RNA In situ hybridization (ISH) in paraffin sections 
Preparation of antisense riboprobes 
 Plasmids were digested for linearization using the appropriate enzymes to 
produce antisense riboprobes (Table 5) and purified using a PCR purification kit 
(Qiagen). Plasmids were run in agarose gels to confirm complete linearization. For 
detection of the riboprobe, RNA transcription was conducted using a nucleotide mix 
containing Digoxigenin-11-2'-deoxy-uridine-5'-triphosphate (DIG-UTP). In this 
manner, DIG is incorporated into the RNA molecule and can be posteriorly detected 
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using antibodies. Transcription reactions consisted of: 1µg of linearized plasmid 
DNA, DIG-RNA labelling mix, 10X transcription buffer, RNase inhibitor, and RNA-
polymerase (T3, T7 or SP6).  Transcription was conducted for 2 hours at 37oC. 1µl 
of the reaction product was run on a 1% agarose gel to verify transcription of a 
product of the appropriate size. Purification of the probe was conducted on CHROMA 
SPIN 100 columns (Clonetech) according to manufacturer’s instructions. 
Probe Enzyme for linearisation Polymerase 
Cxcr4 HindIII SP6 
Cxcr7 SphI SP6 
Cxcl12 SalI T3 
Cxcr2 XhoI T3 
Wnt6 NotI T3 
Bmp4 EcoRI Sp6 
Shh EcoRI T7 
Axin2 NotI T3 
Lhx3 XhoI Sp6 
CXCR2 XhoI T3 
Fgf8 HindIII T3 
Table 7. List of probes used for ISH.  
Cxcr4, Cxcr7, Cxcl12, Wnt6, Bmp4, Shh, Axin2 and Fgf8 antisense riboprobes were 
previously validated (Andoniadou et al. 2012; Sánchez-Alcañiz et al. 2011; 
Andoniadou et al. 2013; Gaston-Massuet et al. 2008). 
 
In situ hybridization in paraffin sections 
 In situ hybridisation was performed as previously described (Andoniadou et 
al. 2012). All solutions were treated overnight with 0.1% di-ethyl-pyrocarbonate 
(DEPC) in double distilled MiliQ water and subsequently autoclaved. Paraffin 
sections were de-waxed in HistoClear (National Diagnostics) and re-hydrated using 
ethanol series. Slides were then fixed for 20 minutes in cold 4% PFA, treated with 
Proteinase K (20ug/ml) for 8 minutes, re-fixed in 4 % PFA and treated with 0.1M 
triethalolamine and 0.25% acetic anhydride. Slides were then de-hydrated and air-
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dried. Antisense riboprobes were diluted 1:100 in 50:50 formamide: 0.3M sodium 
chloride, 20mM Tris-hydrochloric acid, 5mM EDTA, 10% Dextran sulphate, 1X 
Denhardt’s reagent and RNAse inhibitor. Following overnight incubation at 65⁰C, 
slides were washed in high high-stringency conditions in formamide and saline 
sodium citrate washes at 65⁰C. Slides are then blocked in 0.1M Tris-HCl pH 7.5, 
0.15M NaCl solution supplemented with 10% FCS for 1 hour. The detection of DIG-
labelled RNA was conducted using a sheep anti-DIG antibody conjugated to alkaline 
phosphatase at 1:1000 dilution overnight. Subsequently, slides were washed in 0.1M 
Tris-HCl pH 9.5, 0.15M NaCl, 0.05 MgCl2 buffer. Chromogenic detection of 
hybridised probes was conducted by adding nitro-blue tetrazolium chloride (NBT, 4.5 
µl /ml) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP, 3.5 µl/ml) in 10% polyvinyl 
alcohol.  
2.5 Protein methods 
2.5.1 Immunohistochemistry and immunofluorescence on 
paraffin sections  
Immunohistochemical and immunofluorescent stainings were conducted on 6 
µm-thick paraffin sections. Sections were dewaxed and rehydrated using ethanol 
gradients. Epitope unmasking was conducted in an antigen retrieval unit (BioCare 
Medical Decloaking Chamber NXGEN) for 2 minutes at 95⁰C. Optimisation of staining 
conditions were conducted for each primary antibody by testing different antigen 
retrieval buffer solutions: 1) 1 M Sodium Citrate pH 6.0, 2) 1mM EDTA pH 8.0 or 3) 
20 mM Tris, 0.65 mM EDTA, 0.005% Tween pH 9.0. Subsequently, slides were rinsed 
and permeabilised for 5 minutes in PBT (PBS, 0.1% Triton-X). Blocking was 
conducted for 1 hour at room temperature in blocking buffer (PBS, 0.1% Triton-X, 
0.15% Glycine, 0.2% Bovine Serum Albumin (BSA)) supplemented with 10% Heat-
Inactivated Sheep Serum (HISS). Primary antibodies were then incubated overnight 
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at 4⁰C in blocking buffer supplemented with 1% HISS. Primary antibodies, dilutions 
and retrieval conditions are shown in Table 6. After incubation, slides were rinsed 
with PBT and incubated with the appropriate secondary antibodies for 1 hour at room 
temperature. Except for β-catenin, all primary antibodies were detected using biotin-
conjugated secondary antibodies (Dako). For immunofluorescence, the biotinylated 
secondary was detected by incubation with Streptavidin conjugated to a fluorochrome 
such as Alexa-Fluor 555 (Thermo) for 1 hour at room temperature. After washing 
excess antibodies, the slides were subjected to auto fluorescence blocking by 
incubation in 0.1% Sudan Black (Sigma) in 70% EtOH for 2 minutes at RT in 
darkness. Excess Sudan Black was then washed with 0.02% Triton-X in PBS. DNA 
counterstaining was conducted by incubation with 4',6-Diamidino-2-Phenylindole 
(DAPI, Thermo) for 10 minutes at room temperature. For immunohistochemical 
stainings, slides were first incubated with an Avidin-Biotinylated Peroxidase Complex 
(Vector). Chromogenic detection was then conducted by addition of 3,3'-
diaminobenzidine (DAB, Vector) for 2-5 minutes and then counterstained with 
Mayer’s haematoxylin (Sigma). Immunolabelling of EdU uptake in paraffin samples 
was conducted using the EdU Click-It Imaging Kit (Thermo). EdU immunostainings 
with the help of Dr. Christina Stache. Immunostainings for the NF-κB pathway 
characterisation were conducted alongside Dr. Grace Kaushal. Triple 
immunostainings presented in Chapter 7 were conducted with the help of Dr. Alicia 
Villa-Osaba. 
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Target Clonality Clone Company Catalog Number Dilution 
Retrieval 
Method 
4EBP1 
(pThr37/46) Monoclonal 236B4 Cell Signaling 2855 1:200 
Tris-EDTA 
pH9.0 
ACTH Monoclonal N/A Fitzgerald	 N/A 1:1000 
Sodium 
Citrate pH 
6.0 
ATM 
(pSer1981) Monoclonal 
10H11.E
12 NovusBio 
NB100-
306 1:100 
Tris-EDTA 
pH9.0 
CD-31 Polyclonal N/A Abcam ab28364 1:50 Tris-EDTA pH9.0 
Cleaved 
Caspase 3 Polyclonal Asp175 Cell Signaling 9661 1:300 
Tris-EDTA 
pH9.0 
CXCR4 Monoclonal UMB-2 Abcam ab124824 1:200 Tris-EDTA pH9.0 
Cyclin D2 Polyclonal M-20 Santa Cruz sc-593 1:200 Tris-EDTA pH9.0 
DNA PKcs 
(pT2609) Monoclonal 10B1 Abcam ab18356 1:200 
Tris-EDTA 
pH9.0 
E-cadherin Monoclonal 36/E-Cadherin 
BD 
Biosciences 610181 1:200 
Tris-EDTA 
pH9.0 
Endomucin Monoclonal V.5C7 Santa Cruz SC-53941 1:250 Tris-EDTA pH9.0 
FSH Polyclonal N/A DSHB	 N/A 1:1000 
Sodium 
Citrate pH 
6.0 
GFP Polyclonal N/A	 Abcam ab13970 1:300 Tris-EDTA pH9.0 
GH Polyclonal N/A DSHB	 N/A 1:1000 
Sodium 
Citrate pH 
6.0 
GSU Polyclonal N/A DSHB	 N/A 1:500 
Sodium 
Citrate pH 
6.0 
H2AX 
(pSer139) Monoclonal 2F3 Biolegend 613402 
1:400-
1:800 
Sodium 
Citrate pH 
6.0 
H2AX 
(pSer139) Monoclonal JBW301 Millipore 05-636 1:800 
Sodium 
Citrate pH 
6.0 
Histone H3 
(pSer10) Polyclonal N/A Millipore 06-570 1:500 
Tris-EDTA 
pH9.0 
IκBα 
(pSer32/36) Monoclonal 5A5 Cell Signaling 9246 1:100 
Tris-EDTA 
pH9.0 
Ki67 Polyclonal N/A Leica NCL-Ki67p 1:100 Tris-EDTA pH9.0 
Ki67 Monoclonal SP6 Abcam ab16667 1:100 Tris-EDTA pH9.0 
LAMP-1 Polyclonal N/A Abcam ab42170 1:200 Tris-EDTA pH9.0 
LAMP-2 Monoclonal H4B4 Abcam ab25631 1:200 Tris-EDTA pH9.0 
LC3 Polyclonal N/A	 AbD Serotec AHP2167 1:1000 Tris-EDTA pH9.0 
LH Polyclonal N/A DSHB	 N/A 1:500 
Sodium 
Citrate pH 
6.0 
Lysozyme Polyclonal A009 Dako A0099 1:200 Tris-EDTA pH9.0 
Lyzozomal β-
Galactosidase 
(GLB1) 
Polyclonal N/A Proteintech 15518-1AP 1:100 
Tris-EDTA 
pH9.0 
N-cadherin Polyclonal N/A Abcam ab76057 1:100 Tris-EDTA pH9.0 
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P16INK4a Monoclonal JC8 Santa Cruz sc-56330 1:200 Tris-EDTA pH9.0 
P21 Polyclonal M-19 Santa Cruz sc-471 1:400 Tris-EDTA pH9.0 
P53 Polyclonal CM5 Leica NCL-p53-CM5p 1:100 
Tris-EDTA 
pH9.0 
P62/SQSTM1 N/A 
3/P62 
LCK 
LIGAND 
BD 
Biosciences 610833 1:200 
Tris-EDTA 
pH9.0 
P65/RELA Monoclonal D14E12 Cell Signaling 8242 1:200 Tris-EDTA pH9.0 
Pan-
Cytokeratin Monoclonal AE1/AE3 Santa Cruz sc-81714 1:100 
Tris-EDTA 
pH9.0 
PARP-1 Monoclonal F-2 Santa Cruz sc-8007 1:300 Tris-EDTA pH9.0 
Pit1 N/A	 N/A	 DSHB	 N/A	 1:500 Tris-EDTA pH9.0 
PRL Polyclonal N/A DSHB	 N/A 1:1000 
Sodium 
Citrate pH 
6.0 
S6 Ribosomal 
Protein 
(pSer240/244) 
Monoclonal D78F8 Cell Signaling 5364 1:200 Tris-EDTA pH9.0 
SOX2 Polyclonal N/A Millipore AB5603 1:200 Tris-EDTA pH9.0 
SOX9 Polyclonal N/A Millipore AB5535 1:400 Tris-EDTA pH9.0 
Synaptophysin Monoclonal 27G12 Leica 
RTU-
SYNAP-
299 
Ready-
to-use Any 
TPit N/A	 N/A	 Provided	by	Jacques	Drouin	 N/A	 1:200 
Tris-EDTA 
pH9.0 
TSH Polyclonal N/A DSHB	 N/A 1:1000 
Sodium 
Citrate pH 
6.0 
β-Catenin Monoclonal 6F9 Sigma C7082 1:300 Tris-EDTA pH9.0 
β-Catenin Polyclonal N/A Thermo RB-9035-P1	 1:300 Tris-EDTA pH9.0 
Table 8. List of primary antibodies, dilutions and retrieval conditions. 
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2.5.2 Enzyme-Linked Immunosorbent Assay (ELISA) Arrays 
The use of semi-quantitative ELISA cytokine arrays for the detection of SASP 
factors has been previously described (Coppé et al. 2008; Coppé, Patil, et al. 2010). 
Mouse C1000 cytokine arrays (AAM-CYT-1000-4, RayBiotech) were used to quantify 
the expression of SASP factors in protein extracts from whole pituitaries dissected at 
18.5 dpc according to manufacturer’s instructions. For each experimental sample, 
total protein was extracted from 4 pituitaries using a cell lysis solution provided by the 
kit in combination with a TissueRuptor (Qiagen) and passed through a Qiashredder 
column (Qiagen). Samples were centrifuged for 5 minutes at 10000 x g and 
supernatants were then transferred for protein quantification. All extraction 
procedures were conducted on ice. Total protein was then measured using 
BradfordUltra reagent (Expedeon) 1:1 in double distilled MiliQ water using a 
spectrophotometer and actual protein concentrations were determined from a 
standard curve of BSA concentrations. ELISA membranes were blocked for 30 
minutes using blocking buffer provided by the manufacturer and then incubated 
overnight at 4⁰C with 70 µg of total protein after a 7.5X dilution to prevent negative 
effects from detergent present in the cell lysis solution. Membranes were then 
incubated with biotinylated antibodies and subsequently with HRP-Streptavidin and 
provided detection reagents, according to manufacturer’s instructions. Membranes 
were developed for 2 minutes prior to imaging.  
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2.6 Microscopy, Imaging and Statistical Analyses  
Whole-mount imaging was conducted in a Leica MZ FLIII stereomicroscope 
connected to a Leica DC500 camera. Imaging of freshly dissected tumours was 
conducted at 0.8X magnification. For endogenous fluorescence imaging, the 
exposure was set to 3.7 seconds. The scale of the image was then calculated from 
graticule images at the same magnification and Fiji/ImageJ software (Schindelin et 
al. 2012) was used to measure tumour sizes. Tumour diameters were calculated from 
averaging the longest side of the tumour and its perpendicular. 
Immunofluorescent stainings on paraffin sections were visualized with a Leica 
DMLM widefield microscope and imaged with a CoolSnap monochrome camera. 
Visualization of immunohistochemical, ISH and H&E stainings was conducted in a 
Zeiss Axioplan2 microscope and captured with a Zeiss Axiocam HRc colour camera. 
Image processing was conducted using Photoshop CC 2015 (Adobe), which included 
brightness/contrast enhancement and merging of fluorescence channels to produce 
composite images.  
Cell counting from microscope images was conducted manually using 
Fiji/ImageJ and the cell counter plugin. For tumours, a minimum of 3 histologically 
distinct regions were counted and in each region a total of 800-1000 cells were 
counted.  
Cell clusters were counted manually for the quantification of colocalisation of 
senescence markers and clusters. A cluster was defined as group of more than 3 
nucleo-cytoplasmic β-catenin accumulating cells. At least 3 sections from each 
pituitary were counted. Selected sections were considerably apart in distance to 
prevent counting the same cluster more than once (surrounding structures such as 
the brain and the basisphenoid bone were used as reference). Colocalisation of the 
marker was defined as at least 1 cell of the cluster being positive for the marker. 
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For the quantification of EMCN+ area, appropriately scaled photographs of 
EMCN stainings were used and regions of 800-1000 cells were randomly selected 
using Fiji/ImageJ. Using the auto threshold option, a binary image was then created 
and the total area with positive signal contained within the region was calculated.    
Chemiluminescence detection was conducted with a ChemiDoc gel 
documentation system (BioRad) and imaged using ImageLab Software (Version 
5.2.1, BioRad). Different imaging parameters were tested and it was concluded that 
Chemiluminescence/High Resolution/Intense Bands settings provided best results. 
Analysis of high resolution images from each membrane was conducted using 
Fiji/ImageJ and the Protein Microarray Analysis macro (IRB, Barcelona). Overall 
background was subtracted using a 25-pixel rolling-ball radius. Each ELISA spot was 
then circumscribed in identically sized circular regions of interest (ROIs). The 
diameter of the ROI circle was selected to be around 1.5 times larger than the largest 
signal spot in the membrane. Each ROI was then manually centred around the 
chemiluminescent spot, avoiding overlap between ROIs. ROI size was maintained 
consistent to allow comparison between different membranes. The average signal 
value from negative control and blank spots was subtracted from each target spot 
signal value. Normalised signal density for each target spot was then calculated 
according to the following formula: X(NMut) = X(Mut) * P1/P(MUT). Where: P1 is the 
mean signal density for positive control spots on the reference (wild type) array 
membrane; P(MUT) is the mean signal density for the positive control spots on the 
mutant array membrane; X(MUT) is the mean signal density for spot “X” on mutant 
membrane and X(NMUT) is the normalized signal intensity for spot X in the mutant 
array. A fold increase in signal intensity for spot X between the mutant and wild type 
membranes was then calculated as the ratio between X(NMUT) and X(wild type). 
Statistical analysis was conducted using SPSS Statistics software (IBM). Statistical 
significance level was set as 0.05.   
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2.7 Gene-Set Enrichment Analysis (GSEA) and 
hierarchical clustering 
All GSEA analyses were performed using GSEAv. 2.2.0 (Broad Institute) using 
the pre-ranked tool, weighted enrichment statistic and 1000 permutations and 
interpreted according to recommendations found in the original GSEA article 
(Subramanian et al. 2005).    
GSEA assesses where genes in a gene set fall within a list of genes that has 
been ranked according to their expression.  It performs statistical analyses to assess 
whether the ranked gene list is enriched for the genes within the gene set (i.e. they 
are overrepresented either at the top or bottom of the list than would be expected by 
chance alone).  
For human analyses, Laser Capture Microdissection (LCM), RNA isolation, 
RNA amplification and RNAseq raw data processing (as well as hierarchical 
clustering) were conducted by Dr. John Apps. Briefly, RNA-sequencing data was 
obtained from clusters and palisaded-epithelium tissue isolated by laser capture 
microdissection (LCM) conducted on two different human ACP samples. A list of 
17,779 genes was generated by ranking expression from the most upregulated in 
clusters to the most upregulated in palisading epithelium (non-clusters) as determined 
by the DESeq2 method in the bioconductor R package (estimated log2 fold 
change/standard error of log2 fold change using the Wald statistic)(Love et al. 2014). 
 For analysis of data obtained from the Hesx1Cre/+;Ctnnb1lox(ex3)/+ model, 
previously published microarray expression analysis data was used (Andoniadou et 
al. 2012). This microarray data was obtained from dissociated 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;BAT-gal pituitaries and flow sorting for the BAT-gal positive 
and negative populations. This sorting strategy allows to compare the β-catenin 
cluster population versus non-cluster. Expression data was then ranked by gene 
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expression from highest fold-change of expression in clusters compared to non-
clusters also using the Wald statistic (21891 genes). 
Oncogene-Induced Senescence and SASP gene sets were kindly provided by 
Professor Jesús Gil. The OIS geneset was obtained by RNA-sequencing and the 
SASP gene sets was derived from proteomics data, both conducted on human IMR90 
ER: RAS fibroblasts. These cells express an Esteroid Receptor-KRASV12D chimeric 
fusion protein that triggers growth arrest, senescence and SASP when induced 
(Acosta et al. 2013).  
For hierarchical clustering analysis, mouse gene symbols were 
converted to human homologs using BiomaRt (Durinck et al. 2009) and 
merged with human rLog-scaled read counts obtained from DESeq2. Genes 
were filtered for differential expression in between human clusters and non-
clusters according to a log2 fold-change larger than 2 and a p-adjusted-value 
lower than 0.05. Consensus clustering was performed using average 
clustering algorithms in the BioConductor Consensus Cluster Plus package. 
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3. INVOLVEMENT OF CELLULAR 
SENESCENCE AND ITS ASSOCIATED 
SECRETORY PHENOTYPE IN THE NON-CELL 
AUTONOMOUS INDUCTION OF PITUITARY 
TUMOURS 
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3.1 Introduction 
A gain of function mutation in the β-catenin gene (CTNNB1) and the consequent 
accumulation of nucleo-cytoplasmic β-catenin with activation of the Wnt signalling 
pathway in neoplastic cells is characteristic of many tumours and cancers (Reya & 
Clevers 2005). However, in mouse ACP models, cells targeted with oncogenic β-
catenin stop dividing and remain mostly as cell clusters. Indeed, it has been shown 
that  human ACP clusters are not actively dividing (Buslei et al. 2007; Gaston-
Massuet et al. 2011) nor undergo apoptosis (Zhu & You 2015). Why is this small cell 
population spared and persists during tumour progression? Interestingly, the clusters 
in both mice and humans are the source of many secreted factors with well-known 
roles in tumourigenesis and cancer progression, such as: SHH, FGFs, BMPs, WNT 
ligands and a variety of cytokines and pro-inflammatory factors, suggesting that these 
cell structures may play an active role in ACP development (Andoniadou et al. 2012). 
Previous lineage tracing studies conducted in an inducible mouse model 
expressing oncogenic β-catenin in adult pituitary stem cells 
(Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+) unexpectedly revealed the emergence of 
pituitary tumours in a non-cell-autonomous manner (Andoniadou et al. 2013). In this 
study, it was proposed that β-catenin clusters undergo cellular senescence, therefore 
preventing them from further dividing, but also allowing them to acquire a 
Senescence-Associated Secretory Phenotype (SASP) capable of mediating 
oncogenesis in a paracrine manner.  
In order to test this hypothesis, the Hesx1Cre/+;Ctnnb1lox(ex3)/+ model was used to 
assess if conditional expression of oncogenic β-catenin in embryonic pituitary stem 
cells could also induce tumours non-cell autonomously. Moreover, it was investigated 
if this oncogenic process is preceded by the onset of senescence and SASP 
acquisition in targeted cells. The clinical significance of senescence and the SASP in 
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human ACP was evaluated in individual human ACP tissue sections and corroborated 
in tissue microarrays containing 23 different ACP cases and brain tissue as control.  
3.2 Lineage tracing of targeted cells during tumour 
progression in Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+  
Lineage tracing analysis was conducted in Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ 
pituitaries at different stages of tumour development, which are described 
chronologically in this section as: embryonic, early postnatal, intermediate stage 
tumour and end-stage tumour. At embryonic stage 18.5 dpc, the pituitary parenchyma 
was mainly composed of YFP+ cells derived from the Hesx1 lineage (Figure 3.1a), 
while the pituitary stroma resulted negative. Early postnatal pituitaries contained 
anaplastic regions of YFP+ cell islands which intermingled with and expanded YFP- 
stroma. These “pre-tumourigenic” regions were consistently localised ventrally in the 
pituitary anterior lobe (Figure 3.1b, delimited by dotted line). The same pre-
tumourigenic regions could be observed at later postnatal stages with no drastic 
changes, except for occasional cyst formation (Figure 3.1c, delimited by dotted line). 
In intermediate stage tumours, the YFP- tissue expanded and rapidly displaced the 
YFP+ cells, forming a clear boundary between the growing YFP- tumour (Figure 3.1d, 
asterisk) and the normal pituitary tissue (Figure 3.1d, arrow). Importantly, 64.7% of 
observed end stage tumours (N=17) were mostly composed of YFP- cells (Figure 
3.1e, asterisk), while residual YFP+ tissue could still be observed at the periphery of 
these tumours (Figure 3.1e, arrow). The analysis conducted for this thesis focused 
only on YFP negative Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ tumours. 
Double immunostaining for YFP and the proliferation marker Ki67 showed that 
most of the pituitary YFP+ tissue was proliferative at 18.5 dpc (Figure 3.1f), while at 
early postnatal stages scarce Ki67+ cells were present in the pituitary, including pre-
tumourigenic ventral regions (Figure 3.1g-h, delimited by dotted lines). Finally, 
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intermediate-stage and end-stage YFP- tumours showed increased Ki67 positivity 
(Figure 3.1i-j, asterisks), while the residual YFP+ tissue was essentially non-
proliferative (Figure 3.1i-j, arrows). These observations indicate that tumour formation 
occurs after a latency period as a sporadic, rapid wave of proliferation of YFP- cells, 
rather than being a gradual and continuous process. 
Expression analysis of the neuroendocrine marker synaptophysin throughout 
tumour development showed that the parenchyma (which is YFP+) of the pituitary 
anterior lobe was mostly synaptophysin positive at embryonic and early postnatal 
stages (Figure 3.1k-n), while the pituitary stroma was synaptophysin negative (and is 
also negative for YFP). Notably, the ventral pre-tumourigenic regions contained few 
synaptophysin positive cells at early postnatal stages (Figure 3.1m-n, delimited by 
dotted line), suggesting that most of the YFP+ cells present in these regions were 
also undifferentiated. Intermediate stage tumours showed a marked contrast in 
synaptophysin expression where the normal pituitary epithelium stained positive 
(Figure 3.1l, arrow), whereas the growing tumour tissue was negative (Figure 3.1l, 
asterisk). End-stage tumours were mostly negative for synaptophysin (Figure 3.1o, 
asterisk), while peripheral regions contained residual positive cells (Figure 3.1o, 
arrow in inset), delineating these as undifferentiated tumours, as previously reported 
(Gaston-Massuet et al. 2011). Therefore, the lack of synaptophysin expression 
discriminates pre-tumourigenic regions and full-grown tumours from normal pituitary 
tissue, and suggests that end-stage tumours are derived from cells present in these 
synaptophysin-negative pre-tumourigenic areas.  
Previous characterisation of the Hesx1Cre/+;Ctnnb1lox(ex3)/+ model revealed that 
the nucleo-cytoplasmic β-catenin accumulating clusters are present throughout 
embryonic pituitary development, from 9.5 dpc to 18.5 dpc and after birth at postnatal 
day 11 (Gaston-Massuet et al. 2011). Analysis of the expression of β-catenin at 
different stages of tumour development by immunofluorescence revealed that these 
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clusters were still present at later postnatal stages and that they were mainly localised 
in the ventral pre-tumourigenic regions (Figure 3.1q-r, arrows). Interestingly, 
intermediate and end-stage pituitary tumours expressed high levels of β-catenin 
(Figure 3.1s-t, asterisks), suggesting activation of the Wnt signalling pathway, 
although it was mostly cytoplasmic accumulation (unlike the nucleo-cytoplasmic 
pattern found in the original clusters). Importantly, at intermediate tumour stages, the 
number of β-catenin clusters found in tissue sections was markedly reduced (Figure 
3.1s, arrow in inset), while none could be detected in the end-stage tumours. 
Therefore, the β-catenin clusters are preserved during embryonic and early postnatal 
stages of tumour formation, until a point where they become dispensable for tumour 
formation and progression. 
In conclusion, pituitary embryonic progenitors bearing the oncogenic β-catenin 
mutation do not give rise to a proportion of Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+  pituitary 
tumours cell-autonomously, further supporting the paracrine-tumourigenesis model 
derived from lineage tracing experiments in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice 
(Andoniadou et al. 2013). This observation also suggests that both mouse models 
share a common and age-independent mechanism, where oncogenic β-catenin 
activation in pituitary stem cells leads first to cell cluster formation, after which pituitary 
tumours can arise from a non-targeted population. 
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Figure 3.1 Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary tumours are not derived from 
targeted embryonic progenitors nor display a differentiated phenotype. 
(a-e) Fluorescent immunostaining for YFP in representative specimens at different 
stages of tumour development, showing that most of the pituitary anterior lobe 
parenchyma is derived from the Hesx1 lineage (YFP+) at embryonic (a) and early 
postnatal stages (b,c), while the stroma is YFP-. Note the presence of anaplastic 
regions localised ventrally in the anterior lobe of early postnatal stages (delimited from 
normal pituitary tissue by dotted line). Intermediate (d) and end-stage tumours (e) 
show a drastic expansion of the YFP- population. (f-j) Double immunofluorescence 
for the proliferation marker Ki67 and YFP at different stages of development, showing 
that the embryonic pituitary contains YFP+ proliferating cells (f), while the early 
postnatal stages have low numbers of Ki67+ cells (g,h). Intermediate and end-stage 
tumours possess large numbers of Ki67+ cells present mostly in YFP- regions (i,j 
respectively). (k-o) Immunohistochemistry for the neuroendocrine marker 
synaptophysin show positive cells in the anterior lobe parenchyma of embryonic (k) 
and early postnatal pituitaries (m,n), while their stroma is negative. Note that ventral 
anaplastic regions contain mostly non-differentiated cells (m,n; delimited by dotted 
line). Intermediate and end-stage tumours do not contain synaptophysin positive cells 
(l,o; asterisks) except in residual peripheral regions (l,o; arrows). (p-t) 
Immunofluorescence for β-catenin shows the presence of nucleo-cytoplasmic β-
catenin accumulating clusters at 18.5 dpc (p) exclusively in the ventral pre-anaplastic 
regions of early postnatal pituitaries (q,r; arrows). Cytoplasmic β-catenin 
accumulation can be observed in growing intermediate and end-stage tumours (s,t; 
asterisks), while stereotypical clusters could rarely be observed in peripheral regions 
(s, arrow). al: anterior lobe; il: intermediate lobe; pl: posterior lob; dpc: days post 
coitum; wk: weeks. Scale bars: a, 250 μm; b,c,d, 100 μm. 
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3.3 Characterisation of the senescent phenotype in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and human ACP cell clusters 
Cellular senescence is a complex state that cannot be defined by a single 
molecular marker (Sharpless & Sherr 2015; Campisi 2013; Collado & Serrano 2010). 
Therefore, the presence of several well-established markers that reflect key biological 
processes of the senescent phenotype was evaluated in vivo with focus on the β-
catenin clusters. These include markers of cell proliferation, DNA replication, 
lysosomal activity, DNA damage and the Senescence-associated Secretory 
Phenotype (SASP). Analysis of crucial pathways related to, or known to mediate 
these processes, such as the DNA-Damage Response (DDR), the NF-κB pathway, 
mTOR signalling and autophagy, was also conducted. Finally, an in vivo 
characterisation of the progression of the senescent phenotype at different stages of 
embryonic pituitary development was performed to gain a better understanding of the 
evolution of the senescent phenotype in this context, as current understanding of the 
development of the senescent phenotype derived mainly from in vitro experiments. 
3.3.1 Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters contain cells that are 
viable and non-proliferative  
It was previously shown that the clusters of Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries 
at 18.5 dpc do not express the proliferation marker Ki67, suggesting a quiescent state 
(Gaston-Massuet et al. 2011). To confirm the absence of proliferation at this stage, 
immunostaining was performed for the mitosis marker phospho-histone H3 (p-HH3) 
and 5-ethynyl-2'-deoxyuridine (EdU). These experiments showed the general lack of 
colocalisation of phospho-histone H3 (Figure 3.2a, 2.94% colocalisation, N=34 
clusters in 3 embryos) and EdU (Figure 3.2b, 2.5% colocalisation, N=35 clusters in 3 
embryos) with the β-catenin clusters at 18.5 dpc. Additionally, colocalisation between 
β-catenin clusters and the apoptosis marker activated cleaved caspase 3 (CASP3) 
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could only be observed in single cells in a minority of clusters (Figure 3.2c, 6.98% 
colocalisation, N=43 clusters in 3 embryos). Therefore, the vast majority of nucleo-
cytoplasmic β-catenin accumulating cell clusters in Hesx1Cre/+;Ctnnb1lox(ex3)/+  
pituitaries do not divide, do not replicate their DNA nor undergo programmed cell 
death at 18.5 dpc, suggesting a senescent phenotype.  
 
Figure 3.2 Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryonic pituitaries at 18.5 dpc contain 
nucleo-cytoplasmic accumulating β-catenin clusters that are non-proliferating 
and non-apoptotic.  
(a-b) Double immunofluorescence for proliferation markers phosphorylated histone 
H3 (p-HH3) and EdU showing presence of proliferating cells in the pituitary’s anterior 
lobe but not in β-catenin clusters (arrows). (c) Activated caspase 3 staining shows 
absence of apoptosis in clusters (arrows). Scale bars: 50 μm.  
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3.3.2 Characterisation of the lysosomal compartment in β-
catenin clusters 
 The most widely used method for identifying senescent cells is the 
senescence-associated β-galactosidase detection assay (SA-β-Gal) at pH 6.0 (Dimri 
2005; Debacq-Chainiaux et al. 2009). This assay produces a blue coloured 
precipitate in cells containing large amounts of lysosomal β-galactosidase. SA-β-Gal 
staining of Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries at postnatal day 7 revealed a strong 
positive signal in round cellular formations of the pituitary anterior lobe resembling β-
catenin clusters (Figure 3.3a, arrow), whereas in matching wild type pituitaries only 
the posterior lobe (which contains neuropeptide secreting axons) and the pituitary 
stroma showed a faint blue signal. In order to better show colocalisation between this 
senescence marker and the β-catenin clusters, double immunostaining experiments 
were conducted  using an antibody directed against the enzyme responsible for the 
SA-β-Gal activity (encoded by the GLB1 gene in mice and humans) (Lee et al. 2006).  
Fluorescent immunostaining for GLB1 in 18.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries showed that the pituitary parenchyma itself contains GLB1 protein, possibly 
reflecting the secretory nature of  pituitary endocrine cells. However, an evident and 
strong punctuated signal colocalised with β-catenin clusters in the anterior lobe 
(Figure 3.3b, arrows, 62% colocalisation, N=60 clusters in 4 embryos). These results 
were recapitulated in human ACP samples, where positive GLB1 staining localised 
mostly with the β-catenin clusters (Figure 3.3c, arrows; Figure 3.4a, arrow, 100% 
colocalisation, N=16 clusters). 
Because the accumulation of lysosomal β-galactosidase that characterises 
senescent cells is a reflection of the overall increase of the lysosomal compartment 
(Kurz et al. 2000), an assessment of other lysosomal markers was conducted. Double 
immunofluorescence for β-catenin and lysosomal markers LAMP1 and Lysozyme C 
also showed their expression in the pituitary parenchyma, although the strongest 
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signal was localised to the β-catenin clusters (Fig 3.3d, arrows; 82% colocalisation 
for LAMP1, N=62 clusters in 4 embryos). Moreover, these patterns were also 
observed in human ACP sections where both LAMP1 and Lysozyme C colocalised 
with nucleo-cytoplasmic β-catenin clusters (Figure 3.3e, arrows; 100% colocalisation 
for LAMP1, N=12 clusters; 100% colocalisation for Lysozyme, N=7 clusters). 
Additionally, the expression of another crucial lysosomal component, LAMP2, was 
observed to accumulate in human ACP clusters (Figure 3.4 b, arrow; 100% 
colocalisation, N=21 clusters).  
In summary, although the expression of lysosomal markers was observed in 
different compartments of the Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary and human ACP, 
their accumulation could be detected  in nucleo-cytoplasmic accumulating β-catenin 
clusters in an objective manner. This suggests that these cells have an expanded 
lysosomal compartment, which is a characteristic of metabolically-active senescent 
cells. 
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Figure 3.3 β-catenin clusters of the embryonic mouse ACP model possess an 
expanded lysosomal compartment, a characteristic of senescent cells. 
 (a) Senescence-Associated β-Galactosidase (SA-β-Gal) staining at pH 6.0 (blue 
staining, eosin counterstain) in wild-type and mouse ACP postnatal day 7 pituitaries. 
SA-β-Gal staining faintly labels the posterior lobe and stroma in wild type pituitaries, 
while it strongly labels round structures resembling β-catenin clusters in mutant 
pituitaries (arrow, inset). (b-c) Double immunofluorescence for β-catenin and 
lysosomal β-Galactosidase (GLB1) shows accumulation of GLB1 puncta in the 
nucleocytoplasmic accumulating β-catenin clusters (arrows) of 18.5 dpc mouse ACP 
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pituitaries (b) and human ACP (c).  (d-e) Lysosomal proteins LAMP1 and Lysozyme 
C also accumulate in the clusters of 18.5 dpc mouse ACP pituitaries (d) and human 
ACP (e). Scale bars: a, 200 μm; b, 50 μm (inset: 25 μm); c,d, 50 μm; e, 100 μm . pl: 
posterior lobe, il: intermediate lobe, al: anterior lobe. Merged figures: DAPI 
counterstain. 
 
 
Figure 3.4. Human ACP clusters express LAMP2 an essential lysosome 
component. 
Double immunostaining for β-catenin and lysosomal markers GLB1 and LAMP2 (a-
b) in human ACP sections shows colocalisation with β-catenin accumulating clusters. 
Scale bars: 100 μm. Merged figures: DAPI counterstain. 
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3.3.3 Cell cycle inhibitor expression in β-catenin clusters 
The p53/p21 and p16/Rb pathways are main drivers of the senescent cell-cycle 
arrest (Serrano et al. 1997; Ventura et al. 2007; Sarkisian et al. 2007; Feldser et al. 
2010), therefore it was investigated if β-catenin clusters show an increased 
expression of the cell cycle inhibitors p16, p21 and p53 in both 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries at 18.5 dpc and in human ACP. In the mouse, all 
observed β-catenin clusters contained p16, p21 and p53 positive cells (Figure 3.5a-
c, arrows). Quantification of p16 and nucleo-cytoplasmic β-catenin showed that 89% 
of cluster cells were p16 positive (Spearman correlation coefficient R=0.929, p<0.001, 
N= 209 cells), while 77% of cluster cells were p21 positive (Spearman correlation 
coefficient R=0.926, p<0.001, N=143 cells). 
In human ACP, p16 was detected in mainly in cells of the palisaded epithelium 
and within β-catenin clusters (Figure 3.5d, arrows; 93% colocalisation, N=29 
clusters). Positive staining for p21 was almost exclusively found in cluster cells 
(Figure 3.5e, arrows; 94% colocalisation, N=32 clusters), while p53 protein was 
detected in various cells in both glial reactive tissue and the tumour parenchyma, 
including β-catenin clusters where the staining intensity was strongest (Figure 3.5f, 
arrows; 100% colocalisation, N= 16 clusters). The co-expression of these crucial cell-
cycle inhibiting proteins suggests that a stable senescent phenotype is enforced by 
the p53/p21 and p16/Rb pathways in both murine and human β-catenin clusters. 
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Figure 3.5 β-catenin clusters have elevated expression of cell cycle inhibitors.  
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(a-c) Double immunofluorescence shows accumulation of p16, p21 and p53 with β-
catenin clusters of the embryonic mouse ACP model at 18.5 dpc (arrows). (d-f) 
Results are recapitulated in human ACP clusters (arrows). Scale bars: a-c, 25 μm; d-
f, 100 μm. Merged figures: DAPI counterstain. 
 
3.3.4 DNA damage and the DNA damage response (DDR) in β-
catenin clusters 
The acquisition of DNA damage by the β-catenin clusters was evaluated 
through the expression of the well-established DNA damage marker γ-H2A.X, which 
accumulates at double-strand break sites (Bonner et al. 2008). Additionally, the 
expression of PARP-1 and phospho-DNA-PKcs, two other key DDR effectors, was 
analysed. Strong positive staining for γ-H2A.X was observed in the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters at 18.5 dpc (Figure 3.6a, arrow) and in cells 
dispersed throughout the pituitary anterior lobe. Furthermore, phosphorylated-DNA-
PKcs and PARP-1 positive staining was exclusively observed within the murine 
clusters (Figure 3.6b-c, arrows). These results were recapitulated in human ACP 
samples where γ-H2A.X, PARP-1 and phospho-DNA-PKcs immunostaining 
consistently colocalised with nucleo-cytoplasmic β-catenin (Figure 3.6 d,e,f 
respectively, arrows). 
Another factor shown to be crucial for the activation of the DDR is the protein 
kinase ATM (Aird et al. 2015). Although, the detection of this protein by 
immunofluorescence was not successful in the mouse tissue, it was possible to label 
phosphorylated ATM in human ACP tissue, where it was found to colocalise mainly 
with β-catenin clusters (Figure 3.7b). Collectively, these results indicate that both 
murine and human β-catenin clusters undergo DNA-damage and activate the DDR, 
further supporting a senescent phenotype in these cellular structures.  
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Figure 3.6 β-catenin clusters express markers of DNA damage and the DNA-
damage response (DDR).  
(a-c) Double immunofluorescence for DNA damage marker γH2A.X and DDR 
effectors DNA-PKcs and PARP-1 shows colocalisation with nucleo-cytoplasmic 
accumulating β-catenin clusters in 18.5 dpc mouse ACP pituitaries (arrows). (d-f) 
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Colocalisation of DNA-damage marker expression and β-catenin clusters is 
recapitulated in human ACP (arrows). Scale bars: a-c, 75 μm; d-f, 125 μm. Merged 
figures: DAPI counterstain. 
 
 
Figure 3.7 Human ACP clusters express the essential DNA-damage response 
element ATM.  
Double immunostaining for β-catenin and DNA-damage indicators γ-H2A.X (a) and 
phosphorylated ATM (b) in human ACP sections shows positive staining 
colocalisation with the β-catenin clusters (arrows). Scale bars: 100 μm. Merged 
figures: DAPI counterstain. 
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3.4 Characterisation of the mTOR and autophagy 
pathways 
3.4.1 Hesx1Cre/+;Ctnnb1lox(ex3)/+   and human ACP clusters differ 
in their expression of key mTOR effectors 
The mTOR pathway has been shown to be involved in the establishment of 
cellular senescence (Castilho et al. 2009) and also to mediate the SASP (Laberge et 
al. 2015; Herranz et al. 2015). The activation of the mTOR pathway can be 
determined by assessing the presence of phosphorylated ribosomal protein S6 (pS6) 
and phosphorylated 4E-BP1 (p4E-BP1). In Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries, pS6 
expression was observed throughout the anterior and intermediate lobes of the 
pituitary gland, mostly as scattered single cells. Particularly, around 50% of  β-catenin 
clusters were positive for p-S6 (Figure 3.8a, arrows), while the rest did not contain 
positively labelled cells (Figure 3.8a, arrowheads). On the other hand, p4E-BP1 
expression was only observed in rare occasions confined to scattered single cells in 
the anterior lobe (Figure 3.8b, arrows), while expression in the β-catenin clusters was 
not observed (Figure 3.8b, arrowheads). However, positive p4E-BP1 cells were 
observed in the hypothalamic region of the brain, mainly in cells lining the third 
ventricle (Figure 3.8b, inset), serving as a positive control and showing that p4E-BP1 
immunostaining worked properly in mouse tissue. 
Analysis of human ACP samples revealed a striking contrast with the mouse 
model. While pS6 protein expression never colocalised with the β-catenin clusters, it 
was consistently observed in the palisaded epithelium (Figure 3.8c, arrows), in 
proximity to the clusters (Figure 3.8c, arrowheads), as well as in reactive tissue. 
Conversely, the expression pattern of p4E-BP1 was more variable in human samples, 
where positive signal was observed in a proportion (~50%) of β-catenin clusters 
(Figure 3.8d, arrows) as well as in the palisaded epithelium. 
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In summary, the expression pattern of pS6 in murine clusters resembled more 
that of p4E-BP1 in human ACP, as pS6 is restricted to the palisaded epithelium 
adjacent to the human ACP clusters. These results suggest that mTOR signalling 
may play a role in ACP pathogenesis, in both Hesx1Cre/+;Ctnnb1lox(ex3)/+ and humans, 
but through different mechanisms and cellular compartments.  
 
Figure. 3.8 The mTOR signalling pathway is activated in β-catenin clusters of 
murine and human ACP through different downstream effectors. 
 (a) Phosphorylated ribosomal protein S6 (pS6) positive staining is observed in 
scattered cells of the pituitary anterior lobe at 18.5 dpc. A number of β-catenin clusters 
contain pS6 expressing cells (arrow), while others are negative (arrowhead). (b) 
Phosphorylated 4E-BP1 staining is not observed in most of the anterior lobe tissue, 
including the clusters (arrowhead), but was observed occasionally in single cells 
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(arrow) and consistently expressed in neurons of the lining of the third ventricle of the 
hypothalamus (inset). (c) Staining for pS6 in human ACP shows absence of 
colocalisation with β-catenin clusters (arrowheads), while the palisaded epithelium 
adjacent to the clusters shows strong positive pS6 staining (arrow). (d) Positive 
staining for phosphorylated 4E-BP1 is found in the clusters of human ACP (arrow). 
Scale bars: a,b 50 μm; c,d 100 μm. Merged figures: DAPI counterstain. 
 
3.4.2 The autophagy pathway in β-catenin clusters 
The autophagy pathway is a main target of mTOR, which has been implicated 
in the regulation of senescence and the SASP (Dörr et al. 2013; Kang et al. 2015). 
The status of the autophagic machinery in β-catenin clusters was investigated by 
immunostaining for key autophagy markers p62/SQSTM1 (a downstream target of 
the pathway) and LC3 (a crucial component of the autophagosome). Both p62 and 
LC3 were observed throughout the anterior lobe epithelium of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ 18.5 dpc pituitaries. However, only P62 appeared to 
accumulate in the clusters (Figure 3.9a-b, arrows), while LC3 staining was reduced 
in the β-catenin clusters (Figure 3.9c-d; arrowheads) compared to the surrounding 
pituitary epithelium, which was strongly positive for this marker. In human ACP, P62 
colocalised with β-catenin clusters (Figure 3.9e-f, arrows), as well with the palisaded 
epithelium. Additionally, LC3 positive staining appeared to colocalise specifically in 
the β-catenin clusters (Figure 3.9g-h, arrows) within the tumour tissue, as well as in 
the reactive glial tissue surrounding the tumours. In conclusion, p62 protein 
expression was found to accumulate in the β-catenin clusters of both mouse and 
human ACP, while LC3 only accumulated in the human clusters.    
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Figure 3.9 The expression of autophagy markers in β-catenin clusters differs 
between mouse and human ACP.  
Double immunofluorescence for components of the autophagy pathway in Hesx1Cre/+; 
Ctnnb1lox(ex3)/+ pituitaries at 18.5 dpc and human ACP (DAPI counterstain in merge). 
(a-b) p62/SQSTM staining is observed throughout the pituitary epithelium, including 
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the β-catenin clusters (arrows), while the pituitary stroma is mainly negative. (c-d) 
Expression of the essential autophagosome component LC3 in β-catenin clusters 
(arrowheads) is clearly reduced in comparison to the surrounding pituitary epithelium. 
(e-f) In human ACP, p62/SQSTM1 is expressed in the palisaded epithelium and in 
the β-catenin accumulating clusters (arrows). (g-h) Increased LC3 protein expression 
was observed in human ACP clusters (arrows) and in surrounding reactive glial 
tissue. Scale bars: a-f, 50 μm; g-h, 100 μm. Merged figures: DAPI counterstain.  
 
3.5 Characterisation of the NF-κB pathway and the 
SASP in Hesx1Cre/+;Ctnnb1lox(ex3)/+ and human ACP 
clusters 
3.5.1 The NF-κB pathway in β-catenin clusters 
Activation of the NF-κB pathway is essential for induction and maintenance of 
the SASP (Acosta et al. 2008; Ohanna et al. 2011; Chien et al. 2011; Freund et al. 
2011). Therefore, the activation of the NF-κB pathway in cluster cells was evaluated 
by using antibodies against key pathway members such as RelA/p65, phosphorylated 
IkBα and NEMO/IKKγ. Immunostaining for RELA/P65 revealed that this protein was 
expressed throughout the pituitary parenchyma and stroma, including in the β-catenin 
clusters of Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos at 18.5 dpc (Figure 3.10a, arrows). 
Importantly, phosphorylated IkBα was mainly localised to the β-catenin clusters 
(Figure 3.10b, arrows), although single positive cells were also observed scattered 
around the pituitary tissue. Additionally, IKKγ (NEMO) was also detected throughout 
the pituitary anterior lobe, including the β-catenin accumulating clusters (Figure 3.10c, 
arrows). Expression analysis in human ACP samples showed that RELA was 
expressed in various cell compartments of the tumour, such as the palisaded 
epithelium, but a clear accumulation was observed in β-catenin accumulating clusters 
(Figure 3.10d, arrows). Moreover, a robust accumulation of phospho-IkBα and NEMO 
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proteins was observed in the β-catenin clusters of human ACP samples (Figure 
3.10d-e, arrows). In summary, oncogenic β-catenin leads to the activation of the NF-
κB pathway in senescent β-catenin accumulating clusters in both 18.5 dpc 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries and human ACP.  
 
Figure 3.10 Activation of the NF-κB pathway occurs in β-catenin clusters from 
mouse and human ACP.  
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Double immunofluorescence for key members of the NF-κB pathway shows they are 
expressed in β-catenin clusters. (a) Staining for RELA/P65, (b) phosphorylated IκBα 
and (c) NEMO shows colocalisation with clusters in 18.5 dpc mouse ACP pituitaries 
(arrows). (d-f) The clusters of human ACP also show increased expression of NF-κB 
pathway effectors (arrows). Scale bars: a,b,c 50 μm; d,e,f 100 μm. Merged figures: 
DAPI counterstain. 
 
3.5.2 SASP factors are overexpressed in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+  pituitaries and human ACP 
The demonstration of a senescent phenotype and the activation of the NF-κB 
pathway in β-catenin accumulating clusters suggested that they develop a 
Senescence-Associated Secretory Phenotype (SASP) responsible for driving 
paracrine tumourigenesis. Previously published data showed that the β-catenin 
clusters of the Hesx1Cre/+;Ctnnb1lox(ex3)/+  (Andoniadou et al. 2012) and 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+  (Andoniadou et al. 2013) models are the source of a wide 
variety of secreted factors able to promote inflammation and oncogenesis, some of 
which are well recognised SASP members. Detection of the SASP factors in the β-
catenin clusters was unsuccessfully attempted by immunohistochemistry and in situ 
hybridisation. However, an unbiased analysis for senescence and SASP gene 
expression was conducted using previously published expression microarray data 
(Andoniadou et al., 2012; Accession E-MEXP-3492). Microarray data was derived 
from dissociated 18.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+;BAT-gal pituitaries, which were 
then flow-sorted for the BAT-gal positive and negative populations. The BAT-gal 
mouse is a reporter of Wnt/β-catenin pathway activation that expresses E,coli β-
galactosidase under the control of a tandem repeat of LEF1/TCFs consensus binding 
sites (Maretto et al. 2003). This sorting strategy allowed to produce RNA expression 
data comparing the β-catenin cluster population (BAT-gal+ve) versus non-cluster 
cells (BAT-gal –ve).  
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Gene Set Enrichment Analysis (GSEA) showed that genes associated with 
oncogene-induced senescence (OIS) and the SASP were significantly enriched in the 
mouse β-catenin clusters (Figure 3.11a) (see Materials and Methods for details of the 
reference data sets). Validation of key SASP members IL1a, Il1b, IL6, Cxcl1, CCL20 
and Tgfb1 by qRT-PCR confirmed that their expression was significantly upregulated 
in Hesx1Cre/+;Ctnnb1lox(ex3)/+  pituitaries at 18.5 dpc when compared to wild types 
(p<0.05, Student’s t test) (Figure 3.11b). Additionally, the expression of 96 different 
inflammatory cytokines and chemokines in whole pituitary extracts was quantified 
using ELISA microarrays (Figure 3.11c). Comparison between 
Hesx1Cre/+;Ctnnb1lox(ex3)/+  18.5 dpc pituitaries and wild-type littermates showed 
upregulation (up to 8-Log2 fold change) of 17 factors previously recognised as 
hallmark SASP factors (Coppé, Desprez, et al. 2010). 
A similar analysis was conducted in human ACP samples by performing RNA-
sequencing of laser-microdissected (LCM) β-catenin clusters (using surrounding 
palisaded epithelium as non-cluster comparison) from two ACP cases. LCM and 
RNAseq data processing, as well as hierarchical clustering were conducted by John 
Apps. GSEA using ranked gene lists was conducted by the candidate. GSEA of the 
human cluster vs. non-cluster data revealed that the OIS and SASP gene sets were 
also significantly enriched in the β-catenin cluster fraction (Figure 3.11d). Importantly, 
when human and mouse gene expression profiles were compared by hierarchical 
clustering, it was observed that murine and human clusters grouped together, 
whereas the mouse non-cluster signature grouped with human non-cluster tissue 
(Figure 3.11e). This analysis indicates that mouse and human clusters share overall 
similar gene expression profiles, including an enrichment for OIS and SASP genes, 
which further supports the relevance of the embryonic mouse ACP model.  
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Figure 3.11 Mouse and human ACP clusters are similar structures with 
enriched gene expression for oncogene-induced senescence (OIS) and the 
Senescence Associated Secretory Phenotype (SASP) signatures. 
 (a) Gene Set Enrichment Analysis (GSEA) of differentially upregulated genes in β-
catenin clusters of 18.5 dpc mouse APC pituitaries shows enrichment for the OIS and 
SASP gene sets produced in human senescent fibroblasts. (b) qRT-PCR for cell cycle 
inhibitors Cdkn1a (p21) and Cdkn2a (p16) as well as key SASP factors Il1a, Il1b, Il6 
Cxcl1, Ccl20 and Tgfb1 shows their upregulation in 18.5 dpc mouse ACP pituitaries 
compared to wild type pituitaries (n=3). (c) Heat map showing log2-fold changes in 
protein content of 95 inflammatory cytokines and soluble factors between 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and wild type pituitaries at 18.5 dpc (n=2). Asterisks indicate 
upregulated factors previously recognised as part of the SASP.  (d) Genes 
upregulated in human ACP laser capture micro-dissected β-catenin clusters also 
show enrichment for the OIS and SASP signatures.  (e) Hierarchical clustering 
analysis shows that the clusters of mouse and human ACP group together and vice 
versa for non-cluster tissues. NES: Normalized Enrichment Score; FDR: False 
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Discovery Rate; OIS: Oncogene-Induced Senescence; SASP: Senescence-
Associated Secretory Phenotype. 
 
3.6 Dynamics of cellular senescence during pituitary 
oncogenesis 
3.6.1 Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters stop dividing and 
replicating their DNA early in pituitary development  
To gain a better understanding of the in vivo senescence process in murine β-
catenin clusters, an analysis of the senescent phenotype was conducted at different 
stages of pituitary embryonic development. DNA replication was assessed by EdU 
uptake 90 minutes after injection at the specified stage. As previously shown (Figure 
3.2b), mutant pituitaries did not contain clusters with EdU positive cells at 18.5 dpc. 
However, EdU staining colocalised with β-catenin accumulating cells at 10.5, 12.5, 
14.5 and 16.5 dpc, indicating that β-catenin clusters contain few cells that replicate 
their DNA before 18.5 dpc (Figure 3.12a, arrows). Quantification of total EdU+ cluster 
cells showed that at 10.5 dpc 33% of cluster cells were EdU+, in comparison with 
6.45% at 14.5 dpc and 2.5% at 18.5 dpc. Ki67 immunostaining revealed that most 
clusters had exited the cell cycle by 12.5 dpc (Figure 3.12b), as Ki67 and nucleo-
cytoplasmic β-catenin were found to colocalise evidently only at 10.5 dpc (Figure 
3.12b, arrowhead). Quantification of Ki67+ cluster cells showed that 12% of cluster 
cells were positive at 10.5 dpc., while at 14.5 and 18.5 dpc., this proportion was 
reduced to 2.6% and 2%, respectively. 
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Figure 3.12 The expression of proliferation markers in β-catenin clusters has a 
dynamic profile during pituitary embryonic development.  
(a) Double immunofluorescence for EdU (indicative of DNA replication) and β-catenin 
shows colocalisation in the clusters at 10.5, 12.5 and 16.5 dpc (arrows) but not at 
18.5 dpc. (b) Ki67+ staining (indicative of cell cycle progression) is only observed to 
colocalise with clusters at 10.5 dpc and not at later stages (DAPI counterstain). RP= 
Rathke’s Pouch, VD= Ventral Diencephalon, 3V=Third ventricle, il= intermediate lobe 
of the pituitary, al= anterior lobe of the pituitary.  
 
3.6.2 Cell cycle inhibiting pathways are active in clusters 
throughout pituitary development 
The absence of Ki67 in the clusters after 12.5 dpc suggested that the activation 
of cell cycle inhibiting pathways occurs early in pituitary development. This hypothesis 
was investigated by immunofluorescence for the crucial effectors p16 and p21 at 
different stages of development. Expression of both p21 and p16 in β-catenin clusters 
was observed at all analysed stages (Figure 3.13a), suggesting that cell cycle 
inhibitor expression is an acute response of the activation of the β-catenin oncogene. 
Quantification of p21 expression in cluster cells showed that the proportion of p21+ 
cluster cells was 73.3% at 10.5 dpc, 75% at 14.5 dpc and 76% at 18.5 dpc.  
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Figure 3.13 The cell cycle inhibitors p21 and p16 are expressed in β-catenin 
clusters throughout embryonic pituitary development.  
Double immunostaining for main cell cycle inhibitors and β-catenin at different stages 
of development in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. (a) p21 positive staining 
colocalises with nucleo-cytoplasmic β-catenin accumulating cells at all analysed 
stages (10.5, 12.5, 14.5 16.5 and 18.5 dpc). (b) p16 expression is observed 
exclusively in β-catenin clusters at all stages analysed. VD= Ventral diencephalon, 
RP= Rathke’s Pouch. DAPI counterstain. 
 
3.6.3 Other senescence-associated markers have a dynamic 
expression profile in β-catenin clusters during pituitary 
development 
An analysis of additional important cellular senescence markers (shown in this 
chapter to be expressed at the 18.5 dpc stage) was conducted at different 
developmental stages. Interestingly, the expression of GLB1 (SA-β-Gal) was not 
observed until 16.5 dpc, indicating that there is a progressive accumulation of 
lysosomal β-galactosidase within the β-catenin clusters in the mouse (Figure 3.14a). 
Importantly, elevated expression of GLB1 protein was detected in the form of puncta 
in cells of the mesonephric tubules in 14.5 dpc embryos (Figure 3.15), a pattern that 
coincides with increased levels of SA-β-Gal expression in these structures as 
previously reported (Storer et al. 2013), validating the absence of GLB1 accumulation 
in the β-catenin clusters at this stage. Additionally, expression of the DNA-damage 
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response marker DNA-PKcs, was observed at all analysed stages with no clear 
change in staining intensity (Figure 3.14b). Similar results were obtained for 
phosphorylated IkBα, which colocalised with all β-catenin clusters at each stage 
analysed (Figure 3.14c). The results presented in this section suggest that while the 
expression of some markers of the senescent phenotype might be a direct response 
to the activation of the β-catenin oncogene (DNA-damage, cell cycle inhibitor 
expression and NF-κB activation), others, such as the lysosomal compartment and 
DNA replication, show a dynamic progression during pituitary development. 
 
 
Figure 3.14 There is a dynamic behaviour in the expression of senescence-
associated markers in the β-catenin clusters throughout embryonic pituitary 
development. 
Double immunostaining for markers of senescence and β-catenin at different stages 
of development in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. (a) An accumulation of GLB1 
staining is observed only at the 16.5 and 18.5 dpc stages (arrows). (b) Positive 
staining for the DNA-Damage Response marker DNA-PKcs is observed at all 
observed stages. (c) Activation of the NF-κB pathway in clusters is observed by 
accumulation of phospho-IkB staining at 12.5, 14.5, 16.5 and 18.5 dpc stages. 
Negative clusters can be observed at the 10.5 dpc stage (arrowhead). DAPI 
counterstain. 
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Figure 3.15 Specific detection of GLB1 protein at embryonic stage 14.5 dpc.  
Double immunostaining for GLB1 in different regions of a Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
embryo at 14.5 dpc. Note the absence of GLB1 accumulation in the β-catenin clusters 
at this stage in the pituitary gland, while the mesonephric tubules still show protein 
accumulation. Merged figures: DAPI counterstain. 
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3.7 The effect of SASP paracrine signalling on the 
tumourigenic microenvironment 
3.7.1 A population of endothelial-like cells expands in the 
stroma during early pituitary tumourigenesis 
The demonstration of a non-cell autonomous induction of pituitary tumours in 
the murine ACP model suggested that β-catenin clusters modify their 
microenvironment by means of the SASP. Because increased angiogenesis and the 
recruitment of different pro-oncogenic cell types into the tumour stroma are a 
characteristic effect of the SASP (Coppé et al. 2010), an analysis of the vascular and 
stromal compartment of Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries was conducted.  
To assess the state of the pituitary vasculature, immunostaining was conducted 
for Endomucin (EMCN), a O-sialoglycoprotein routinely used as a marker of 
endothelial cells (Samulowitz et al. 2002; Kinoshita et al. 2001)). Additionally, the 
expression of fibronectin and laminin were analysed to explore the stromal 
compartment. 
In 18.5 dpc wild type pituitaries EMCN expression was restricted to cells with a 
thin and elongated morphology surrounding the lumen of blood vessels in the anterior 
lobe (Figure 3.16a,c). Interestingly, 18.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries 
displayed a drastic expansion of the EMCN+ population, which formed large and 
dense groups of cells without the presence of a lumen throughout the pituitary anterior 
lobe (hereafter also referred as “swarms”)  (Figure 3.16b,d). 
 
 
 
 
 118 
 
Figure 3.16 Cells expressing the endothelial marker endomucin (EMCN) are 
present in larger numbers in Hesx1Cre/+;Ctnnb1lox(ex3)+/ pituitaries.  
Fluorescent immunostaining for EMCN at 18.5 dpc (a) The vasculature of the wild 
type pituitary anterior lobe contains EMCN+ cells with an elongated thin/elongated 
morphology. (b) Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries contain larger numbers of 
EMCN+ cells throughout the anterior lobe. (c) EMCN+ cells of the wild type pituitary 
often surround the lumen of blood vessels (note empty spaces within positive signal 
strands). (d) In mutant pituitaries, the EMCN+ population forms large, tightly-packed, 
cell groups which do not form a lumen. Scale bars: 100 μm 
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To investigate the origin of this peculiar EMCN+ population, concomitant 
lineage tracing of the pituitary lineage was conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/;R26YFP/+ at 18.5 dpc. Double immunostaining against YFP 
and EMCN showed a clear absence of colocalisation between both markers in mutant 
pituitary glands and showed that EMCN+ cells occupied YFP- areas in their entirety 
(Fig 3.17a). Interestingly, EMCN cells frequently formed ring-like structures by 
surrounding islands of YFP+ epithelial tissue, which resembled the β-catenin clusters 
in size and shape (arrows, Figure 3.17a).  
This extensive YFP- expression domain suggested that EMCN+ cells formed 
most of the pituitary stroma in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice. In fact, EMCN staining 
widely colocalised with the extra-cellular matrix (ECM) component fibronectin 
throughout the pituitary stroma (Figure 3.17b), suggesting active secretion of ECM-
modifying factors by EMCN+ cells. Moreover, laminin immunostaining showed that 
the basal lamina clearly separated EMCN+ cells from the pituitary epithelium (Figure 
3.17c), which appeared to be displaced by EMCN+ cell groups branching-off from 
larger EMCN+ cell masses (arrows, Figure 3.17c). Therefore, EMCN+ cells occupy 
most of the Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary stroma at 18.5 dpc, possibly by actively 
migrating and displacing the Hesx1-derived pituitary epithelium. 
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Figure 3.17 EMCN+ endothelial-like cells occupy most of the stroma in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ pituitaries.  
 (a) Double immunofluorescence for YFP and EMCN at 18.5 dpc shows that EMCN+ 
cells are present throughout the YFP- stroma of the tumourigenic pituitary gland in 
the form of large groups. Arrows: EMCN+ cells form “rings” that surround YFP+ 
epithelia. (b) The expression of the extracellular matrix (ECM) component fibronectin 
colocalises with EMCN+ cells throughout the pituitary anterior lobe. (c) Laminin 
immunostaining shows that EMCN+ cells are separated from the pituitary 
parenchyma by a basal lamina. Note that EMCN+ cells protrude from main cell groups 
and displace the pituitary epithelium (arrows). DAPI counterstain. 
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3.7.2 EMCN+ cells have an aberrant phenotype and interact 
closely with β-catenin clusters 
To better understand the identity of the EMCN+ cells, immunostaining was 
conducted against another common endothelial marker: PECAM (CD31). In wild type 
18.5 dpc pituitaries, EMCN and PECAM colocalised in endothelial cells showing the 
thin and elongated morphology that is characteristic of normal pituitary blood vessels 
(Figure 3.18a,b,e,f). Surprisingly, this pattern was not recapitulated in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries, as PECAM+ cells retained a wild type vascular 
morphology and did not form large cell swarms, unlike EMCN+ cells (Figure 3.18d). 
Moreover, double immunostaining for EMCN and PECAM showed that scarce, single 
PECAM+ cells could be found both within and outside the EMCN+ cell groups 
(arrows, Figure 3.18g,h). These results suggest that the EMCN+ cells from 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries have a different phenotype from those found in the 
normal pituitary vasculature. Additionally, immunostaining for the mesenchymal 
marker vimentin suggested that in both the wild type and oncogenic contexts, EMCN+ 
cells possess a mesenchymal phenotype (Figure 3.18i-p).  
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Figure 3.18 Phenotypic characterisation of EMCN+ cells in wild type and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries.  
(a-b) 18.5 dpc wild-type pituitaries contain elongated blood vessels that express 
PECAM and EMCN. (c) PECAM staining in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries shows 
a similar expression profile restricted to blood vessels. (d) EMCN+ cells form large 
cell groups that do not resemble PECAM+ vessels. (e,f) High magnification image of 
a wild type anterior lobe with PECAM+ and EMCN+ pituitary vessels. (g-h) Double 
immunostaining for PECAM and EMCN shows absence of colocalisation in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. (i-l) Staining for the mesenchymal marker 
Vimentin shows colocalisation with EMCN+ endothelium in wild types. (m-p) Vimentin 
is also expressed in EMCN+ cell swarms from Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries. 
DAPI counterstain. 
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Because β-catenin clusters are known to express a plethora of chemokines, it 
was hypothesized that cluster signalling may be responsible for attracting EMCN+ 
cells into the tumourigenic microenvironment. Double immunostaining for β-catenin 
and EMCN at 18.5 dpc showed that the clusters are in close contact with the EMCN+ 
cell swarms, which formed “ring” structures surrounding the clusters and separated 
them from the rest of the pituitary epithelium (arrows, Figure 3.19a-d). 
It has been previously reported that the clusters are often found surrounded by 
large numbers of SOX9+ cells (Gaston-Massuet et al. 2011) and therefore it was 
assessed if these were positive for EMCN. In 18.5 dpc wild type pituitaries, SOX9 
expression was mainly found restricted to scattered epithelial cells of the anterior lobe 
and in those lining the MZ (Figure 3.19e), but rarely in EMCN+ cells. Surprisingly, 
strong SOX9 expression was found in large EMCN+ ring formations of mutant 
pituitaries (arrows, Figure 3.19f-g). Increased SOX9 staining intensity (SOX9+high) 
was also present in large patches of EMCN+ cells and was not restricted only to those 
directly in contact with the epithelium (arrows, Figure 3.19h). Moreover, triple 
immunostaining for SOX9, β-catenin and EMCN confirmed that the 
SOX9+high/EMCN+ ring formations closely interacted with β-catenin clusters (Figure 
3.19i-l). Therefore, the secretory phenotype of the β-catenin clusters is possibly 
involved in attracting and inducing abnormal levels of SOX9 expression in 
endothelial-like EMCN+ cells during embryonic pituitary development. 
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Figure 3.19 EMCN+ cells are attracted to the β-catenin clusters and express 
SOX9 in an aberrant manner.  
(a-d) Double fluorescent immunostaining against β-catenin and EMCN shows 
EMCN+ cell swarms forming ring structures around β-catenin clusters (arrows) of the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary. (e) Double immunostaining for EMCN and SOX9 in 
an 18.5 dpc wild type pituitary shows the presence of few SOX9+/EMCN+ cells in the 
anterior lobe. (f-g) Mutant pituitaries contain large numbers of SOX9+high/EMCN+ 
cells (arrows) that form ring structures around pituitary epithelial islands. (h) 
Extensive patches of SOX9+high/EMCN+ are also found in mutant pituitaries. (i-l) 
Triple immunostaining for β-catenin, EMCN and SOX9 shows SOX9+high/EMCN+ 
cells closely interacting with a β-catenin cluster. Note stronger SOX9 expression in 
EMCN+ closer to the cluster. DAPI counterstain: e-h. 
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3.7.3 EMCN+ cells initiate contact with the β-catenin clusters 
early in development but cease EMCN expression after birth 
A broader characterisation of the EMCN+ population and its relationship with 
the β-catenin clusters was conducted throughout pituitary embryonic development. 
Characterisation of the EMCN+/SOX9+ population in wild type embryos showed that 
double-positive cells were present as a layer surrounding Rathke’s Pouch as early as 
10.5 dpc (Figure 3.20a) and through 12.5 dpc (Figure 3.20b). At 14.5 dpc, a wave of 
EMCN+/SOX9+ cells invaded the pituitary parenchyma of the future anterior lobe 
(arrow, Figure 3.20c). However, 16.5 dpc wild type pituitaries did not contain a similar 
population of EMCN+/SOX9+ cells within the anterior lobe. Instead, most EMCN+ 
cells lacked SOX9 expression and displayed an endothelial-like phenotype restricted 
to the lining of developing blood vessels (Figure 3.20d). This suggests that in wild 
type developing pituitaries the EMCN+/SOX9+ population differentiates after invading 
the anterior lobe parenchyma, to form part of the normal pituitary vasculature.  
A similar analysis conducted in Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos showed that 
few EMCN and SOX9+ cells interacted with the β-catenin clusters at 10.5 dpc (Figure 
3.20e), while at 12.5 dpc, double positive cells could be found in their vicinity (arrow, 
Figure 3.20f). Interestingly, a drastic increase in the number of double-positive cells 
was evident in mutant embryos at 14.5 dpc (Figure 3.20g) and importantly this 
expanded population was maintained through 16.5 dpc, where the EMCN+/SOX9+ 
cells already formed swarms surrounding the β-catenin clusters (arrows, Figure 
3.20h). These observations suggest that the clusters act upon a population of 
EMCN+/SOX9+ vascular precursors by affecting their differentiation and proliferation 
early in pituitary development.  
The postnatal expression of EMCN was then analysed to explore the possibility 
that the expanded EMCN+/SOX9+ population was involved in the non-cell 
autonomous formation of pituitary tumours. Unexpectedly, the number of EMCN+ 
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cells was not evidently increased in adult Hesx1Cre/+;Ctnnb1lox(ex3)/+  pituitaries in 
comparison to wild types (Figure 3.20j). Instead, abnormally scarce numbers of 
EMCN+ cells were found in the ventral pre-neoplastic regions (asterisk, Figure 3.20l), 
suggesting that the expanded EMCN+/SOX9+ population differentiated postnatally, 
downregulated EMCN expression and became part of the YFP- pre-neoplastic 
regions. 
 
Figure 3.20 EMCN+/SOX9+ cells interact with β-catenin clusters early in 
pituitary development.  
Triple immunostaining for EMCN, SOX9 and β-catenin at different stages of pituitary 
development. (a) At 10.5 dpc, a layer of EMCN+/SOX9+ cells surrounds the wild type 
Rathke’s Pouch (RP). (b) At 12.5 dpc, the pouch is still surrounded by a layer of 
EMCN+/SOX9+ cells (arrow). A small population of EMCN+/SOX9+ cells can be 
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observed outside the ventral region of the anterior lobe (AL) (arrow). At this stage, 
the developing posterior lobe (PL) and basisphenoid bone (BB) also express high 
levels of SOX9. (c) At 14.5 dpc, a wave of EMCN+/SOX9+ cells has invaded the 
epithelium of developing AL (arrow). (d) By 16.5 dpc, EMCN expression is restricted 
to the lining of blood vessels that mostly do not express SOX9. (e) The 10.5 dpc RP 
of Hesx1Cre/+;Ctnnb1lox(ex3)/+  embryos contains β-catenin clusters that interact with 
both SOX9+ and EMCN+ cells. (f) At 12.5 dpc, EMCN+/SOX9+ cells interact closely 
with clusters at the RP surface. (g) The number of EMCN+/SOX9+ cells has 
increased at 14.5 dpc (arrows). (h) At 16.5 dpc, the mutant anterior lobe contains an 
expanded EMCN+/SOX9+ compartment that maintains close contact with the β-
catenin clusters (arrows). (i-j) EMCN staining in wild type pituitaries at 18.5 dpc and 
3 months of age adult shows that positive cells are restricted to normal vasculature 
of the anterior and posterior lobes. (k) Mutant pituitaries at 18.5 dpc contain an 
expanded EMCN+ compartment. (i) Adult mutant pituitaries lack an expansion of the 
EMCN compartment compared to wild types. While the AL appears to have normal 
vascularisation, ventral pre-neoplastic regions (delimited by dotted line) contain 
decreased numbers of EMCN+ vessels (asterisk). Scale bars: i,k: 500 μm. RP: 
Rathke’s Pouch; 3V: Third Ventricle; PL: Posterior Lobe; AL: Anterior Lobe; BB: 
Basisphenoid Bone. 
 
3.7.2 Large groups of EMCN+ endothelial-like cells are also 
present in human ACP 
To determine if an expanded EMCN+ cell population also exists in human ACP, 
double immunostaining for β-catenin and EMCN was conducted in ACP paraffin 
sections (including a tissue microarray containing 23 different cases). This revealed 
that all samples contained EMCN+ cells, albeit with a variety of phenotypes. EMCN+ 
cells were rarely observed within the tumour parenchyma but were found in the lining 
of blood vessels of most tumours (arrowheads Figure 3.21a,c,g). Besides blood 
vessel-associated cells, EMCN+ staining was observed in non-vascular EMCN+ 
populations present both outside the tumour parenchyma (Figure 3.21b) and within 
tumour microcysts (arrow, Figure 3.21c). Interestingly, a number of tumours 
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contained large numbers of non-vascular EMCN+ cells that occupied most of the 
extra-tumoural tissue (Figure 3.21d,e,f). Closer inspection showed that in low-
EMCN+ content tumours, positive cells within microcysts were either found as large 
cell agglomerates (arrow, Figure 3.21g) or single round-shaped cells (Figure 3.21h). 
Conversely, in tumours with high-EMCN+ content, positively-labelled cells had a 
distinctive mesenchymal phenotype with an elongated morphology and formed large 
cell-groups that intermingled with the tumour epithelium (Figure 3.21i-l). This last 
phenotype resembled, rather strikingly, the EMCN+ cell-swarms found in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryonic pituitaries during early stages of tumourigenesis. 
 
Figure 3.21 EMCN+ cells display different phenotypes in human ACP.  
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Double immunostaining for EMCN and β-catenin showing representative examples 
of different phenotypes found in human ACP. (a) EMCN+ staining is often detected 
in vascular cells present within microcysts (arrowheads). Inset: control staining in 
normal brain. (b) A different ACP case shows EMCN+ cells with a different elongated 
phenotype present outside the tumour parenchyma. (c) Large non-vascular EMCN+ 
cell groups are found within microcysts (arrow). Note positive staining in a large blood 
vessel (arrowhead). (d-f) Representative examples of tumours with high content of 
EMCN+ cells which are present throughout the extra-tumoural tissue. (g) High 
magnification photograph from (c) shows vascular (arrowhead) and non-vascular 
(arrow) EMCN+ phenotypes. (h) Single round-shaped EMCN+ phenotype found 
occasionally found within cysts and vessels. (i-l) High magnification images from 
high-EMCN+ content tumours showing the mesenchymal, elongated phenotype of 
EMCN+ cells that occupy the extra-tumoural space.  
 
3.7 Chapter 3 conclusions 
In summary, the results presented in this chapter show that pituitary tumours 
can develop non-cell autonomously in an embryonic mouse model for ACP. 
Additionally, analysis of a wide array of markers for key senescence pathways 
demonstrates that the β-catenin clusters of mouse and human ACP become 
senescent and activate the SASP. Unbiased transcriptomic analyses provided further 
support for the validity of mouse models of ACP by demonstrating that human and 
mouse clusters are similar biological structures. Further experiments are required to 
clarify the role of pathways such as mTOR and autophagy in mouse in human 
clusters.  
Finally, evidence is presented of the effects the SASP may have on the 
tumourigenic microenvironment in mice and humans. In mice, it is possible that the 
SASP is directly involved in the recruitment and transformation of the cell-of-origin, 
while in humans it might have a role in remodelling of the microenvironment or to 
provide growth signals to dividing cells.    
 130 
 
 
 
 
 
 
4. THE ROLE OF THE CXCR4/SDF-1 
SIGNALLING AXIS IN NORMAL PITUITARY 
DEVELOPMENT AND ONCOGENESIS  
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4.1 Introduction 
In the previous chapter, a mechanism was described by which the β-catenin 
accumulating clusters of murine ACP models provide signals to their environment and 
possibly induce the changes necessary for non-cell autonomous tumourigenesis to 
occur. Although these clusters secrete a wide number of signalling factors, the role 
that some of these cytokines play during oncogenesis is better understood than 
others, at least in the context of senescence and the SASP. Chemokine signalling is 
such an example, as increasing evidence has shown how SASP chemokines are able 
to recruit and/or alter the phenotype of various cell types of the microenvironment 
(e.g. leukocytes, fibroblasts, vasculature and other supportive cells) during both 
homeostatic and pathologic processes (Tasdemir et al. 2016; Lujambio et al. 2013; 
Storer et al. 2013; Muñoz-Espín et al. 2013). Therefore, this chapter aims to shed 
insight into the role of chemokine-mediated paracrine signalling during normal 
pituitary development and oncogenesis, with focus on the CXCR4/SDF-1 signalling 
axis. 
The importance of the CXCR4/SDF-1 signalling axis in cancer and stem cell 
biology has been widely described (Teicher & Fricker 2010), making it an attractive 
candidate for studying chemotaxis and paracrine signalling, as SDF-1 is the only 
known ligand for CXCR4; a rather non-promiscuous interaction considering that most 
chemokine receptors bind various different ligands (Busillo & Benovic 2007). 
Importantly, its role during normal pituitary development and pituitary oncogenesis in 
vivo has not been investigated in detail (Barbieri et al. 2007), especially in 
adamantinomatous craniopharyngiomas (ACP).  
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4.2 The role of the CXCR4/SDF-1 axis in normal 
pituitary development 
The expression of both Cxcr4 and Sdf-1 mRNA in the developing pituitary gland 
has been previously reported (McGrath et al. 1999). However, a comprehensive 
description of both CXCR4 mRNA and protein expression patterns throughout 
pituitary development has yet to be reported, and the question of its function in vivo 
remains to be addressed (Rostène et al. 2011). 
The expression pattern of Cxcr4 during normal pituitary development was 
analysed as part of a masters’ project (Gonzalez-Meljem 2012) and it was shown that 
CXCR4 protein and mRNA expression are mainly restricted to the prospective 
pituitary intermediate lobe throughout development. For this chapter, a more detailed 
analysis was conducted and novel data is presented, while making emphasis on 
aspects not explored or discussed in the masters’ thesis. 
4.2.1 The expression pattern of CXCR4, CXCR7 and SDF-1 
during normal pituitary development 
CXCR4 is expressed early in Rathke’s Pouch and is mainly restricted to the 
intermediate lobe during development 
The expression pattern of Cxcr4 during normal pituitary development was 
determined by in situ hybridisation (ISH) (Gonzalez-Meljem 2012; section 3.2) and 
immunostaining at different stages of pituitary development. CXCR4 protein 
expression was observed at all stages of pituitary development (10.5 to 18.5 dpc) and 
localised mainly to the dorso-medial region of Rathke’s Pouch, which is the 
prospective intermediate lobe (IL) (Figure 4.1a). Positive staining was also observed 
in regions where the IL and the posterior lobe (PL) are physically in contact (inset, 
Figure 4.1b) as well in cells lying between the IL and PL (arrowhead in inset, Figure 
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4.1b). At 18.5 dpc and postnatal stages, CXCR4 expression was restricted mostly to 
cells of the intermediate lobe (Figure 4.1c,d). Interestingly, CXCR4 protein was also 
observed occasionally in cells of the anterior lobe (AL) that resembled endothelial 
cells (inset, Figure 4.1c). This observation was corroborated using the endothelial 
marker endomucin (EMCN), which colocalised with CXCR4+ cells at 15.5 and 18.5 
dpc stages (Figure 4.1e,f). 
 
Figure 4.1 Expression pattern of CXCR4 at different stages of murine pituitary 
development.   
Fluorescent immunostaining showing CXCR4 expression in mouse pituitaries at 
different stages of development. (a) At 10.5 dpc CXCR4 expression is observed in 
the ventral diencephalon (VD) and the prospective intermediate lobe (IL) of Rathke’s 
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Pouch (RP). (b) At 12.5 dpc, CXCR4+ cells are observed throughout the IL, including 
in regions directly in contact with the posterior lobe (PL) and in cells lying between 
both structures (arrowhead). (c) The IL of the 18.5 pituitary also contains CXCR4+ 
cells, while positive staining can also be observed in the PL. Inset: CXCR4+ cells with 
endothelial morphology are observed in the anterior lobe. (d) Adult pituitaries contain 
CXCR4+ cells mainly localised in the IL lining of the pituitary lumen. (e-f) Double 
immunostaining for the endothelial marker endomucin (EMCN) and CXCR4 shows 
double positive cells are present among the developing pituitary vasculature at 15.5 
and 18.5 dpc. Scale bars: a,b: 200 μm; c,d,e: 100 μm; e: 50 μm. 3V: Third ventricle; 
VD: Ventral diencephalon; IL; Intermediate lobe; RP: Rathke’s Pouch; AL: Anterior 
Lobe; PL: Posterior Lobe. 
 
The alternative SDF-1 receptor, CXCR7, is expressed in a domain that is 
complementary to CXCR4 
Expression analysis of the SDF-1 alternative receptor, CXCR7, was conducted 
by immunostaining and ISH. Interestingly, CXCR7 displayed an expression pattern 
complementary to that of CXCR4. Cxcr7 mRNA expression was observed in the oral 
epithelium and the ventral region of Rathke’s Pouch as early as 10.5 dpc (arrows, 
Figure 4.2a). At 12.5 dpc and 15.5 dpc, its expression was observed in the PL and 
AL (arrows, Figure 4.2b,c), while low or absent expression levels were observed in 
the IL. By 18.5 dpc, Cxcr7 was expressed in cells lining the pituitary cleft in the AL, 
commonly known as the periluminal area or marginal zone (MZ) (arrows, Figure 4.2d). 
Interestingly, Cxcr7 was not expressed in the PL at this later stage, while Cxcr4 
expression was maintained in this structure. The mRNA expression pattern was 
recapitulated by immunostaining of CXCR7-GFP pituitaries at 12.5 dpc (Figure 4.2i), 
while double immunostaining with CXCR4 antibody confirmed mutual exclusivity 
between CXCR4 and CXCR7 expression domains (Figure 4.2j). 
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Figure 4.2 Expression pattern of CXCR7 during pituitary development. 
 (a-d) ISH showing Cxcr7 expression during normal pituitary development is restricted 
mainly to the AL (arrows) and the PL. Note reduced mRNA levels in the IL. (e-h) ISH 
for Cxcr4 at each stage and matched histological regions shows strong expression 
confined to the IL, opposite to that of Cxcr7. (i) Immunofluorescence for GFP in 
CXCR7-GFP pituitaries at 12.5 dpc showing expression in both AL and PL. (j) Double 
immunostaining for GFP and CXCR4 in 12.5 dpc Cxcr7GFP/+ embryos shows opposite 
expression patterns of both proteins. DAPI counterstain: i-j. Scale bars: 200 μm. 3V: 
Third Ventricle; VD: Ventral diencephalon; IL; Intermediate lobe; RP: Rathke’s Pouch; 
AL: Anterior Lobe; PL: Posterior Lobe. 
  
 136 
The CXCR4 ligand, SDF-1, is mainly expressed by the mesenchyme 
surrounding Rathke's Pouch and in cells of the anterior lobe 
The expression of Sdf-1 was characterised by ISH and was observed to mainly 
localise in mesenchymal cells surrounding the pituitary gland throughout its 
development (arrows, Figure 4.3a,b). Additionally, it was also observed at later stages 
in cells of the anterior lobe and in the MZ (arrowheads, Figure 4.3b).  
 
Figure 4.3 In situ hybridisation showing the expression of Sdf-1 during normal 
pituitary development.  
(a) At 12.5 dpc, expression is mainly observed in mesenchymal tissue surrounding 
the developing pituitary gland (arrow). (b) At 18.5 dpc, the supportive mesenchyme 
still expresses Sdf-1 (arrows), although Sdf-1+ cells can also be observed in the 
anterior lobe and the periluminal region (arrowheads). Scale bars: a,b: 200 μm. 3V: 
Third Ventricle; AL: Anterior Lobe; PL: Posterior Lobe; MZ: Marginal Zone. 
 
4.2.2 The expression pattern of CXCR4 during human pituitary 
development 
The expression pattern of CXCR4 was also analysed in foetal human pituitaries 
at stages CS18 and CS20 by immunostaining. At both stages, CXCR4 expression 
resembled that of the mouse embryonic pituitary, localising mainly to the prospective 
intermediate lobe and posteriorly to the pouch’s cleft (Figure 4.4a-f). Interestingly, a 
group of cells with high CXCR4 expression were identified in proximity to the 
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developing pituitary gland at these stages (arrowheads, Figure 4.4b,c,e,f). These 
cells displayed filopodial processes and formed luminal structures, suggesting these 
might be endothelial progenitors involved in the formation of the pituitary vasculature 
at later stages. Therefore, the expression pattern of CXCR4 during pituitary 
development is strikingly similar between mice and humans, suggesting a conserved 
function between species. 
 
Figure 4.4 Immunofluorescence for CXCR4 at different stages of human 
embryonic pituitary development.  
(a-c) CXCR4 positive cells are found throughout the dorsomedial region of Rathke’s 
Pouch (prospective intermediate lobe) at the CS18 stage. Positive staining is also 
observed in the developing infundibulum (prospective posterior lobe). Strong positive 
signal is observed in endothelial cells located near the future anterior lobe and were 
only observed in more lateral regions of RP (arrowheads). (d-f) A similar expression 
pattern is observed at CS20, with strong CXCR4 expression in the postero-dorsal 
region of RP (arrows) and in developing blood vessels in lateral regions (arrowheads). 
IL; Intermediate lobe; PL: Posterior Lobe 
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4.2.3 Conditional knockout of CXCR4 in the developing 
pituitary gland 
Mice with null mutations in members of the CXCR4/SDF-1 pathway are 
characterised by embryonic and perinatal lethality mainly due to vascular defects 
(Cavallero et al. 2015; Ivins et al. 2015). Therefore, specific ablation of CXCR4 in the 
pituitary gland was conducted using the Cre-loxP system to study this signalling 
pathway in the absence of potentially confounding systemic effects. The Hesx1Cre/+ 
line was used to drive Cre recombinase expression as most of the mature pituitary 
gland is formed by the descendants of Hesx1-expressing cells (Jayakody et al. 2012).  
Conditional ablation of CXCR4 in Hesx1Cre/+;Cxcr4fl/fl mice does not affect normal 
pituitary development 
Successful and specific removal of Cxcr4 mRNA and protein in 
Hesx1Cre/+;Cxcr4fl/fl embryos was evaluated by ISH and IHC and previously reported 
(Gonzalez-Meljem, 2012; section 3.2). A representative immunostaining at 15.5 dpc 
is shown in Figure 4.5. Although CXCR4 protein was clearly removed from the IL of 
Hesx1Cre/+;Cxcr4fl/fl pituitaries, positive cells could still be observed in the boundary 
between the IL and PL (arrowheads, Figure 4.5a,b). Additionally, cells with 
endothelial morphology where also located in the AL stroma of Hesx1Cre/+;Cxcr4fl/fl 
pituitaries (arrowhead, Figure 4.5b). This indicated that CXCR4+ cell populations 
present in between the IL and PL, as well as in the AL stroma are not derived from 
the Hesx1 lineage. 
A phenotypic characterisation of Hesx1Cre/+;Cxcr4fl/fl  mice was also previously 
reported (Gonzalez-Meljem, 2012; results section 3). Litters derived from crossing 
Hesx1Cre/+;Cxcr4fl/+ and Cxcr4fl/fl  mice displayed normal mendelian ratios (N=59 for 
embryos, N=69 for postnatal mice, Chi-square test (P>0.05)), indicating that removal 
of CXCR4 in the developing pituitary does not cause embryonic or postnatal lethality. 
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Mutant pituitaries were morphologically normal and all pituitary endocrine cell 
populations reached normal terminal differentiation as determined by IHC. Born mice 
were healthy and fertile until late adulthood while measurement of pituitary hormone 
content suggested normal function of the adult gland. Finally, the effect of CXCR4 
knockout in the pituitary stem/progenitor cell population was assayed by an in vitro 
assay of colony formation, which showed no difference between mutant and control 
pituitaries (Gonzalez-Meljem, 2012, section 3.1).  
The expression domain of Cxcr7 was characterised by ISH in 
Hesx1Cre/+;Cxcr4fl/fl  pituitaries at 12.5 dpc (Figure 4.5e,f) to assess a possible 
compensation for the lack of CXCR4 function. However, the pattern of Cxcr7 
expression in Cxcr4 mutants was not different from wild type littermates. Additionally, 
no change was observed in the expression domain of genes required for proper 
pituitary development, such as Fgf10 (Figure 4.5g,h) and Lhx3 (Figure 4.5i,j).  
Altogether, these results suggest that the lack of CXCR4 expression in pituitary gland 
progenitors does not affect its normal development or overall function, and that this 
is not due to a compensation mechanism occurring through the canonical 
CXCR4/SDF-1 pathway. 
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Figure 4.5 Characterisation of Hesx1Cre/+;Cxcr4fl/fl pituitaries.  
(a) Immunohistochemistry against CXCR4 in a 15.5 dpc wild type pituitary shows 
stereotypical expression pattern in cells of the intermediate lobe (arrow) as well as in 
cells lying in the boundary between the intermediate and posterior lobes (arrowhead). 
(b). CXCR4 protein is effectively removed from the intermediate lobe in 
Hesx1Cre/+;Cxcr4fl/fl pituitaries. Note that CXCR4+ cells resembling blood vessels are 
still observed in the anterior lobe and also in the boundary between the intermediate 
and posterior lobes (arrowheads). (c-d) In situ hybridisation of Cxcr4 mRNA at 12.5 
dpc shows absence of expression in the intermediate lobe of Hesx1Cre/+;Cxcr4fl/fl  
pituitaries. Note the presence of positive signal in cells lying in the boundary between 
the intermediate and posterior lobes (arrowheads in inset). (e-f) The expression 
pattern of Cxcr7 is not affected in mutant pituitaries at 12.5 dpc. (g-h) The expression 
of the transcription factor Lhx3, essential for pituitary development, is not affected in 
mutant pituitaries. (i-j) The expression domain of Fgf10 in the ventral diencephalon is 
also not affected in mutants. IL; Intermediate lobe; PL: Posterior Lobe. 
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4.2.4 Phenotypic characterisation of Cxcr4-/-, Cxcr7-/- and Sdf-
1-/- pituitaries 
Only Sdf-1-/- mutants show abnormalities in pituitary development 
The lack of a phenotypic alteration in Hesx1Cre/+;Cxcr4fl/fl mice led to the 
hypothesis that CXCR4/SDF-1 signalling could play a role by acting on cells not 
derived from pituitary progenitors (e.g. vasculature, pericytes, fibroblasts), as 
CXCR4+ cells were still observed in these embryos. Therefore, an analysis of the 
pituitary phenotype was conducted on Cxcr4 -/-, Cxcr7-/- and Sdf-1-/- embryos.  
Cxcr4 -/- and Cxcr7 -/- embryos displayed normal pituitary glands at all observed 
stages (Figure 4.6c,d,g,h,k,l). Additionally, immunostaining for markers of normal 
pituitary development like Pit1 and TPit, as well for most pituitary hormones, did not 
reveal any differences when compared to wild type littermates at 18.5 dpc (data not 
shown).  
Surprisingly, Sdf-1 -/- pituitaries had an aberrant morphology at 16.5 and 18.5 
dpc (Figure 4.6f,j). This phenotype consisted of abnormal involutions of the 
intermediate lobe, which were observed fusing with the anterior lobe in some 
histological sections (not shown); as well as structural abnormalities of the 
basisphenoid bone (BB, Figure 4.6f) and presence of ectopic blood vessels (arrows, 
Figure 4.6f,j). However, no evident dysmorphic phenotype was found at 11.5 dpc 
(Figure 4.6b), indicating that the appearance of pituitary phenotype occurs after this 
stage.  
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Figure 4.6 Haematoxylin/Eosin (H&E) staining in wild type, Sdf-1-/-, Cxcr4-/-, 
Cxcr7-/- pituitaries at different developmental stages.  
(a-d) At 11.5 dpc, the RP from Sdf-1-/-, Cxcr4-/- and Cxcr7-/- embryos is not affected. 
(e) At 16.5 dpc the wild type developing pituitary sits on top of the basisphenoid bone 
(BB), which is flanked by large blood vessels (arrows). (f) Sdf-1-/- pituitaries at this 
stage have an abnormal shape, invaginations of the intermediate lobe (IL) and a 
deformed BB. Note ectopic blood vessels intermingling in between the BB (arrows). 
(g-h) Cxcr4-/- and Cxcr7-/- pituitaries resemble wild types at 16.5 dpc. (i-j) The Sdf-1-/- 
pituitary phenotype at 18.5 dpc also presents an invaginated IL and deformed BB with 
ectopic blood vessels (arrows). (k-l) Cxcr4-/- and Cxcr7-/- pituitaries are 
morphologically normal at 18.5 dpc. Scale bars: a-d: 100 μm; i-l: 200 μm. RP: 
Rathke’s Pouch; 3V: Third Ventricle; PL: Posterior Lobe; AL: Anterior Lobe; IL: 
Intermediate Lobe; BB: Basisphenoid Bone. 
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Normal patterning and terminal differentiation occurs in Sdf-1-/- pituitaries  
Proper development of the pituitary gland is highly dependent on factors 
secreted by the ventral diencephalon (VD), all which have specific expression 
domains. Therefore, proper patterning of the Sdf-1-/- VD was evaluated by ISH at 11.5 
dpc, which showed no abnormalities in the expression patterns of Cxcr4, Bmp4, 
Fgf10 and Shh (Figure 4.7a-h). Furthermore, ISH for oxytocin and vasopressin 
revealed proper specification of the hypothalamic nuclei in Sdf-1 mutants (data not 
shown). Finally, expression of Lhx3 was not affected in Sdf-1-/- embryos (Figure 4.7i,j), 
indicating a proper specification of the pituitary lineage in early development. 
An assessment of the terminal differentiation of different pituitary endocrine 
lineages was conducted by immunofluorescence in 18.5 dpc pituitaries and showed 
no differences between Sdf-1-/- pituitaries and wild types (Figure 4.7k-r). Finally, a 
possible vascular phenotype in Sdf-1-/- pituitaries was investigated as CXCR4+ cells 
were previously observed closely associated to endothelial cells in the pituitary 
(Figure 4.1e,f). However, immunostaining against the endothelial marker endomucin 
(EMCN) showed no obvious defects in the architecture of the mutant pituitary 
microvasculature (Figure 4.7s,t).  
Overall, these results suggest that the Sdf-1-/- pituitary phenotype is mostly 
morphological in nature and that it might depend on a complex interaction between 
different tissues and structures not related to the pituitary itself, such as the 
surrounding mesenchyme (basisphenoid bone and cranial blood vessels). 
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Figure 4.7 Molecular characterisation of Sdf1-/- mutants.  
(a-b) In situ hybridisation in 11.5 dpc embryos shows that Cxcr4 expression is not 
significantly altered in Sdf1-/- mutants. (c-h) No differences are found in the expression 
domains of hypothalamic factors crucial for proper pituitary specification and 
patterning such as Bmp4, Fgf10 and Shh. (i-j) The expression of the transcription 
factor Lhx3 (necessary for normal pituitary development) is not altered in Sdf1-/- 
mutants. (k-r) Fluorescent immunostaining against different pituitary hormones at 
18.5 dpc shows proper terminal differentiation of the pituitary endocrine lineages in 
Sdf1-/- mutants. (s-t) Endomucin (EMCN) staining shows a normal pattern of 
vascularization in mutant pituitaries. DAPI counterstain: k-t.  GH: Growth Hormone; 
ACTH: Adeno-Corticotropic Hormone; TSH: Thyroid Stimulating Hormone 
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4.3 The Role of CXCR4/SDF-1 in Pituitary Oncogenesis 
It has been reported that high expression of CXCR4 and SDF-1 predicted 
tumour recurrence in human ACP (Gong et al. 2014). Additionally, overexpression of 
CXCR4 was reported to localise in the β-catenin clusters of both human ACP and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (Andoniadou et al. 2012), while Sdf-1 was 
overexpressed in the non-cluster fraction. This suggested a crosstalk between the 
stroma and the clusters through this axis, which could be potentially targeted to 
prevent or delay tumour growth. Therefore, a detailed expression analysis was 
conducted in order to better understand the relation of CXCR4+ cells with the β-
catenin-accumulating clusters in both the Hesx1Cre/+;Ctnnb1lox(ex3)/+ model and human 
ACP. 
4.3.1 The expression pattern of CXCR4 in the 
craniopharyngioma mouse model. 
CXCR4 is expressed in cells inside and outside β-catenin cell clusters 
Double immunostaining experiments demonstrated that most clusters in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries contain CXCR4+ cells at 18.5 dpc (arrows, Figure 
4.8a-f). The number of CXCR4+ cells varied among the clusters. However, most 
CXCR4-expressing cells were found outside the clusters and interestingly, were often 
closely associated to them (arrowheads, Figure 4.8a-f). This pattern was reproduced 
in a second ACP mouse model (Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice) in which oncogenic 
β-catenin expression was only induced in SOX2+ adult stem cells (Figure 4.8g-i). 
Therefore, CXCR4 is widely expressed in the β-catenin clusters of two different 
mouse models of ACP, as well as in other non β-catenin-accumulating cells that 
closely interact with the clusters.  
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Figure 4.8 Double immunofluorescence for CXCR4 and β-catenin in two mouse 
models of adamantinomatous craniopharyngioma. 
 (a-b) Most nucleo-cytoplasmic β-catenin accumulating clusters in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries contain CXCR4+ cells at 18.5 dpc (arrows). 
However, groups of CXCR4+ cells are often located in the vicinity of some clusters 
(arrowheads). (d-f) Further histological examples showing the close interaction 
between the clusters and the CXCR4+ cells (arrowheads). (g-h) The β-catenin 
clusters of adult pituitaries in the inducible Sox2CreERT2/+;Ctnnb1lox(ex3)/+ model also 
contain CXCR4+ cells. DAPI counterstain. Scale bars: 25 μm  
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4.3.2 The expression pattern of Sdf-1, Cxcr7 and Cxcr2 in 
mouse ACP 
The increased expression of Cxcr4 in cells of both the pituitary and stroma in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (including the β-catenin clusters) suggested 
activation of the pathway by ligand binding and therefore, the presence of a nearby 
source of SDF-1 secretion. It was previously reported a 4.92-fold up regulation in Sdf-
1 expression in non-cluster cells at 18.5 dpc (Andoniadou et al. 2012) and that Sdf-1 
mRNA expression was not present in cluster formations (Reddy 2011). However, this 
last study failed to report any in situ expression of Sdf-1 that could reconcile the rather 
drastic 4.92-fold up regulation detected by microarray analysis. Therefore, a more 
detailed analysis of Sdf-1 in situ expression was conducted.  
A similar analysis was conducted for Cxcr7, which is often involved in regulating 
CXCR4 signalling. Finally, the expression of Cxcr2 was investigated as this receptor 
is known to antagonise CXCR4 signalling cell-autonomously (Eash et al. 2010), and 
also because microarray data revealed the overexpression of the three main Cxcr2 
ligands (Cxcl1, Cxcl2 and Cxcl3) in the β-catenin clusters (Andoniadou et al. 2012). 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries and tumours are invaded by Sdf-1 and Cxcr2 
expressing cells   
Unlike wild type pituitaries, where the strongest Sdf-1 expression was found in 
the supportive mesenchymal tissue (arrows, Figure 4.9a), Hesx1Cre/+;Ctnnb1lox(ex3)/+  
pituitaries showed strong Sdf-1 staining in large cell masses within the anterior lobe 
(arrowheads, Figure 4.9b,c). Several of these cell groups were found per pituitary and 
commonly located in the ventral-most region. Interestingly, these cell groups were 
also observed clearly invading the pituitary anterior lobe and remaining continuous 
with the exterior of the organ, suggesting that high Sdf-1+ cells also invade the 
pituitary gland from an external compartment (inset, Figure 4.9c).  
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Conversely, the expression pattern of Cxcr7 was not different between mutant 
and wild type pituitaries, where mRNA expression was strongest in the lining of the 
third ventricle (arrows, Fig 4.9d,e,f), surrounding mesenchyme and some cells of the 
MZ. 
While no clear expression of Cxcr2 could be observed in 18.5 dpc wild type 
pituitaries (Figure 4.9g), strong Cxcr2+ staining was observed throughout mutant 
pituitaries (arrows, Figure 4.9h), suggesting that secretion of CXCR2 ligands by the 
clusters is involved in crosstalk with other cell types during embryonic stages. 
Interestingly, end-stage tumours also contained large numbers of Cxcr2+ cells that 
accumulated mainly in regions surrounding cysts within the tumours (arrows, Figure 
4.9i). Therefore, in late stage tumours, there is possibly a different source of ligands 
contributing to CXCR2 signalling and reinforcing cell recruitment into the 
microenvironment of these tumours when they have become independent from 
signals secreted by the clusters. 
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Figure 4.9 Expression of other members of the CXCR4/SDF-1 signalling axis in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries.   
(a) Sdf-1 is strongly expressed in the mesenchymal supportive tissue surrounding the 
wild type pituitary gland at 18.5 (arrows). Lower levels of expression can be observed 
in cells of the anterior lobe. (b) Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries also show strong 
Sdf-1 expression in ventrally located cell groups (arrowheads). (c) High-Sdf-1 cells 
invade the mutant pituitary gland ventrally (arrowheads). Inset: Sdf-1 cells 
(arrowhead) embedded within the anterior lobe epithelium (dotted line) are 
continuous with the exterior of the pituitary. (d-f) The expression pattern of Cxcr7 is 
not altered in mutants, but is still observed in the lining of the third ventricle (arrows). 
(g) Cxcr2 is not expressed in wild type pituitaries at 18.5 dpc. (h) Strong expression 
of Cxcr2 is evident in cell groups present throughout mutant pituitaries (arrows). (i) 
Large numbers of Cxcr2-positive cells are observed in end-stage tumours, mostly 
surrounding cystic areas (arrows). Scale bars: a-h: 100 μm; i: 200 100 μm. PL: 
Posterior Lobe; AL: Anterior Lobe 
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4.3.3 The expression pattern of CXCR4 in human ACP 
The CXCR4 and SDF-1 genes are highly conserved between mice and 
humans, as is their role in cancer (Teicher & Fricker 2010). The expression pattern 
of CXCR4 was studied in four independent human adamantinomatous 
craniopharyngioma (ACP) samples, as well in a tissue microarray containing 23 
different ACP samples and normal brain control tissue. Surprisingly, CXCR4+ cells 
mostly did not colocalise with β-catenin clusters, in contrast with the two murine ACP 
models where CXCR4+ cells were frequently seen inside the clusters (Figure 4.8). 
However, CXCR4+ cells and the β-catenin clusters were consistently found in close 
association with each other in human ACP, in part recapitulating previous 
observations from the mouse models (arrowheads, Figure 4.10a-f). This expression 
pattern of mutual exclusivity, yet invariable proximity, was observed in a clear majority 
of human clusters and suggests an active cross-talk between both cell populations. 
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Figure 4.10 Double immunofluorescence for CXCR4 and β-catenin in human 
adamantinomatous craniopharyngioma.  
(a) CXCR4-positive cells (arrowheads) are seen commonly in close contact with β-
catenin clusters (arrow) but appear to be mutually exclusive. (b-d) Further examples 
of β-catenin clusters interacting with CXCR4+ cells within human ACP samples. DAPI 
counterstain. Scale bars: a: 50 μm; b,c,d: 100 μm 
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4.3.4 The expression of SDF-1, CXCR7, and CXCR2 in human 
ACP 
ISH was conducted in ACP samples to determine the expression pattern of 
other CXCR4 pathway signalling members. SDF-1 mRNA expression was observed 
in discreet areas within the tumours (arrows, Figure 4.11a-c) and did not correlate to 
cluster/whorl-like formations. Furthermore, CXCR2 expression was observed 
throughout the tumour, including the palisaded epithelium and whorl-like cell 
structures (Figure 4.11d-f), suggesting CXCR2 activation occurs throughout ACP 
tumours by binding IL-8 (or its analogues CXCL1, CXCL2 and CXCL3) possibly 
secreted by the clusters. Clear CXCR7 expression could not be observed in tumours 
(not shown). Therefore, the expression of CXCR4 signalling members appears to be 
restricted to specific and different compartments within the tumour parenchyma. 
 
Figure 4.11 In situ hybridisation for SDF-1 and CXCR2 in human ACP.  
(a) SDF-1 expression can only be observed in restricted regions of human ACP. (b-
c) Higher magnification photographs of another region (same tumour). (d) CXCR2 is 
widely expressed in the tumour parenchyma. (e-f) CXCR2 expression is mainly 
localised to the palisaded epithelium and whorl-like cell structures (arrow), while the 
stellate-reticulum appears to be CXCR2-negative. Scale bars: 250 μm. 
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4.3.5 Conditional knockout of CXCR4 in the murine ACP 
background 
The notable specificity of CXCR4 co-expression within nucleocytoplasmic 
accumulating β-catenin in the murine clusters, as well as the absence of a detrimental 
phenotype in Hesx1Cre/+;Cxcr4fl/fl mice, suggested that CXCR4-knockout in the 
developing pituitary gland could potentially restrict the clusters from an important 
growth/survival factor and therefore abrogate tumour progression in the mouse ACP 
model. Additionally, other CXCR4+ cells were found to interact closely with the 
clusters in both murine and human ACP, suggesting a supportive/trophic role for 
these cells. 
 In order to study the role CXCR4 signalling within the β-catenin clusters and 
tumour progression, knockout of CXCR4 expression was conditionally targeted to 
pituitary embryonic progenitors in the context of mouse ACP resulting in mice carrying 
the genotype Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  (hereafter also referred as Cxcr4 triple 
mutants). 
CXCR4 is successfully removed in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  clusters  
Double immunostaining for CXCR4 and β-catenin showed successful ablation 
of CXCR4 expression in all the nucleocytoplasmic accumulating β-catenin clusters of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries at 18.5 dpc (Figure 4.12; 45.95% 
colocalisation in heterozygous control, N=37 clusters in 3 embryos; 0% colocalisation 
in homozygous mutant, N=41 clusters counted in 3 embryos). No evident differences 
were observed in the number or size of the β-catenin clusters between 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/+ genotypes. 
Interestingly, Cxcr4fl/fl pituitaries still contained considerable numbers of CXCR4+ 
cells present outside the clusters (arrowheads, Figure 4.12), a similar observation to 
that made during the analysis of Hesx1Cre/+;Cxcr4fl/fl pituitaries at the same stage (See 
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Figure 4.5b). This indicates that CXCR4+ cells in the β-catenin clusters are derived 
from the Hesx1 lineage and that the non-cluster/CXCR4+ population is not derived 
from Hesx1 progenitors at this stage. 
 
Figure 4.12 The expression of CXCR4 in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl 
pituitaries and controls.  
(a) Double immunofluorescence for CXCR4 and β-catenin in mutant pituitaries where 
CXCR4 has been conditionally ablated in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ background. 
The β-catenin clusters of control Cxcr4fl/+ pituitaries contain CXCR4+ cells (arrows) 
but several CXCR4+ cells also present outside of them (arrowhead). The β-catenin 
clusters of Cxcr4fl/fl pituitaries lack CXCR4 expression (arrows), although individual 
CXCR4+ cells remain outside the clusters (arrowhead). DAPI counterstain. Scale 
bars: 25 μm. 
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Removal of CXCR4 does not alter the embryonic pituitary phenotype in the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ background 
It was previously reported that Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryonic pituitaries 
are hyperplastic and characterised by reduced differentiation of Pit1-dependent 
endocrine lineages, leading to hypopituitarism in adult mice (Gaston-Massuet et al. 
2011). In order to assess the impact of removing CXCR4 in the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ background, the pituitary phenotype of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl embryos was analysed at 18.5 dpc by H&E staining 
and immunohistochemistry against pituitary hormones.  
Triple mutant pituitaries were also hypertrophic and with morphological 
aberrations that resembled that of Hesx1Cre/+;Ctnnb1lox(ex3)/+ controls such as multiple 
involutions of the intermediate lobe which altered the otherwise stereotypic 
appearance of the wild type pituitary lumen (Figure 4.13a-d). A common feature 
observed in Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos is an abnormal closure of the 
basisphenoid bone, which is filled by remnants of the growing Rathke’s Pouch and 
leads to an open canal in the bone that is also present postnatally. This altered 
closure of the basisphenoid bone appeared to be more pronounced in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl embryos at the 18.5 dpc stage with ectopic pituitary 
tissue present in between the bone (arrows, Figure 4.13d).  
 Immunohistochemical characterisation of pituitary endocrine lineages revealed 
an impaired terminal differentiation of the somatotroph and thyrotroph lineages in both 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries when 
compared to wild types (Figure 4.13e-j), whereas differentiation of the corticotroph 
lineage was not affected (Figure 4.13k-m). Therefore, ablation of CXCR4 did not 
rescue defects in endocrine lineage commitment that occur in the context of 
oncogenic β-catenin. 
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Figure 4.13 Characterisation of Hesx1Cre/+;Ctnnb1lox(ex3)/+;CXCR4fl/fl pituitaries.  
(a) H&E staining of a wild type pituitary at 18.5 dpc shows the normal appearance of 
the different pituitary compartments with a stereotypical lumen separating the 
intermediate and anterior lobes. Note proper fusion of the basisphenoid bone. (b) 
Hesx1Cre/+;Ctnnb1lox(ex3)/+  pituitary at the same stage shows an hyperplastic anterior 
lobe and ectopic intermediate lobe involutions (asterisk). (c-d) 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries are also hyperplastic with intermediate 
lobe involutions (asterisk). Basisphenoid bone fusion is occasionally prevented by 
ectopic growth of the pituitary (arrows).  (e-g) IHC against GH shows that somatotroph 
differentiation is affected in both Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Cxcr4 triple mutant 
pituitaries. (h-j) The thyrotroph lineage is also affected in both mutants. (k-m) 
Corticotroph differentiation is not affected in either Hesx1Cre/+;Ctnnb1lox(ex3)/+  and 
Cxcr4 triple mutants. GH: Growth Hormone; ACTH: Adeno-Corticotropic Hormone; 
TSH: Thyroid Stimulating Hormone; PL: Posterior Lobe; AL: Anterior Lobe; BB: 
Basisphenoid Bone.   
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Removal of CXCR4 does not affect the molecular nor secretory phenotype of 
the embryonic β-catenin clusters 
A molecular characterisation was conducted by immunofluorescence in order 
to determine the effect of CXCR4 ablation in the β-catenin clusters of the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ background. It was previously shown that the majority of the 
clusters express the stem cell factor SOX2, but rarely express SOX9 and lack the 
proliferation marker Ki67 (Gaston-Massuet et al. 2011). Double immunostaining 
experiments showed no difference in the expression of SOX2 in the clusters of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  pituitaries and controls (Figure 4.14a,b). 
Conversely, SOX9 expression was extremely rare within the clusters of both 
Hesx1Cre/+;Ctnnb1lox(ex3)/+  and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  pituitaries, whereas it 
was strongly expressed in cells directly surrounding the clusters of both genotypes 
(arrowheads, Figure 4.14c,d). Finally, Ki67 staining did not reveal any differences in 
the proliferation of the β-catenin clusters (Figure 4.14e,f), suggesting the senescent 
phenotype is also not altered in the absence of CXCR4. 
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Figure 4.14 Molecular analysis of the β-catenin clusters after CXCR4 ablation.  
(a-b) Double immunofluorescence for SOX2 and β-catenin shows positive staining in 
progenitor areas of the marginal zone (arrowheads) and in β-catenin clusters of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/;Cxcr4fl/fl pituitaries at 18.5 dpc 
(arrows). (c-d) SOX9 is rarely expressed within the clusters but SOX9+ cell groups 
surround the β-catenin clusters in both genotypes (arrowheads). Asterisk indicates 
osteogenic cells of the basisphenoid bone, which normally express high levels of 
SOX9. (e-f) CXCR4 ablation in the clusters does not have an impact on proliferation 
of these structures as indicated by the absence of Ki67 positive staining. Scale bars: 
a,b,c,d: 50 μm; e,f: 25 μm 
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CXCR4/SDF-1 signalling has been shown to crosstalk and promote the 
expression of members of the SHH, WNT, BMP and FGF families (Sengupta et al. 
2012; Holland et al. 2013; Singh et al. 2012; C. Liu et al. 2013). An ISH analysis of 
factors known to be overexpressed by Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters (Andoniadou 
et al. 2012) was conducted but showed no differences between  
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries at 18.5 dpc 
(Figure 4.15). These results suggest that CXCR4 signalling is not required for 
inducing nor maintaining the molecular and secretory phenotype of the β-catenin 
clusters at embryonic stages.  
 
Figure 4.15 Characterisation of the secretory phenotype in β-catenin clusters 
after CXCR4 ablation. 
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In situ hybridisation shows the clusters of both Hesx1Cre/+;Ctnnb1lox(ex3)/+ and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries at 18.5 dpc overexpress Shh, Wnt6, 
Bmp4, and Fgf3 (arrows).  
 
Removal of CXCR4 in pituitary cells does not have a beneficial effect on tumour 
progression 
In the previous chapter it was shown that after birth, Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries undergo a period of latency during which the β-catenin clusters persist in 
pre-neoplastic regions until tumours eventually develop (see Figure 3.1), suggesting 
a role for the β-catenin clusters in postnatal stages of tumour progression. In order to 
assess the importance of CXCR4 signalling in postnatal tumour development, an 
analysis of tumourigenic pituitaries and end-stage tumours was conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl mice and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/+ controls. 
Mendelian ratios at weaning showed no significant difference between possible 
genotypes obtained from crossing Ctnnb1lox(ex3)/lox(ex3);Cxcr4fl/+ and Hesx1Cre/+;Cxcr4fl/fl 
mice (Figure 4.16a), indicating that removal of CXCR4 in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
background does not result in perinatal lethality. At 30 days of age there was no 
obvious difference between Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/+ pituitaries, as in both genotypes these were 
characterised by dysmorphic anterior lobes (Figure 4.16b) due to the presence of 
ventrally located pre-neoplastic regions containing β-catenin clusters (Figure 4.16c). 
End-stage tumours did not show any obvious histological differences between triple 
mutants and their controls (Figure 4.16d). Finally, a survival analysis between 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/+ mice 
indicated that CXCR4 knockout did not have a beneficial effect on tumour 
development and growth (Figure 4.16e). In fact, by the end of this experiment 20% of 
Cxcr4 heterozygous mice died from tumour burden compared to 60% of Cxcr4 
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homozygotes. Although the resulting survival curve suggested that CXCR4 removal 
could have a negative effect on survival rate, this difference was not statistically 
significant (p=0.191, Log-Rank Mantel-Cox Test, n=5 for 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/+ and n=13 for Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl). 
Overall, these results indicate that the absence of CXCR4 in cells from the Hesx1 
lineage does not impair early development and progression of the murine tumours 
derived from oncogenic β-catenin activation. 
 
 
Figure 4.16 Postnatal characterisation of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl mice 
and tumours.  
(a) Normal mendelian ratios are observed after weaning litters derived from 
Ctnnb1lox(ex3)/lox(ex3);Cxcr4fl/fl and Hesx1Cre/+;Cxcr4fl/fl crosses (Chi Square test,  p=0.62). 
(b) A dysmorphic anterior lobe phenotype is observed in freshly dissected pituitaries 
from both Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  and controls. (c) Immunostaining for β-
catenin at the same stage shows the presence of β-catenin clusters in the anterior 
lobe pre-neoplastic regions of both genotypes. (d) H&E staining in end-stage tumours 
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shows a common histological landscape between Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl  
and controls. (e) A postnatal survival analysis indicates that absence of CXCR4 does 
not alter tumour progression beneficially (p=0.191, Log-Rank Mantel-Cox Test, 
N=18). 
4.3.6 CXCR4+ cells invade the murine ACP pituitary 
CXCR4-expressing cells are present in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl 
pituitaries and tumours 
In section 4.2 it was shown that CXCR4+ cells are present in the stroma of the 
embryonic pituitary gland, even when CXCR4 expression is removed from the Hesx1 
lineage, and that they are closely associated to the developing pituitary vasculature. 
It was also shown that CXCR4+ cells invade the pre-neoplastic regions postnatally 
and later form extensive vascular networks in end-stage tumours from Hesx1Cre/+; 
Ctnnb1lox(ex3)/+ mice. Because removal of CXCR4 in the Hesx1 lineage did not affect 
the β-catenin clusters’ phenotype nor impair the development of pituitary tumours, a 
possible role of CXCR4 signalling in mediating angiogenesis during tumour 
development was investigated. 
Immunostaining for CXCR4 at 16.5 dpc revealed that both Hesx1Cre/+; 
Ctnnb1lox(ex3)/+;Cxcr4fl/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries contain 
CXCR4+ endothelial-like cells (Figure 4.17a,b), recapitulating observations made in 
Hesx1Cre/+;Cxcr4fl/fl pituitaries. Additionally, strong positive staining was found in tip 
cells displaying filopodial processes (arrows, Figure 4.17a), suggesting a role for 
CXCR4-mediated chemotaxis in these cells. Furthermore, all end-stage tumours from 
both genotypes contained profuse CXCR4+ vascular structures (14 weeks, Figure 
4.17c,d). In both tumour types CXCR4+ cells were also found in larger, tightly packed 
groups (insets). Therefore, CXCR4 signalling potentially drives angiogenesis 
throughout the tumourigenic process in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice. 
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CXCR4+ cells exist within invading EMCN+ swarms 
In section 3.7 it was shown that mutant pituitaries are invaded by large numbers 
of EMCN+ cells, suggesting an active migration process in this population. Double 
immunostaining for CXCR4 and EMCN was conducted in 16.5 dpc pituitaries and 
showed the presence of CXCR4+ cells within the EMCN+ population (Figure 4.17e), 
suggesting active migration occurs in a proportion of EMCN+/CXCR4+ cells at this 
stage.  
 
Figure 4.17 CXCR4 expression in endothelial-like cells of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl pituitaries and tumours. 
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(a-b) Immunofluorescence for CXCR4 shows positive staining in cells with endothelial 
morphology that are present even after CXCR4 ablation in pituitary progenitors and 
their lineage. Note the presence of filopodia in leading tip cells (arrows). (c-d) 
CXCR4+ cells are also present in blood vessels of end-stage tumours and in larger 
groups forming anastomoses (insets). (e) Double immunostaining for CXCR4 and the 
endothelial marker endomucin (EMCN) reveals CXCR4+/EMCN+ cells are present 
within a much larger population of EMCN+ cells.  Scale bars: a,b: 20 μm. 
The number of CXCR4+ cells increases with tumour progression 
As described in the previous chapter, postnatal Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries contained pre-neoplastic regions largely formed by cells not derived from 
the Hesx1 lineage nor targeted with oncogenic β-catenin but that eventually 
progressed to full-grown tumours. Because these regions contained low numbers of 
proliferating cells (see Figure 3.1), CXCR4-mediated cell migration could explain in 
part the initial growth of these lesions. The presence of CXCR4+ cells was analysed 
in detail during tumour progression by CXCR4 immunostaining in combination with 
lineage-tracing in Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ pituitaries at different postnatal 
stages of tumour progression.  
In early postnatal pituitaries (around 4 weeks), increased expression of CXCR4 
was observed in epithelial cells of the anterior lobe and colocalised with YFP 
expression (arrows, Figure 4.18a,b). This high expression of CXCR4 was absent in 
adult wild type pituitaries, where clear membranous CXCR4 protein expression was 
only observed in the intermediate lobe (see Figure 4.1d), suggesting that increased 
CXCR4 expression in Hesx1-derived cells is an outcome of oncogenic β-catenin 
expression and increased WNT signalling. Interestingly, the stroma of the pre-
neoplastic regions also contained mesenchymal CXCR4+/YFP- cells (arrowheads, 
Figure 4.18b), which could also be observed in later stage pituitaries (arrows, Figure 
4.18c,d). The expression pattern of CXCR4 in end-stage tumours was region-
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dependent, where it could be observed in large patches of mesenchymal YFP- cells 
(Figure 4.18e,f). 
Besides the epithelial/YFP+/CXCR4+ and mesenchymal/YFP-/CXCR4+ cells 
already described, other types of CXCR4+ cells were identified during this analysis. 
A number intermediate stage specimens (2/5, around 10 weeks of age,) contained 
large numbers of mesenchymal CXCR4+ cells possessing filopodial processes, 
which were only found in restricted regions of pre-neoplastic tissue (Figure 4.18g). 
Finally, all end-stage tumours contained large numbers of CXCR4+ blood vessels 
(Figure 4.18i), where CXCR4 expression appeared stronger in vascular branches and 
tip cells (arrows, Figure 4.18j). 
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Figure 4.18 Characterisation of CXCR4 expression during mouse ACP 
progression. 
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 (a) Double immunofluorescence for YFP and CXCR4 in Hesx1Cre/+;  
Ctnnb1lox(ex3)/+;R26YFP/+  pituitaries in a 4-week old specimen shows that pre-
neoplastic areas are formed of YFP+ epithelium and a YFP- stroma. Most CXCR4+ 
cells are found in the YFP+ fraction (arrow). (b) Closer inspection of one of such 
regions shows that some CXCR4+/YFP- cells are present in the stroma (arrowheads) 
which intermingles with the epithelium containing CXCR4+/YFP+ cells (arrows). (c-
d) Later stage specimens (10 weeks of age example) show an expanded pre-
neoplastic region (delimited by dotted line) containing CXCR4+ cells with a clear 
mesenchymal phenotype. These cells were often observed forming elongated vessel-
like structures (arrows). (e-f) End-stage tumours contain regions with high numbers 
of CXCR4+/YFP- cells. Note how the YFP+ pituitary tissue has been displaced to the 
tumour periphery (arrowhead). (g-h) CXCR4+ cells with a distinctive mesenchymal 
morphology were found in large numbers in the pre-neoplastic regions in 3 out of 5 
specimens around 10 weeks of age. (i-j) All end-stage tumours (20 weeks of age 
specimen shown) contained profuse CXCR4+ vasculature. Note a stronger staining 
intensity in cells branching off from a main vessel (arrows). Scale bars: b,d,h: 25 μm; 
a,c,j: 50 μm; f,j: 100 μm; e,g,i: 200 μm. PL: Posterior Lobe; IL: Intermediate Lobe; AL; 
Anterior Lobe. 
 
4.4 Chapter 4 conclusions 
In summary, this chapter provides evidence suggesting that CXCR4/SDF-1 
signalling is not essential in cells derived from pituitary embryonic progenitors during 
development and adulthood, but might play a role in the proper formation of 
supportive tissues of the pituitary gland during development, such as the vascular 
system. Additionally, it is shown that CXCR4 is not necessary for the survival of the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ β-catenin clusters and that its ablation does not disrupt the 
cluster’s paracrine signalling and non-cell autonomous tumourigenesis. However, the 
data here presented suggests that CXCR4/SDF-1 signalling could be involved in pro 
tumourigenic cell recruitment to the microenvironment in mouse and human ACP, as 
CXCR4+ cells are observed closely interacting with the clusters.   
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5. CHALLENGING SENESCENCE IN 
EMBRYONIC AND INDUCIBLE MODELS OF 
PITUITARY TUMOURIGENESIS 
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5.1 Introduction 
In the previous chapter, it was shown that restricting the clusters from a well-
known pro-oncogenic growth factor (CXCR4) did not lead to their ablation nor impede 
tumour growth. Importantly, the clusters remained in a non-proliferative state and still 
induced changes in their microenvironment early in development. Therefore, it was 
hypothesized that preventing the clusters from becoming senescent and 
consequently activating the SASP could abrogate tumour formation or growth.  
There is a growing body of evidence demonstrating a crucial role for the tumour 
suppressor p53 (encoded by the Trp53 gene in mice) in the induction and 
maintenance of cellular senescence (Campisi 2013; Sharpless & Sherr 2015). 
Indeed, p53 activation is a convergence point for many senescence-activating stimuli 
such as DNA-damage and oncogenic signalling (Muñoz-Espín & Serrano 2014). 
Therefore, conditional knockout of p53 in pituitary embryonic precursors was 
conducted by crossing Hesx1Cre/+;Trp53fl/fl and Ctnnb1lox(ex3)/ lox(ex3);Trp53fl/+;R26YFP/YFP 
genotypes, in order to obtain Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice 
(hereafter also referred as Trp53fl/fl mutants).  
 
5.2 Analysis of the Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl 
embryonic phenotype 
5.2.1 Demonstration of p53 knockout in β-catenin clusters 
from Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl mutants 
To assess efficient knockout of p53 protein in the β-catenin clusters from the 
Hesx1Cre/+; Ctnnb1lox(ex3)/+ background, double immunostaining for p53 and β-catenin 
was conducted in 18.5 dpc pituitaries. While p53 protein accumulation was observed 
in clusters from Hesx1Cre/+; Ctnnb1lox(ex3)/+ and Hesx1Cre/+; Ctnnb1lox(ex3)/+;Trp53fl/+ 
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control pituitaries (Figure 5.1a,b), the β-catenin clusters from Trp53fl/fl mutant 
pituitaries did not show positive staining (Figure 5.1c,d). However, residual p53 signal 
could be observed in these pituitaries, mainly in the intermediate lobe, an area known 
to be populated by cells that are not derived from the Hesx1 cell lineage and therefore, 
where Hesx1-mediated recombination is less efficient (Jayakody et al. 2012) 
(asterisk, Figure 5.1d). Therefore, p53 knockout was efficiently achieved in the 
nucleo-cytoplasmic β-catenin accumulating clusters of the Hesx1Cre/+; Ctnnb1lox(ex3)/+ 
model. 
 
 
Figure 5.1 Double immunostaining for p53 and β-catenin in control and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries at 18.5 dpc.  
(a) Hesx1Cre/+; Ctnnb1lox(ex3)/+ pituitaries contain β-catenin clusters that accumulate 
p53 protein (arrow). (b) The clusters from Hesx1Cre/+; Ctnnb1lox(ex3)/+;Trp53fl/+ also 
contain p53- β-catenin accumulating clusters (arrow). (c) The β-catenin clusters from 
Hesx1Cre/+; Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries are negative for p53 (arrow). (d) 
Example from a different Trp53fl/fl mutant embryo where a cluster negative for p53 
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(arrow) is observed next to positively-stained cells of the pituitary intermediate lobe 
(asterisk). 
 
5.2.2 Analysis of the senescent phenotype in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl embryonic clusters 
In the third chapter, it was shown that the murine β-catenin clusters display a 
full senescent phenotype at 18.5 dpc. Therefore, a similar analysis was conducted at 
this stage for markers of proliferation, apoptosis, cell-cycle inhibition and DNA-
damage. Finally, the impact of p53 knockout on the expression of SASP factors by 
the β-catenin clusters and their effect on the pituitary microenvironment were also 
evaluated. 
Knockout of p53 in the β-catenin clusters does not prevent proliferative arrest 
nor induce apoptosis 
Double immunostaining for Ki67 and β-catenin showed that the clusters present 
in control Hesx1Cre/+; Ctnnb1lox(ex3)/+ and Hesx1Cre/+; Ctnnb1lox(ex3)/+;Trp53fl/+ pituitaries 
do not proliferate at this stage (Figure 5.2a,b). Unexpectedly, all clusters in Hesx1Cre/+; 
Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries also lacked Ki67 expression (Figure 5.2c,d). This 
suggested that p53 is not necessary to prevent or maintain the proliferative arrest in 
these structures up to 18.5 dpc. Additionally, immunostaining for cleaved Caspase 3 
showed that absence of p53 did not promote apoptosis in Trp53fl/fl mutant β-catenin 
clusters (Figure 5.3).  
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Figure 5.2 Double immunostaining for the proliferation marker Ki67 and β-
catenin in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries and controls at 18.5 dpc.  
(a) Hesx1Cre/+; Ctnnb1lox(ex3)/+ β-catenin clusters do not express Ki67, whereas cells 
surrounding them are positively stained. (b) The clusters from control Hesx1Cre/+; 
Ctnnb1lox(ex3)/+;Trp53fl/+ embryos are also negative for Ki67. (c-d) Hesx1Cre/+; 
Ctnnb1lox(ex3)/+;Trp53fl/fl β-catenin clusters are also Ki67-negative.  
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Figure 5.3 Double immunostaining for cleaved Caspase 3 and β-catenin in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries and controls at 18.5 dpc. 
 (a) Positive staining for Caspase 3 is only observed sporadically in isolated cells of 
the anterior lobe, but not in clusters. (b) Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries 
show a similar pattern of cleaved Caspase 3 expression. 
 
Knockout of p53 does not alter the activation of cell cycle-inhibiting pathways 
or the DNA-damage response  
Activation of p53 during the senescent response is known to lead to the 
activation of its transcriptional target p21 (Cdkn1a), which is a strong inducer of cell 
cycle arrest (Gire & Dulic 2015). Additionally, the senescent cell cycle arrest has also 
shown to be strongly dependent on the p16/Rb pathway, either independently or by 
reinforcing the activity of the p53/p21 pathway (Beauséjour et al. 2003).  
The effect of p53 inactivation in the β-catenin clusters was analysed at 18.5 dpc 
by double immunostaining, which showed no difference in the expression of p21 
(Figure 5.4a,b) and p16 proteins (Figure 5.4c,d) between Trp53fl/fl mutants and 
Hesx1Cre/+; Ctnnb1lox(ex3)/+ controls, consistent with the absence of proliferation 
markers previously shown.  
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Figure 5.4 The expression of markers of cell cycle inhibition in β-catenin 
clusters of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl  18.5 dpc pituitaries and controls 
(a) p21 protein is highly expressed in Hesx1Cre/+Ctnnb1lox(ex3)/+ clusters (arrows). (b) 
Knockout of p53 does not prevent the accumulation of p21 in clusters from 
Hesx1Cre/+Ctnnb1lox(ex3)/+;Trp53fl/fl embryos. (c) p16 protein also accumulates in 
Hesx1Cre/+Ctnnb1lox(ex3)/+ clusters. (d) The expression of p16 is not altered upon p53 
knockout in the β-catenin clusters of Trp53fl/fl mutants. 
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The effect of p53 knockout on the activation of the DNA-damage response 
(DDR) was also evaluated, as p53 is known to mediate this process in senescent 
cells (Williams, 2016). However, immunostaining against phospho-DNA-PKcs (Figure 
5.5a,b) and PARP-1 (Figure 5.5d,c) revealed that these markers were highly 
expressed in all the clusters found within control and Trp53fl/fl  mutant pituitaries. 
Together, these results indicate that absence of p53 expression does not result in 
senescence bypass in the β-catenin clusters during embryonic stages.  
 
 
Figure 5.5 Characterisation of DDR marker expression in clusters from 18.5 dpc 
Hesx1Cre/+Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries.  
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(a) Double immunostaining against phosphorylated DNA-PKcs and β-catenin shows 
colocalisation in a β-catenin accumulating cluster from a Hesx1Cre/+Ctnnb1lox(ex3)/+ 
pituitary. (b) This expression pattern is not altered in Trp53fl/fl mutant clusters. (c) 
PARP-1 accumulation is observed in control β-catenin clusters. (d) The clusters from 
p53 Trp53fl/fl mutants also accumulate PARP-1 protein.  
 
5.2.3 The SASP is maintained in embryonic β-catenin clusters 
after p53 knockout 
The induction of cellular senescence by p53-independent pathways has been 
previously reported, including cases where p21-mediated cell cycle arrest also 
occurred in the absence of p53 (Prieur et al. 2011; Chan et al. 2011; Cipriano et al. 
2011; Aliouat-Denis et al. 2005; Phalke et al. 2012) and under the expression of 
oncogenic β-catenin (Xu et al. 2008). However, it has been reported that inactivation 
of p53 in senescent cells leads to exacerbation of the SASP and its promalignant 
activities (Coppé et al. 2008). In order to explore this possibility, an analysis of the 
expression of secretory factors expressed by the clusters was conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries at 18.5 dpc.  
Knockout of p53 does not alter the expression of SASP factors  
  In situ hybridization (ISH) analysis showed that the β–catenin clusters 
(observed by Axin2 overexpression, Figure 5.6 a,b) from both 
Hesx1Cre/+Ctnnb1lox(ex3)/+ and Hesx1Cre/+Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries 
overexpressed the secretory factors Shh, Bmp4, Ffg3 and Wnt6 (arrows, Figure 
5.6c,e,g,i). Moreover, qRT-PCR analysis in control and Trp53fl/fl mutant pituitaries 
showed no statistically significant differences in the expression of hallmark 
senescence and SASP factors (Figure 5.7), further indicating that p53 knockout did 
not alter the secretory phenotype of the β-catenin clusters. 
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Figure 5.6 In situ hybridisation (ISH) analysis of the secretory phenotype in β-
catenin clusters after p53 ablation. 
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 (a-b) Axin2 overexpression is used as control for the presence of clusters in both 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries. ISH in 
consecutive sections shows increased mRNA expression of the secretory factors: 
Shh (c-d), Bmp4 (e-f), Fgf3 (g-h) and Wnt6 (i-j) in cluster formations of both controls 
and Trp53fl/fl mutants. 
 
  
 
Figure 5.7 Quantitative expression analysis of hallmark senescence and SASP 
factors in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries at 18.5 dpc. 
qRT-PCR for markers of senescence: Trp53, Cdkn1a (p21) and Cdkn2a (p16), as 
well as the SASP: Il1a, Il1b, Il6, Cxcl1, Cxcl2 and Ccl20. Bars represent mean 
expression± SEM relative to wild type littermates of target genes in individual 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+ (blue) and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl (red) 
pituitaries (p>0.05, Student’s t-test, n=3). 
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P53 knockout does not prevent remodelling of the microenvironment by the 
clusters 
The persistence of the SASP after p53 ablation suggested that the clusters also 
maintained their capacity to affect the tumourigenic microenvironment. In the third 
chapter it was shown that a population of EMCN+ endothelial-like cells expanded 
early in development, interacted closely with the clusters and maintained an aberrant 
expression of SOX9 up to 18.5 dpc. 
Double immunostaining for EMCN and YFP in 18.5 dpc pituitaries revealed that 
a non-Hesx1-derived EMCN+ population also expanded drastically in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ embryos (Figure 5.8a,b). Similarly to 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ controls, Trp53fl/fl mutants also contained swarms of 
EMCN+/SOX9high cells that formed “rings” around islands of epithelial tissue 
resembling the β-catenin clusters (arrows, Figure 5.8c,d).  
Altogether, these results indicate that p53 is not required at embryonic stages 
for the onset and maintenance of senescence in the β-catenin clusters, as well for 
SASP induction and the non-cell autonomous modification of the tumourigenic 
microenvironment.  
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Figure 5.8 Characterisation of the effect of p53 knockout on the embryonic 
pituitary microenvironment.  
(a) Double immunostaining for the endothelial marker Endomucin (EMCN) and YFP 
shows Hesx1Cre/+;Ctnnb1lox(ex3)/+ 18.5 dpc pituitaries contain an expanded 
EMCN+/YFP- population that occupies the totality of the stromal compartment. (b) 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries contain a similar expanded EMCN+/YFP- 
population. (c) Nests of EMCN+/SOX9high cells are observed surrounding islands of 
pituitary epithelium in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (arrows). (d) 
EMCN+/SOX9high ring structures are also found in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl 
pituitaries (arrows). Scale bars: a,b: 200 μm; c,d: 100 μm. 
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5.3 Analysis of the Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl 
postnatal phenotype 
It has been previously shown (see Figure 3.1) that the postnatal development 
of pituitary tumours in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice displays a latency period. During 
this latency-period, non-proliferative pre-neoplastic regions exist in the pituitary 
anterior lobe, in which a sudden proliferative burst eventually initiates in non-Hesx1 
lineage cells, leading to tumour formation. Because these pre-neoplastic regions also 
contain β-catenin clusters, the possibility that p53 knockout affected tumour 
development or progression during postnatal stages was investigated in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice. 
 
5.3.1 Survival analysis and lineage tracing in tumours derived 
from Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl mice 
p53 knockout in the Hesx1Cre/+;Ctnnb1lox(ex3)/+ background leads to decreased 
survival rates and an increase in pituitary tumour size 
A survival analysis of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice was 
conducted alongside with Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ littermates (also 
referred to as Trp53fl/+) and Hesx1Cre/+;Trp53fl/fl;R26YFP/+ controls (Figure 5.9a).  
Hesx1Cre/+;Trp53fl/fl;R26YFP/+ control mice were viable and sexually reproductive; 
and no mice from this genotype died during the course of the survival experiment. 
Additionally, they did not display pituitary tumours (a maximum of 24 months follow 
up) when sacrificed and dissected (n=4), suggesting that absence of p53 by itself is 
not sufficient to induce pituitary tumours when expressed in embryonic progenitors.  
Interestingly, a significant difference was found in the cumulative survival rate 
between Trp53fl/fl and Trp53fl/+ mice (p=0.02, Log-rank Mantel-Cox test). While 
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Trp53fl/fl mice displayed a mean survival time of 272 days (95% confidence interval, 
207-338 days, n=33), the mean for Trp53fl/+ mice was 422 days (95% confidence 
interval, 323-520 days, n=25). Additionally, measurement of average tumour 
diameter upon dissection revealed a significant increase (p=0.01, ANOVA, Figure 
5.9b) in mean tumour size in Trp53fl/fl (5.73±0.346 mm) compared to those from 
Trp53fl/+ (4.2±0.39 mm). Therefore, knockout of p53 has a detrimental effect in 
survival rate and leads to a significant increase in pituitary tumour size. 
 
 
Figure 5.9 Survival and tumour size analysis of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl mice. 
(a)  Kaplan-Meier survival curve for Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice 
(red line), Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ (blue line) and 
Hesx1Cre/+;Trp53fl/fl;R26YFP/+ mice (black line). Comparison between Trp53fl/fl (n=33) 
and Trp53fl/+ (n=25) genotypes was conducted by log-rank test (p=0.02). (b) Box plot 
representation of mean tumour diameters (p=0.01, single variable ANOVA, N=18). 
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P53 knockout promotes the cell-autonomous formation of pituitary tumours 
To assess the effect of p53 knockout on the non-cell autonomous origin of the 
pituitary tumours, lineage tracing of the Hesx1 lineage was conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours. YFP positivity was assessed 
upon fresh dissection and corroborated by YFP immunostaining in paraffin sections. 
YFP+ tumours developed in both Trp53fl/fl and Trp53fl/+ backgrounds, albeit with 
different frequencies (Figure5.10a-h). While YFP immunostaining in the non-
fluorescent Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ and Trp53fl/+ tumours showed the 
presence of residual YFP+ cells at the periphery of the tumour mass (arrows, Figure 
5.10i-j), immunostaining in sections from Trp53fl/fl tumours confirmed that the tumour 
bulk mass was composed of YFP+ cells (Figure 5.10k). Staining for p53 protein in 
non-fluorescent Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours showed strong nuclear p53 signal 
(Figure 5.10l). Non-fluorescent Trp53fl/+ tumours were also positive for p53 (Figure 
5.10m). Conversely, no signal was observed in Trp53fl/fl tumours (Figure 5.10n). 
While 35.3% of tumours obtained from control 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice were YFP- (n=17),  44.4% of Trp53fl/+ (n=10) 
and 100% of Trp53fl/fl tumours (n=12) were YFP+ (p=0.006, Fisher’s exact test, Figure 
5.10o). The difference between Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ and Trp53fl/+ 
tumours is not significant. Therefore, complete p53 inactivation generates a bias for 
fully penetrant cell-autonomously derived tumours. 
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Figure 5.10 Lineage tracing in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ 
tumours and controls. 
(a-d) Representative end-point tumours from Trp53fl/+ mice at fresh dissection. Shown 
examples: (a,b) tumours fully negative for endogenous YFP fluorescence, (c) a YFP- 
tumour displaying peripheral pituitary remnants (asterisk), (d) a Trp53fl/+ YFP+ 
tumour. (e-h) Representative examples of Trp53fl/fl tumours which display strong 
endogenous YFP fluorescence. (i) Immunostaining in a 
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Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ tumour shows absence of YFP positive signal 
except in residual cells displaced to the tumour periphery (arrow). (j) Immunostaining 
in a section from Trp53fl/+ tumour shown in (c). Note presence of YFP+ pituitary cells 
in the periphery of the tumour mass (arrow). (k) Immunostaining against YFP in a 
section from Trp53fl/fl tumour shown in (f). (l-n) p53 immunostaining for tumours 
shown in (i-k). (o) Bar chart showing significant increase in the proportion of YFP+ 
tumours observed in Trp53fl/fl tumours (p=0.006, Fisher’s exact test). “Control” 
denotes Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ tumours. Scale bars: a, b, c, d, e, f, g, h: 
2.5 mm; i,j,k: 200 μm; l,m,n: 100 μm. 
 
5.3.2 Histological characterisation and proliferation analysis 
of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours 
The detrimental effect of p53 knockout on survival and tumour size, together 
with the finding that tumours formed cell-autonomously suggested they also displayed 
different histopathologic and molecular characteristics compared to the non-cell 
autonomously-derived tumours found in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice. It must be 
noted that for this thesis, all phenotypic comparisons were made between YFP+ 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+  and YFP- Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
;R26YFP/+   and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+    tumours. 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours display histological features 
indicative of higher malignancy 
Histological analysis of Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours has been previously 
reported (Gaston-Massuet et al. 2011). These tumours showed a consistent histology 
characterised by the presence of large cysts and were formed mostly by non-
epithelial undifferentiated cells that often formed “whorl-like” arrangements (Figure 
5.11a,e). The majority of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours had less cystic 
content (i.e. displayed a larger solid content) but also displayed non-epithelial 
histology (Figure 5.11b,c). However, these tumours contained high numbers of mitotic 
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bodies (arrows, Figure 5.11f), suggesting increased proliferation, as well the 
presence of cell debris resembling “dirty necrosis” (Figure 5.11g), a feature of 
invasive colorectal carcinomas. Interestingly, two Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl 
tumours displayed a very distinct histology with features not previously observed or 
reported (Figure 5.11d). These tumours were characterised by an overall serrated 
morphology and closer inspection revealed they were mostly composed of compact 
sheets of folded epithelial tissue separated by microcysts (Figure 5.11h).  These 
findings were corroborated with expert histopathologist, Dr. Tom Jacques, and it was 
concluded that in general, the histopathological features observed in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours indicate a higher level of malignancy. 
 
 
Figure 5.11 Histological characterisation of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours.  
Haematoxylin/eosin (H&E) staining of representative specimens. (a)  
Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours are characterised by the presence of large cysts 
within a mass of non-epithelial tumour cells. (b-c) Histological sections from 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours shown in Figure 5.10 f and g, respectively. 
Note higher solid tumour content. (d) Example of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl 
tumour (shown in Figure 5.10e) displaying a distinct histologic phenotype 
characterised by a “serrated” tissue morphology in contrast to the “smooth” 
morphology from other specimens. (e) High magnification photograph of (a) shows a 
compact “whorl-like” arrangement of non-epithelial cells in Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
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tumours. (f) High magnification image from (b) shows presence of multiple mitotic 
bodies in Trp53fl/fl tumours. (g) High magnification of (c) showing presence of “dirty 
necrosis”. (h) High magnification image of (d) showing compact epithelial sheets and 
presence of microcysts. Scale bars: a, b, c, d: 500 μm; e, f, g, h: 50 μm. 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours display higher proliferation rates 
The significant increase in tumour size and number of mitotic bodies suggested 
that p53 knockout lead to an increase in proliferation in Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
tumours. Therefore, double immunostaining for proliferation markers Ki67 and 
phosphorylated Histone H3 (pHH3), in conjunction with YFP, was conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumour sections and compared with 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ tumours shown to have low or absent 
YFP+ expression. While Trp53fl/+ tumours displayed low levels of Ki67 and pHH3 
positivity (Figure 5.12a,b), Trp53fl/fl tumours displayed an evident increase in the 
expression of both markers (Figure 5.12c,d). Quantification of the proportion of Ki67+ 
cells (Figure 5.12e) showed a significant difference between Trp53fl/+ (15.7±8.5%) 
and Trp53fl/fl (64±9.8%) tumours (p=0.01, single variable ANOVA, N=7), suggesting 
further that p53 knockout promotes a higher malignancy phenotype in oncogenic β-
catenin-driven tumours. 
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Figure 5.12 Proliferation analysis of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ 
tumours.  
(a) Double fluorescent immunostaining for the proliferation marker Ki67 and YFP in a 
representative example of a mostly YFP- Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ 
tumour, showing the presence of scarce Ki67+ cells. (b) Double immunostaining for 
phosphorylated-histone H3 (pHH3) and YFP also reveals a small proportion pHH3+ 
cells are present in Trp53fl/+ tumours. (c) Double fluorescent immunostaining for Ki67 
and YFP in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumour shows a drastic 
increase in the number of Ki67+ cells. (d) The proportion of pHH3+ cells is also higher 
in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours. (e) Bar chart showing the mean 
percentage of Ki67+ cells found in Trp53fl/+ (15.7±8.5%, n=4) and Trp53fl/fl tumours 
(64±9.8%, n=3). Bars in (e) represent mean±SEM; ** p=0.01, ANOVA. Scale bars: 
200 μm. 
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5.3.3 Molecular characterisation of tumours after p53 ablation 
Previous characterisation of Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours determined they 
were mainly composed by undifferentiated cells, as determined by the lack of 
expression of pituitary hormones, cytokeratins, pituitary-specific transcription factors 
PIT1 and TPIT; as well as synaptophysin, a neuroendocrine phenotype marker 
(Gaston-Massuet et al. 2011). Therefore, a similar analysis was conducted to 
evaluate the effect in tumour cell differentiation after p53 ablation in the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ background.  
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours retain a non-differentiated phenotype  
Immunostainings were conducted in Trp53fl/fl mutant tumours and controls for 
synaptophysin, a cocktail of pituitary hormones (GH, PRL, TSH, ACTH, LH, FSH), 
PIT1 and TPIT (only synaptophysin and pan-cytokeratin shown). While clear 
synaptophysin-positive staining was only observed in peripheral pituitary remnants of 
control tumours (arrow Figure 5.13a), the tumours themselves did not contain positive 
cells (asterisk, Figure 5.13a). Similarly, Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours did 
not contain synaptophysin-positive cells (Figure 5.13b). A similar pattern was 
observed for a pan-cytokeratin antibody, which revealed positive signal only in 
remnants of the anterior lobe in control tumours and not in the tumour mass (Figure 
5.13c). Trp53fl/fl mutant tumours also did not contain pan-cytokeratin-positive cells 
(Figure 5.13d). These results were recapitulated for pan-hormonal, PIT1 and TPIT 
stainings. Together, these results suggest that although 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours are derived from a different cell of origin 
than Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours, they are also composed of non-differentiated 
cells, at least in terms of pituitary-related markers. 
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Figure 5.13 Analysis of the expression of pituitary differentiation markers in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours.  
(a) Immunohistochemical staining against the neuroendocrine marker synaptophysin 
in a Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumour. Remnants of the pituitary anterior lobe (al) are 
positively stained (arrow) while the tumour mass does not contain positive cells 
(asterisk). (b) Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours do not contain 
synaptophysin-positive cells. (c) Pan-cytokeratin immunostaining labels cells are 
present in remnants of the pituitary anterior lobe while the tumour is mostly negative. 
(d)  Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours are also negative for pan-cytokeratin 
staining. Haematoxylin counterstain.  Scale bars: 100 μm a,b; 250 μm, c,d.   
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Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours differ in their expression of E/N-
cadherin 
It has been shown that the expression patterns of N- and E-cadherin change 
dynamically throughout pituitary development and postnatal maturation. Because 
early postnatal Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries already contain pre-neoplastic 
regions from which tumours eventually arise, possible alterations in cadherin 
expression were investigated in early postnatal stages and end-point tumours.  
During most of embryonic development, E-cadherin is expressed throughout 
Rathke’s Pouch, while N-cadherin expression is only observed from 15.5 dpc in 
regions of the anterior lobe containing differentiated or committed cell types. After 
birth, E-cadherin expression is drastically downregulated in most of the pituitary gland 
parenchyma and eventually is restricted to the marginal zone (MZ), a region known 
to contain high numbers of pituitary stem cells, while N-cadherin is expressed 
throughout most of the pituitary parenchyma (Kikuchi et al. 2007; Chauvet et al. 
2009).  
Consistent with previous reports, wild type pituitaries only displayed E-cadherin 
expression in cells lining the MZ, while N-cadherin was expressed throughout cells of 
the anterior lobe (Figure 5.14a). Intriguingly, the epithelial cells present in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pre-neoplastic regions also expressed E-cadherin (Figure 
5.14b), suggesting that these regions are remnants of the embryonic pituitary. This 
abnormal E-cadherin expression was maintained at later stages of tumourigenesis 
(Figure 5.14c). Conversely, non-epithelial cells of the pre-neoplastic tissue (which 
were shown previously to be negative for YFP) were negative for both cadherin types.  
 Interestingly, growing Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours displayed low or 
absent N/E-cadherin expression (Figure 5.14d), suggesting the absence of cadherin 
expression in YFP- tumour-forming cells is maintained in early growing tumours. 
Earlier analysis of E-cadherin expression at 18.5 dpc showed its expression in β-
 192 
catenin clusters (Figure 5.14e-h). End-point tumours displayed different levels of 
diffuse and cytoplasmic N-cadherin expression, (Figure 5.14i-l), while E-cadherin 
expression was only observed sporadically in the tumour periphery or in the lining of 
cysts. Conversely, analysis of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/f;R26YFP/+ tumours 
revealed they contained higher expression of both N- and E-cadherin. While some 
tumours only displayed N-cadherin expression (Figure 5.14m), others solely 
expressed E-cadherin (Figure 5.14n). Additionally, some tumours were also found to 
contain increased expression of both N- and E-cadherin, which occupied non-
overlapping domains (Figure 5.14o-p). Interestingly, tumours previously observed to 
display a novel epithelial histology (shown in Figure 5.11d,h) possessed clear 
membranous E-cadherin expression in most cells, while membranous N-cadherin 
(i.e. non-diffuse or cytoplasmic) expression was also observed throughout the 
tumours (Figure 5.14q-t).  
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Figure 5.14 The expression of N- and E-cadherin in Hesx1Cre/+;Ctnnb1lox(ex3)/+ and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumours. 
 (a) Double immunostaining for N- and E-cadherin in a 5-week-old wild type pituitary 
showing that E-cadherin expression is mainly restricted to cells of the marginal zone 
(MZ) lining the pituitary lumen, while N-cadherin is expressed throughout the anterior 
lobe. (b) A Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary at the same stage shows accumulation 
of E-cadherin expression in the ventral pre-neoplastic regions (delineated by dotted 
line), while N-cadherin expression remains in normal anterior lobe regions. (c) A 15-
week-old Hesx1Cre/+;Ctnnb1lox(ex3)/+ specimen recapitulates this expression pattern. (d) 
A 20-week-old specimen in which non-cell autonomous tumour growth has initiated 
(growing tumour indicated by asterisk). Note the absence of expression of either N- 
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and E-cadherin in the early stage tumour. (e-h) Double immunostaining for β–catenin 
and E-cadherin in a 18.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitary showing the co-
expression of E-cadherin in β–catenin accumulating clusters and also in contiguous 
epithelial cells. Note the lack of E-cadherin expression in other cells surrounding the 
clusters. (i-l) Examples of different Hesx1Cre/+;Ctnnb1lox(ex3)/+ end-point tumours where 
diffuse N-cadherin expression can be found throughout the tumour tissue, while E-
cadherin expression is restricted to peripheral remnants or cysts linings. (m) A 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl tumour showing a similar cadherin expression 
pattern (diffuse N-cadherin in tumour cells and peripheral E-cadherin). (n) Example 
of a Trp53fl/fl tumour showing predominant E-cadherin expression. (o) Trp53fl/fl tumour 
displaying patches of cells with strong membranous E-cadherin expression. (p) A 
different region in same tumour as in (k) showing a large patch of membranous E-
cadherin expressing cells. (q-t) Examples from different regions in an epithelial 
Trp53fl/fl tumour. E-cadherin is expressed in most epithelial tumour cells, while N-
cadherin is also expressed in large patches of epithelial cells throughout the tumour. 
(t) High magnification of (s) showing the tumour is composed of sheets of folded 
epithelium mostly positive for membranous E-cadherin, while some membrane N-
cadherin+ cells are also observed. al: anterior lobe; il: intermediate lobe. Scale bars: 
a-d;m-t:150 μm, e-h: 75 μm .  
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5.4 Absence of p53 also leads to the cell-autonomous 
formation of pituitary tumours in an inducible mouse 
model for ACP 
5.4.1 p53 knockout demonstration and lineage tracing of 
targeted cells in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ 
pituitaries 
It was previously reported that inducible activation of oncogenic β-catenin in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice also lead to the non-cell autonomous 
development of pituitary tumours, as indicated by lineage tracing of targeted cells 
(Andoniadou et al. 2013). Importantly, preliminary RNA-sequencing data from the 
host lab has shown that the β-catenin clusters present in Sox2ERT2/+;Ctnnb1lox(ex3)/+ 
pituitaries also undergo senescence and possess a SASP (Scott Haston, unpublished 
data). Therefore, Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice were bred, 
induced and analysed postnatally in order to evaluate if p53 knockout could also lead 
to the cell-autonomous development of pituitary tumours in this inducible model.   
Knockout of p53 in the Sox2CreERT2/+;Ctnnb1lox(ex3)/+ β-catenin clusters 
The expression of p53 protein in β-catenin clusters was evaluated by double 
immunostaining in Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ (also referred to as 
Trp53fl/fl) and Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ pituitaries at 16 weeks 
post-tamoxifen induction. While Trp53fl/+ pituitaries showed p53 expression in β-
catenin clusters (arrows, Figure 5.15a), no positive staining was found in Trp53fl/fl 
clusters (Figure 5.15b), indicating successful removal of p53 in the 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ β-catenin clusters. 
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Figure 5.15 Double immunostaining for p53 and β-catenin in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ pituitaries and controls.  
(a) p53 protein accumulates in β-catenin clusters in a 16-week post-induction 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ pituitary (arrows). (b) Successful 
knockout of p53 in the β-catenin clusters of a 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ pituitary at the same stage. 
 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ pituitaries develop neoplastic 
lesions in both cell-autonomous and non-cell autonomous fashions 
To analyse the effect of p53 in the origin of pituitary tumours in the inducible 
model, pituitaries were collected at time of death and analysed for endogenous YFP 
expression as well as by immunostaining in paraffin sections. Notably, both Trp53fl/+ 
and Trp53fl/fl genotypes contained YFP+ and YFP- lesions (Figure 5.16a-d), 
suggesting once again that p53 is not required for senescence and SASP induction, 
but that it is necessary to prevent cell-autonomous tumour formation.  
The analysis of full-grown tumours was precluded as most mice died 
prematurely due to severe gastrointestinal complications between 11 to 13 weeks 
post-induction. These consisted of hypertrophy and neoplastic growth of the pyloric 
region which caused irreversible physical blockage. Consequently, the animals 
developed extreme swelling throughout the intestinal canal. Histologic analysis of 
pyloric lesions (n=2) showed that they were mostly composed of nucleocytoplasmic 
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β-catenin accumulating cells, of which only a small proportion where YFP+ (data not 
shown.)  
  Therefore, only 3 pituitaries (one Trp53fl/+ control and two Trp53fl/fl mutants) 
were found displaying full-grown tumours (over 500 μm across). Interestingly, the 
Trp53fl/+ tumour was mostly YFP- (Figure 5.16e), while both Trp53fl/fl tumours were 
mostly YFP+ (Figure 5.16b,d,f). Quantification of the number of lesions in all obtained 
pituitaries did not reveal any statistically significant differences in the number of YFP+ 
lesions between the Trp53fl/+ and Trp53fl/fl genotypes (Means: 2±0.67 and 2.87±0.65 
YFP+ lesions, respectively; p=0.421, ANOVA, N=11). Additionally, no differences 
were found in the number of YFP- lesions between the Trp53fl/+ and Trp53fl/fl pituitaries 
(Means: 0.4±0.5 and 0.87±0.484 YFP- lesions, respectively; p=0.225; ANOVA, 
N=11). Also, no significant differences were found when both genotype and the age 
of death post-induction were considered together in the statistical analysis (p=0.466 
for YFP+ lesions and p=0.568 for YFP- lesions, ANOVA).  
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Figure 5.16 Lineage tracing analysis of Sox2+ cells in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ and control pituitaries.  
(a) Fresh-dissected 16-week post-induction (PI) Trp53fl/+ pituitary showing 
endogenous YFP fluorescence in the Sox2+ lineage present throughout the pituitary 
anterior and intermediate lobes. (b) Example of a 16-wk. PI Trp53fl/fl pituitary 
displaying a large YFP+ tumour (arrow) and a smaller YFP- lesion. (c) Example of a 
20-wk. PI Trp53fl/+ pituitary with a YFP+ lesion (arrow). (d) Example of a 20-wk. PI 
Trp53fl/fl pituitary with YFP+ tumour (arrow). (e) Fluorescent immunostaining for YFP 
in an end-point Trp53fl/+ tumour shows that most of the tumour is YFP-, while YFP+ 
signal is observed in peripheral cells. (f-g) Immunofluorescence for YFP in sections 
from pituitary shown in (b) exhibiting a large YFP+ tumour (arrows, f) next to a YFP 
negative lesion (arrowhead, f). A larger YFP- lesion is observed in a different non-
consecutive section (contralateral) next to other YFP+ lesions (g, arrows). Scale bars: 
1 mm a,b,c,d; 500 μm e,f,g. 
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5.5 Chapter 5 conclusions 
Altogether, chapter 5 presents evidence indicating that p53 is not necessary to 
induce senescence and the SASP in β-catenin-accumulating clusters. In addition, the 
SASP from these clusters was no different from that found in the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ background, which was reflected in the presence of an 
altered microenvironment (e.g. SOX9+/EMCN+ cell swarms interacting with the 
clusters). Importantly, complete p53 inactivation generated a bias towards cell-
autonomous pituitary tumours with increased malignancy phenotypes. This could 
possible be due to senescence escape from a cluster cell or any other target cell 
bypassing senescence. Despite the objective of ablating p53 being to prevent 
senescence and SASP activation, this result still falls in line with the paracrine model 
of tumourigenesis, as it suggests that a period of latency before tumour formation 
might involve the competition between cell-autonomous and non-cell autonomous 
populations competing. This phenomenon could be visualised in 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ pituitaries in which both types of 
tumours could be observed growing in the same organ. In this regard, it is interesting 
to consider the possibility that the SASP might be necessary for both types of 
tumourigenesis. 
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6. GENERAL DISCUSSION 
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In this thesis, the role of senescence and the SASP during ACP pathogenesis 
were studied under a model of paracrine tumourigenesis. In Chapter 3, an embryonic 
mouse model of ACP was validated for the study of non-cell autonomous tumour 
formation. Additionally, the senescent phenotype and the SASP of the β-catenin 
clusters were characterised in murine and human ACP. Finally, changes in the 
tumourigenic microenvironment mediated by the SASP were investigated. Chapters 
4 and 5 described attempts to ablate the β-catenin clusters and the SASP in order to 
abrogate paracrine tumourigenesis. In Chapter 4, the CXCR4/SDF-1 chemokine 
pathway was targeted to restrict pro-survival signalling in the clusters. In Chapter 5, 
an attempt to challenge senescence was conducted by ablation of the tumour 
suppressor p53 and a potential role for p53 in preventing cell-autonomous 
tumourigenesis was revealed. Additionally, an appendix chapter was included in 
chapter 7, which describes preliminary data of great importance for this discussion 
chapter. 
6.1 A proportion of mouse ACP tumours are not 
derived from embryonic pituitary progenitors 
Lineage tracing studies previously revealed the intriguing non-cell autonomous 
origin of pituitary tumours derived upon activation of oncogenic β-catenin in adult 
SOX2+ pituitary stem cells (Andoniadou et al. 2013). This was surprising as it does 
not fit with the established cancer stem cell paradigm. Similar lineage-tracing studies 
have elegantly demonstrated the cell-autonomous origin of tumours in different 
contexts such as in the intestine, mammary gland, skin and prostate (Schepers et al. 
2012; Nakanishi et al. 2013; Zomer et al. 2013). This evidence helped to reinforce the 
notion that tumours are commonly formed from descendants of those cells carrying 
the initial oncogenic hit.  
In chapter 3, the origin of pituitary tumours was addressed in an embryonic 
mouse model for human ACP (Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice), in which the 
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vast majority of the pituitary progenitor cells would be targeted with oncogenic β-
catenin (instead of only a subset of SOX2+ cells). Tracing of the Hesx1-lineage at 
different time points of tumour formation showed: first, that most of the pituitary 
parenchyma is derived from Hesx1 progenitors at embryonic and postnatal stages; 
and second, that around 65% of pituitary tumours are not derived from the Hesx1-
lineage and are therefore induced non-cell autonomously (Figure. 3.1). Further 
evidence supporting these findings is currently being generated using 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26mTmG/+ mice in which targeted cells (pituitary cells) 
express membrane-EGFP, while tumours only express membrane-Tomato and are 
therefore derived from cells that have not undergone recombination. In conclusion, 
the expression of oncogenic β-catenin either in pituitary embryonic progenitors or 
adult pituitary stem cells leads to WNT-pathway overactivation in β-catenin cluster-
forming cells and the non-cell autonomous formation of pituitary tumours.  
Interestingly, all Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ postnatal pituitaries 
contained dysplastic regions in their ventral sides. These “pre-neoplastic” regions 
were formed by YFP+ epithelium (which contained nucleo-cytoplasmic β-catenin 
accumulating clusters) and an expanded YFP- stroma.  These pre-neoplastic regions 
remained in a non-proliferative state after birth and throughout early postnatal life, 
until a sudden burst of proliferation occurred in YFP- cells leading to their expansion 
until they formed full-grown YFP- tumours (Fig. 3.1). The absence of proliferation, 
followed by a drastic neoplastic growth suggests the existence of a latency period 
necessary for the tumour cell-of-origin to undergo a transformation process, during 
which the continuous paracrine activity of the clusters might also be involved.  
There is increasing evidence showing that tumours can also arise non-cell 
autonomously, which falls in line with findings here reported and also with those 
published in a different mouse model for ACP (Andoniadou et al. 2013). For example, 
cells carrying mutations in Notch1 or β-catenin in mouse epidermis and hair follicle 
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respectively, were shown to induce overactivation of the WNT pathway in 
neighbouring cells and non-cell autonomous tumour formation (Deschene et al. 2014; 
Nicolas et al. 2003). One notable example showed that expression of oncogenic β-
catenin specifically in osteoblasts resulted in the development of transformed 
hematopoietic stem cells (HSCs), which carried a different set of genetic alterations 
and could give rise to acute myeloid leukaemia (AML). Furthermore, after wild-type 
HSCs were transplanted into lethally irradiated mice expressing oncogenic β-catenin 
in osteoblasts, it was demonstrated that the HSCs became proper CSCs able to give 
rise to AML, even when transplanted back into wild type hosts (Kode et al. 2014). 
Therefore, it is proposed that Hesx1Cre/+;Ctnnb1lox(ex3)/+  mice represent a valid model 
for the study of paracrine tumourigenesis.  
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6.2 β-catenin accumulating clusters of mouse and 
human ACP undergo senescence and activate the 
SASP 
 Nucleo-cytoplasmic β-catenin accumulating clusters are a defining feature of 
human ACP. However, their role in the development and progression of ACP is not 
yet fully understood. This thesis provides further evidence supporting a model of a 
paracrine tumourigenesis mechanism orchestrated by the clusters in mice and 
humans. Specifically, it is demonstrated that the clusters undergo cellular senescence 
and it is proposed that this enables them to secrete pro-tumourigenic factors that 
potentially drive ACP development. 
6.2.1 Mouse and human ACP β-catenin clusters express 
markers of senescence 
It was previously suggested that the absence of proliferation markers in the β-
catenin clusters from both murine and human ACP indicated that they undergo a 
quiescent state (Buslei et al. 2007; Gaston-Massuet et al. 2011). This, together with 
the expression of different stem cell markers led to the initial hypothesis that the 
clusters possessed a stem cell-like nature (Gaston-Massuet et al. 2011; Garcia-
Lavandeira et al. 2011; Hölsken et al. 2013). However, the discovery that murine ACP 
tumours are not derived from cluster cells challenges this notion and would make 
difficult to explain the persistence of such as small, non-dividing, cell population 
throughout tumour development, besides being spared by the immune system or not 
being out-competed by growing tumour cells. In this thesis, cellular senescence was 
investigated as a potential mechanism able to explain both the clusters’ proliferative 
inactivity and their paracrine contribution to the tumourigenic microenvironment. 
Here it was confirmed that embryonic Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters lack the 
expression of proliferation markers and do not undergo apoptosis at 18.5 dpc (Fig. 
3.2), which indicates a permanent but viable cell-cycle arrest in accordance with a 
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senescent phenotype in vivo (Michaloglou et al. 2005; Xue et al. 2007). Human ACP 
clusters have previously been described to not be proliferative nor apoptotic (Buslei 
et al. 2007; Gaston-Massuet et al. 2011; Zhu & You 2015).  
Because cellular senescence cannot be determined accurately using a single 
marker, an extensive characterisation was conducted for the expression of markers 
involved in pathways and biological mechanisms shown to be crucial for the induction 
and maintenance of senescence: the lysosomal compartment, cell cycle inhibition 
and the DNA-damage response (DDR).  
First it was shown that Hesx1Cre/+;Ctnnb1lox(ex3)/+ β-catenin clusters accumulate 
SA-β-Gal, the most widely used marker for senescence (Fig. 3.3a). Additionally, an 
antibody against the SA-β-Gal enzyme, GLB1, was used to accurately determine the 
accumulation of this protein in the β-catenin clusters in both mouse and human ACP 
(Fig. 3.3b,c). Finally, Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters and human ACP also 
accumulated lysosomal proteins such as Lysozyme C, LAMP1 and LAMP2 (Figs. 
3.3d,e and 3.4). Together, this indicates that the β-catenin clusters possess an 
expanded lysosomal compartment, in agreement with a senescent phenotype, as 
senescent cells display increased metabolic requirements in order to maintain their 
highly active secretory machinery (Kurz et al. 2000; Dörr et al. 2013).  
The p53/p21 and Rb/p16INK4a pathways are known to be crucial for oncogene-
induced senescence (OIS) in vivo (Serrano et al. 1997; Ventura et al. 2007; Sarkisian 
et al. 2007; Feldser et al. 2010), including senescence induced by WNT pathway 
overactivation (Sato et al. 2015; Debies et al. 2008). Here it was shown that human 
and murine β-catenin clusters are mostly composed of p53+, p21+ and p16+ cells 
(Fig. 3.5), further supporting their senescent phenotype and suggesting that the 
induction and maintenance of senescence could be mediated by at least one of these 
pathways in clusters. Studies in human ACP have focused on showing a correlation 
between the expression of the tumour suppressors p53 and p16 in histological 
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sections with clinico-pathological data, such as tumour recurrence, in hopes of finding 
better molecular prognostic markers. Although this approach has been successful for 
other types of tumours (Collado et al. 2005; Junttila et al. 2010), 
immunohistochemical analysis for p53 in human ACP has reported conflicting results 
(Momota et al. 2003; Lefranc et al. 2003; Tena-Suck et al. 2006), while p16 
expression was reported to be variable between samples (Rodriguez et al. 2007). 
Additionally, mutations in TP53 have not been found in human ACP (Nozaki et al. 
1998; Janzer et al. 2000). Because the analysis of single sections or the sequencing 
of whole tumour samples makes it difficult or impossible to take into account restricted 
cell populations, these results help explain previous confounding data by suggesting 
that cell cycle-inhibiting pathways play an important role in the onset and 
maintenance of senescence mainly in β-catenin clusters rather than throughout the 
tumour tissue.  
DNA damage induced by oncogene signalling and the resulting DDR are 
essential for onset of senescence and the SASP (Bartkova et al. 2006; Mallette et al. 
2007; Fumagalli et al. 2014; Rodier et al. 2009; Kang et al. 2015). Here it is shown 
that both murine and human clusters express the DNA damage marker 𝛾H2AX, as 
well as key DDR effectors PARP-1 and phosphorylated-DNA-PKcs (Figs. 3.6 and 
3.7), in agreement with findings showing that β-catenin/WNT pathway overactivation 
mediates senescence and DNA-damage in vitro and in vivo (Gu et al. 2014; Zhang 
et al. 2011; Xu et al. 2008). 
6.2.2 Differences in senescence-related pathways between 
mouse and human ACP  
There is strong evidence supporting the role of mTOR signalling for senescence 
and SASP induction (Herranz et al. 2015; Laberge et al. 2015). In this thesis, analysis 
of the mTOR and autophagy pathways in murine and human clusters revealed 
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inconclusive results. While ~50% of murine clusters displayed activation of 
downstream mTOR signalling by phosphorylation of ribosomal protein S6 and none 
by phosphorylation of 4E-BP1, phosphorylated S6 was absolutely absent from human 
ACP clusters and ~50% displayed 4E-BP1 phosphorylation (Fig. 3.8). These 
discrepancies might be related to the presence of distinctly phosphorylated species 
of S6 and 4E-BP1, which might not be detectable with the antibodies used in this 
study. However, it must also be taken in consideration that the p70 S6K and 4E-BP1 
downstream responses are not necessarily redundant and could play context-
dependent or even species-dependent roles. In the developing murine cerebellum, it 
has been shown that these two mTOR signalling branches have very distinct 
functions in the proliferation of neural precursors: while S6K activity lead to cell cycle 
arrest, eIF4E is required for their proliferation (Mainwaring & Kenney 2011). 
Interestingly, these differential responses were shown to depend on SHH signalling, 
a factor known to be highly expressed by the clusters. Additionally, it has also been 
shown that the effect of the mTOR inhibitor rapamycin can have distinct effects on 
S6K and 4E-BP1 (Choo et al. 2008). 
 Activation of mTOR signalling is known to lead to the inhibition of autophagy 
(Sarkar 2013), which can be assessed by the accumulation of autophagy effector 
proteins p62/SQSTM and LC3 (Tanida et al. 2010). While p62/SQSTM protein clearly 
accumulated in clusters from both mouse and human ACP, suggesting impairment of 
autophagy, clear LC3 accumulation could only be observed in human ACP clusters. 
Overall, these results are difficult to reconcile using only immunostaining data, and 
despite p62 and LC3 accumulation determined by immunostaining can serve as 
reliable markers in some contexts, caution should be taken as their accumulation can 
also be context-dependent (He & Klionsky 2009). Therefore, further experiments are 
needed to appropriately determine the status of the autophagic machinery in mouse 
and human ACP. Particularly, the conversion of LC3I to its lipidated form, LC3II, is 
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considered a robust marker for autophagy and should be evaluated by western 
blotting (Klionsky et al. 2016). 
Although further experiments are needed to clarify the results here presented, 
these observations suggest that mTOR signalling could be involved in the onset of 
senescence and the SASP through distinct downstream mechanisms in the β-catenin 
clusters of mice and humans. Importantly, mTOR inhibition by rapamycin treatment 
has also been shown to abrogate the translation of SASP factors and their pro-
tumourigenic effects (Herranz et al. 2015; Laberge et al. 2015). Therefore, further 
insight into the role of mTOR and autophagy in ACP pathogenesis could validate the 
use of mTOR inhibitors as therapeutic options for the treatment of ACP. 
6.2.3 Mouse and human ACP β-catenin clusters activate the 
NF-κB pathway and the SASP 
It was previously shown that the β-catenin clusters of human ACP, as well as 
those from two different mouse ACP models (Hesx1Cre/+;Ctnnb1lox(ex3)/+ and 
Sox2;Ctnnb1lox(ex3)/+ mice), express a wide array of secretory mitogenic and 
inflammatory signalling molecules, some of which are recognised as commonly 
expressed SASP factors (Andoniadou et al. 2012; Andoniadou et al. 2013). 
The activation of the SASP has been shown to depend on the NF-κB pathway 
(Acosta et al. 2008; Ohanna et al. 2011; Freund et al. 2011). Therefore, the 
expression of key markers of NF-κB pathway activation (RelA/p65, NEMO, and 
phosphorylated IκBα) was analysed in the β-catenin clusters, showing a robust 
activation of the pathway in both the Hesx1Cre/+;Ctnnb1lox(ex3)/+ and human ACP 
clusters (Fig. 3.10). This suggests that onset of senescence and NF-κB pathway 
activation enables the clusters to become the source of a broad number of previously 
validated mitogenic factors like SHH, FGFs, BMPs and WNTs (Andoniadou et al. 
2012). In fact, these pathways have been shown to be activated by NF-κB 
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(Kasperczyk et al. 2009; Salminen et al. 2012; Park et al. 2016; Du & Geller 2010). 
Importantly, an unbiased transcriptomic analysis revealed a significant enrichment for 
oncogene-induced senescence (OIS) and SASP genes in Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
and human ACP β-catenin clusters in comparison to non-cluster tissue (Fig. 3.11a,d). 
Interestingly, murine and human ACP cluster gene expression signatures group 
together (Fig. 3.11e), indicating these are analogous biological entities. In the mouse, 
the overexpression of key SASP factors in mutant pituitaries was validated at mRNA 
and protein levels (Fig. 3.11b,c). Additionally, a similar analysis has been conducted 
in FACS-sorted β-catenin cluster cells from Sox2CreERT2/+;Ctnnb1lox(ex3)/+;R26YFP/+ 
pituitaries, which also displayed enrichment for the expression of OIS and SASP 
genes (Scott Haston, unpublished results).  
 
6.3 Remodelling of the tumourigenic 
microenvironment by the SASP precedes non-cell 
autonomous tumourigenesis 
The non-cell autonomous origin pituitary tumours in Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
and Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice, together with the demonstration of a senescent 
phenotype in the β-catenin clusters suggests the SASP is responsible for generating 
a pro-tumourigenic microenvironment that will promote the recruitment and/or 
transformation of an unknown cell of origin. As mentioned in the introduction, the 
SASP can achieve this in part by mediating angiogenesis (Davalos et al. 2010) and 
remodelling of the extracellular matrix (ECM) (Krizhanovsky et al. 2008; Coppé et al. 
2008).  
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6.3.1 A population of EMCN+/SOX9+ endothelial progenitors 
responds to β-catenin cluster signalling 
Here, the effects of the SASP on the vascular compartment and the ECM were 
investigated in Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryonic pituitaries, well before the onset 
of tumour growth. Surprisingly, an aberrant population of EMCN+ cells was 
discovered in mutant embryonic pituitaries, existing in much larger numbers than their 
wild type counterparts (Fig. 3.16). These cells were not derived from pituitary 
embryonic progenitors (as determined by lineage tracing). In addition, they occupied 
the totality of the pituitary stroma and were associated with ECM components (Fig. 
3.17). Initial characterisation of the Hesx1Cre/+;Ctnnb1lox(ex3)/+ EMCN+ population 
showed they did not form part of the normal pituitary vasculature, as they did not 
colocalise with PECAM nor form normal tubular vessels (forming instead large cell 
“swarms”) and expressed the mesenchymal progenitor marker vimentin (Fig. 3.18). 
Interestingly, EMCN+ swarms expressing high levels of SOX9 (EMCN/SOX9high) 
interacted closely with the β-catenin clusters (Fig. 3.19). The EMCN+/SOX9+ 
population was also present during wild type pituitary development and it was 
observed to invade the pituitary parenchyma around 14.5 dpc., consistent with 
observations describing the formation of the pituitary stroma (Hashimoto et al. 1998). 
However, in 16.5 dpc wild type embryos SOX9 expression was already 
downregulated in EMCN+ cells, which formed part of the normal pituitary vasculature 
by that stage (Fig. 3.20a-d). Conversely, in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries 
EMCN+/SOX9+ cells interacted with the clusters as early as 12.5 dpc and this close 
association was maintained throughout embryonic development (Figure 3.20e-h). 
Because EMCN+ cells maintained their large numbers and SOX9 expression was not 
downregulated in the presence of β-catenin clusters, these results suggest that the 
paracrine signals produced by the clusters are involved in the recruitment and 
maintenance of a EMCN+/SOX9+ population of endothelial progenitors. Furthermore, 
 211 
EMCN+/SOX9+ swarms were also found in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl (Figs. 
4.14 and 4.17) and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries (Fig. 5.8). Here, the 
expression of secretory factors in embryonic β-catenin clusters appears to remain 
unaltered, while it was previously shown that Sox2CreERT2/+;Ctnnb1lox(ex3)/+ β-catenin 
clusters also interact closely with EMCN+ blood vessels (Andoniadou et al. 2013).  
6.3.2 Remodelling of the microenvironment and non-cell 
autonomous tumourigenesis does not occur in the presence 
of a dampened secretory phenotype 
The expansion of an EMCN+/SOX9+ population that closely interacts with the 
β-catenin clusters suggests this is a phenomenon mediated by the SASP. In order to 
further interrogate the role of senescence and the SASP in pituitary tumourigenesis, 
these were investigated in Hesx1Cre/+;Apcfl/fl mice, in which overactivation of the WNT 
pathway in embryonic pituitary progenitors occurs in the context of wild-type β-
catenin. An overview of ongoing results is presented as an appendix (Chapter 7). 
Importantly, Hesx1Cre/+;Apcfl/fl pituitaries also contained nucleo-cytoplasmic β-catenin 
accumulating clusters similar to those from Hesx1Cre/+;Ctnnb1lox(ex3)/+ embryos (Fig. 
7.1a,b and 7.2a). Hesx1Cre/+;Apcfl/fl clusters display a senescent phenotype, as they 
are also non-proliferative, express p16 and p21, activate a DDR, and the NF-κB 
pathway (Fig. 7.2b). However, analysis of the expression of SASP factors by qRT-
PCR and ISH revealed these clusters display a dampened SASP signature (Fig. 
7.2c,d). Notably, an expanded EMCN+/SOX9+ population was not observed 
Hesx1Cre/+;Apcfl/fl embryonic pituitaries, while the EMCN+ vasculature resembled 
more that of wild type pituitaries and did not appear to interact with the clusters (Fig. 
7.2e,f). Analysis of postnatal Hesx1Cre/+;Apcfl/fl pituitaries revealed they did not contain 
β-catenin clusters nor pre-neoplastic regions and, crucially, Hesx1Cre/+;Apcfl/fl adult 
mice did not develop pituitary tumours at any point, even after several generations. 
Preliminary data obtained in Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice induced at advanced 
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age indicates that they also do not develop pituitary tumours and that their β-catenin 
clusters also possess a dampened SASP signature (Scott Haston, unpublished 
results). 
These observations provide strong evidence supporting the role of senescence 
and the SASP in the induction of non-cell autonomous tumourigenesis in mouse 
models for ACP. However, it is not possible to dissect the role of WNT signalling from 
senescence and the SASP using the models and tools here presented. Further 
experiments aiming to ablate the clusters should be conducted, either through genetic 
strategies or chemically, by using drugs that selectively target senescent cells 
(senolytics). One promising candidate is ABT263, an inhibitor of BCL-2 and BCL-xL, 
which was recently shown to specifically induce apoptosis in bone marrow senescent 
cells (Chang et al. 2016). Therefore, selective targeting of senescent cluster cells in 
mouse ACP models will provide conclusive evidence demonstrating the role of these 
structures in pituitary tumourigenesis and support their use in the treatment of human 
ACP.  
6.3.3 The EMCN+/SOX9+ cell as candidate cell-of-origin of 
non-cell autonomous pituitary tumourigenesis in mice 
During the writing process of this thesis, the host lab began a thorough analysis 
of 15 Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours by exome sequencing. Preliminary results 
identified 130 different mutations of which 5 were found to be recurrent, which 
indicates that these are indeed neoplastic entities and further supports the idea that 
the SASP might be involved in the transformation of a cell-of-origin. Additionally, the 
host lab is currently analysing transcriptomic data of Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours 
at different time points. Further interrogation of expression data from these tumours 
could potentially provide clues leading to the identity of the cell of origin.  
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However, an interesting possibility arising from the results here presented is 
that a EMCN+/SOX9+ cell could be the cell-of-origin giving rise to 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours. As previously described, this population interacts 
very closely with the clusters throughout pituitary development and suggests these 
cells respond to their signalling. The aberrant expression of SOX9 in these cells also 
suggests alterations in their genetic programme. SOX9 is a transcription factor 
involved in the multipotential capacity of progenitor cells in many tissues and also in 
cancer stem cells (Jo et al. 2014). SOX9 was shown to promote the cancer stem cell 
phenotype and self-renewal in basal cell carcinoma (BCC) (Larsimont et al. 2015). 
Additionally, SOX9+ was found to promote self-renewal in hepatocellular carcinoma 
(HCC) CSCs in vitro (Liu et al. 2016), while SOX9+ was specifically expressed in 
HCC cells with CSC potential as determined by xenotransplantation experiments 
(Kawai et al. 2016). Importantly, SOX9 is thought to lie downstream of SHH, one of 
the most upregulated factors secreted by the β-catenin clusters. In the developing 
neural tube, SOX9 has been shown to mediate SHH-dependent maintenance of 
neural progenitors (Scott et al. 2010), while it was shown that the dependence of 
different types of medulloblastoma for SHH signalling was mediated by SOX9 
(Swartling et al. 2012). Intriguingly, EMCN/SOX9 cells could not be observed 
postnatally, whereas in the embryonic pituitary they occupy vast regions of the 
pituitary stroma. This suggests further phenotypic/molecular changes occurring in 
these cells and that they may eventually become part of the non-epithelial/YFP- 
component of Hesx1Cre/+;Ctnnb1lox(ex3)/+ pre-neoplastic regions from which tumours 
are hypothesised to eventually arise (Fig. 3.1). Further evidence suggesting that the 
pre-neoplastic regions are remnants of the embryonic pituitary is provided in figure 
5.14a-d, where the pre-neoplastic epithelia (which contain the remaining β-catenin 
clusters) maintained the expression of E-cadherin, whereas it is known that E-
cadherin expression in the wild type pituitary is downregulated postnatally and 
restricted only to progenitors of the marginal zone (MZ) (Chauvet et al. 2009; Kikuchi 
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et al. 2007). Therefore, the hypothesis of an EMCN+/SOX9+ cell as candidate cell-
of-origin is supported by the possibility that these cells represent the (non-Hesx1 
derived) population that maintains closest contact with the clusters for an extensive 
period that encompasses embryonic development and postnatal life. 
 To demonstrate the connection between EMCN/SOX9+ cells with the YFP- 
pre-neoplastic regions and YFP- tumours, chimeric experiments using a SOX9-
lineage reporter should be conducted. However, identification of the tumour-cell-of 
origin might require a more extensive approach involving similar chimeric 
experiments with reporter lines for distinct candidate lineages. Although EMCN is a 
well-established endothelial marker, the exact origin of the components of the 
pituitary vasculature has not been extensively investigated in mice and humans. A 
candidate lineage of origin for the pituitary vasculature is the neural crest (NC), as 
SOX9 is strongly involved in NC migration (Cheung & Briscoe 2003; Theveneau & 
Mayor 2012). It is generally accepted that the neural crest contributes to blood vessels 
and connective tissue throughout the embryonic head. Quail-chick transplantation 
experiments showed that neural crest cells indeed contribute to the pituitary 
vasculature and connective tissue (Etchevers et al. 2001; Le Douarin et al. 2004). 
More recently, a NC-lineage reporter line (Wnt1Cre) was shown to label cells migrating 
into the pituitary anterior lobe at 14.5 dpc, similar to the EMCN+/SOX9+ cells 
observed in WT pituitaries (Fig. 3.20). Moreover, ablation of β-catenin in NC cells 
disrupted the pituitary vasculature due to complete loss of pericytes (Davis et al. 
2016).  Besides the NC, other candidate lineages worth investigating are: the Vav1-
lineage, as EMCN also represents a marker of haematopoietic progenitors throughout 
development (Matsubara et al. 2005; Brachtendorf et al. 2001) and the Tie2 lineage, 
which represents the endothelial cell lineage (Kisanuki et al. 2001). 
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6.3.4 Differences in ACP pathogenesis between mouse 
models and humans 
Contrary to the murine models, exome-sequencing of different compartments 
of human ACP (i.e. clusters, stellate reticulum, palisaded epithelium) revealed that 
they all contained equal frequencies of CTNNB1 mutations, indicating human ACPs 
are clonal in origin and that they follow a cell-autonomous origin . Further differences 
between human ACP and the murine model are exemplified by the expression pattern 
of EMCN. Although the expression pattern of EMCN and SOX9 did not resemble that 
found during Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumourigenesis, human EMCN+ cells rarely 
formed part of a developed vascular system in human ACP. Instead, they were often 
present as single cells or large cell agglomerations within microcysts, suggesting 
active remodelling/migration (Fig. 3.21g,h). Additionally, some ACP cases contained 
vast numbers of EMCN+ cells which occupied most of the extra-tumoural tissue (Fig. 
3.21d,e,f,I,j,k,l), otherwise known as reactive glial-tissue, and intermingled with the 
tumour in a pattern reminiscent of the EMCN+/SOX9+ swarms from the mouse ACP 
model. Because β-catenin clusters are often located to the tumour invasion front, it is 
possible that signalling occurs with the extra-tumoural space in order to recruit large 
numbers of EMCN+ cells. In conclusion, although the cell of origin and mechanisms 
underlying ACP formation might differ between mice and humans, the paracrine 
activities of the β-catenin clusters through the SASP might lead to similar pathogenic 
mechanisms such as remodelling of the microenvironment and recruitment of 
endothelial progenitors with pro-tumourigenic activities.  
Of interest, preliminary RNAseq results suggest that the β-catenin clusters from 
both mouse and human ACP share a transcriptional profile reminiscent of the enamel 
knot (John Apps, unpublished results). The enamel knot is a transient signalling 
centre of great importance for proper tooth development. It shares indeed many 
features with the senescent β-catenin clusters, such as the secretion of signalling 
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factors (SHH, FGFs, BMPs) and p21 accumulation (Li et al. 2016). Coincidentally, the 
similarities between human ACP and odontogenic tumours had previously been 
noted such as enamel protein expression and presence of ghost cells (Sekine et al. 
2004; Mehendiratta et al. 2012). Further understanding of the role of key genes and 
signalling pathways involved in the crosstalk between signalling centres, such as the 
enamel knot, and the microenvironment could provide novel targets leading to the 
ablation of senescent β-catenin clusters in mouse and human ACP.    
 
6.4 Chemokine signalling promotes further cell 
recruitment into the tumourigenic microenvironment  
In chapter 4, conditional knockout of the chemokine receptor CXCR4 was 
performed to deprive the β-catenin clusters from a crucial growth/survival factor. 
However, CXCR4 knockout did not affect cluster survival or their secretory phenotype 
(Figs. 4.14 and 4.15) and remodelling of the microenvironment was unchanged as 
evidenced by the recruitment EMCN+ swarms (Fig. 4.17e), while pituitary tumours 
still developed (Fig. 4.16). These results warn against further attempts targeting the 
cluster’s survival through a single growth factor/trophic pathway, as it is possible that 
multiple signalling pathways converge on the same downstream effectors of cell 
survival and compensate for the loss of a single receptor. Resistance of the β-catenin 
clusters to cell death could be a result of the senescent phenotype itself, as senescent 
cells are known to be resistant to apoptosis induced by nutrient-deprivation (Sasaki 
et al. 2001; Burton & Faragher 2015). Additionally, the main pro-survival pathway 
activated by CXCR4/SDF-1 is NF-κB signalling (Rehman & Wang 2009; Teicher & 
Fricker 2010) and in chapter 3 it is demonstrated that the clusters themselves are the 
source of a plethora of pro-survival factors such as IL1A, and IL1B which are crucial 
activators of NF-κB signalling (Lawrence, 2009).  
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Another issue to discuss is the possibility that deletion of CXCR4 might result 
detrimental to tumour formation, as the survival curve of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl mice crossed that of their heterozygous controls, 
giving the impression they might die sooner than expected (Figure 4.16e). Although 
this result was not statistically significant, there were not enough animal numbers to 
reach any conclusion. However, it must be noted that the goal of these experiments 
was to ablate the clusters themselves and to prevent tumour formation, not to 
evaluate rate of tumour growth (data on tumour size was not collected for these 
genotypes).  
Besides showing that CXCR4/SDF-1 signalling is not necessary for β-catenin 
cluster survival, results presented in chapter 4 provide insight into the crosstalk 
occurring across the evolving tumourigenic microenvironment. Notably, CXCR4+ 
cells were found to interact closely with the clusters in both mouse and human ACP 
(Figs. 4.8 and 4.10). However, the source of SDF-1in both mouse and humans was 
not the clusters themselves (Figs. 4.9a-c and 4.11a-c). In the mouse, the source of 
SDF-1 was found to be stromal cells invading the pituitary anterior lobe (Fig. 4.9c). 
This discrepancy suggests that CXCR4 might be instead involved in long distance 
migration of cells from a different compartment to the tumourigenic pituitary gland. 
This is supported by the finding of CXCR4+ tip cells displaying filopodial processes, 
observed even after CXCR4 conditional knockout in the Hesx1 lineage (Fig. 4.17a-d) 
and that these were also present within the EMCN+ swarms (demonstrated to not 
belong to the Hesx1 lineage) (Fig. 4.17). Moreover, analysis of postnatal mutant 
pituitaries at different stages revealed that the pre-neoplastic regions contain large 
numbers of non-Hesx1-derived CXCR4+ cells also displaying filopodia (Fig. 4.18a-
d,g-h). Finally, end-point tumours (which were non-cell autonomous in origin) 
displayed extensive presence of CXCR4+ mesenchymal cells and profuse CXCR4+ 
vascularisation (Fig. 4.18e,f,i,j). Because EMCN+/SOX9+ cells occupy the whole 
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stromal compartment in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries, it is likely that they are 
also the invasive cells that become the source of SDF-1. Additionally, preliminary 
experiments show that Hesx1Cre/+;Apcfl/fl pituitaries do not have an expanded SDF-1-
expressing population and it has been shown that they also do not display swarms of 
EMCN+/SOX9+ cells (Fig. 7g). Indeed, endothelial cells and perivascular stromal 
cells are the most commonly described sources of SDF-1 in normal and pathogenic 
contexts (Pitt et al. 2015; Ding & Morrison 2013). 
Although CXCR4 and SOX9 share a similar expression pattern in cells that 
appear to interact with the β-catenin clusters, it was never shown that these proteins 
are co-expressed in the same cells. Therefore, this would be a necessary 
demonstration. If indeed CXCR4+/SOX9+ cells are shown to be present throughout 
pituitary development and interacting with the clusters, then chemical targeting of 
CXCR4 could potentially prevent the recruitment of these cells to the clusters. 
 Chapter 4 additionally provides evidence of active signalling mediated by 
SASP, as the CXCR2 ligands CXCL1, CXCL2 and CXCL3 (all SASP factors) have 
been shown to be highly overexpressed by the mouse clusters (Andoniadou et al. 
2012). Instead, the expression of the chemokine receptor CXCR2 was upregulated 
in non-cluster cells in Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries and tumours, as well as in 
human ACP (Figs. 4.9g-i and 4.11d-f).  
Together, these observations allow to envision a mechanism by which the 
senescent β-catenin clusters initially recruit and maintain EMCN+/SOX9+ swarms 
which contain a future tumour cell-of-origin. EMCN+/SOX9+ cells in turn secrete SDF-
1 which allows further recruitment of other cell types into the microenvironment which 
might also respond to local cluster signalling (e.g. CXCR2+ cells) and reinforce the 
paracrine tumourigenesis process (e.g. tumour-associated fibroblasts, pro-
inflammatory immune cells, endothelial cells, etc.) (Fig. 6.1). 
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In summary, the results presented in chapters 3 and 4 provide the basis for 
future research on the role of the tumourigenic microenvironment in the non-cell 
autonomous formation of pituitary tumours. Characterisation of the immune response 
is particularly encouraged as SASP factors are inherently pro-inflammatory and 
chronic inflammation is intimately associated with tumourigenesis (Crusz & Balkwill 
2015). Additionally, a better understanding of the inflammatory process occurring in 
mouse models of ACP will provide support for the use of small-molecule inhibitors for 
CXCR4 or CXCR2. The use CXCR4 antagonist AMD3100 (Plerixafor) has shown 
promising results as a chemosensitizer in the treatment of different types of 
leukaemias (Burger & Peled 2009; Uy et al. 2012) and it is currently being evaluated 
in clinical trials for the treatment of solid tumours such as pancreatic ductal 
adenocarcinoma, high grade ovarian, colorectal adenocarcinoma and breast cancers 
(Liu et al. 2015). Additionally, inhibition of CXCR2 has demonstrated to effectively 
impair tumour growth by preventing trafficking of myeloid-derived suppressor cells 
(MDSCs) in colorectal adenocarcinoma, pancreatic adenocarcinoma and 
rhabdomyosarcoma models (Highfill et al. 2014; Steele et al. 2016; Jamieson et al. 
2012). 
6.5 The role of p53 in WNT-driven tumourigenesis in 
the pituitary gland 
The demonstration of a senescent phenotype and the activation of the SASP in 
the β-catenin clusters, as well as their involvement in the modification of the 
tumourigenic microenvironment prompted the hypothesis that targeting the onset of 
senescence in these structures would prevent SASP activation and therefore 
abrogate non-cell autonomous tumourigenesis. As presented in the general 
introduction, the onset and maintenance of senescence has been demonstrated to 
depend on p53 in many contexts, including in vivo cancer studies (Muñoz-Espín & 
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Serrano 2014). Therefore, chapter 5 introduced the characterisation of a Hesx1Cre/+; 
Ctnnb1lox(ex3)/+;Trp53fl/fl mice, in which expression of the tumour suppressor p53 was 
ablated in embryonic pituitary progenitors and therefore, in the clusters (Fig. 5.1).  
6.5.1 p53 is not required for inducing senescence and the 
SASP in the embryonic β-catenin clusters 
Unexpectedly, embryonic Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl clusters lacked the 
expression of proliferation markers (Fig. 5.2), did not undergo apoptosis (Fig 5.3), 
maintained the expression of p21 and p16 (Fig. 5.4) and activated the DDR (Fig. 5.5). 
Moreover, analysis of the clusters’ secretory phenotype by qRT-PCR and ISH 
revealed no significant changes in the expression of mitogenic factors Shh, Bmp4, 
Fgf3 and Wnt6; nor of key SASP factors Il1a, Il1b, Il6, Cxcl1, Cxcl2 and Ccl20. Finally, 
analysis of the stromal compartment revealed that 18.5 dpc 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries also contained an expanded 
EMCN+/SOX9+ population (Fig. 5.8). Together, this evidence indicates that p53 is 
not required for the induction and maintenance of senescence in β-catenin clusters 
and their SASP during embryonic pituitary development and therefore, a different 
pathway must mediate this process. 
A number of studies have demonstrated the dispensability of p53 in oncogene-
induced senescence and identified other pathways responsible for mediating this 
process. Although the p53-dependent cell cycle arrest occurs mainly through 
activation of p21, it has been shown senescence can be achieved in the absence of 
p53 through the induction of p21 by other pathways. It has been demonstrated that 
p21 activation can occur through the DDR-related kinase Chk2 (Aliouat-Denis et al. 
2005), downregulation of protein arginine methyltransferase 6 (PRMT6) (Phalke et al. 
2012) or inactivation of the E3 ligase complex component Skp2 (Lin et al. 2010). p53-
independent OIS has also been reported to be mediated by products of the CDKN2A 
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locus (p16INK4A and p19ARF) (Christoffersen et al. 2010; Ha et al. 2007; Haferkamp et 
al. 2009) or the p38 MAPK pathway (Kwong et al. 2009). Additionally, it has been 
revealed that developmentally programmed senescence is mediated by p21 through 
TGF-β/SMAD signalling, independently of p53 and p16/ARF (Muñoz-Espín et al. 
2013). Further examples have shown that OIS can even be induced without the 
requirement of p53, p21 and p16 (Cipriano et al. 2011; Prieur et al. 2011).  Finally, 
certain isoforms of p63, a member of the p53-family, were demonstrated to induce 
OIS in vivo by activation of p21, also independently of p53 (Guo et al. 2009). 
Interestingly, p63 is highly expressed in human ACP (Cao et al. 2010; Esheba & 
Hassan 2015) and preliminary data has also identified its expression in the human β-
catenin clusters (John Apps, unpublished results).  
Therefore, the induction of senescence in β-catenin clusters might depend on 
one or more of the pathways just described. Also worth of discussion is the fact that 
the expression of several SASP factors was not affected after p53 knockout of in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl embryonic pituitaries (Figs. 5.6 and 5.7), while the 
expansion of EMCN+/SOX9+ cell swarms remained unchanged (Fig. 5.8). This was 
also an unexpected result, as it has been observed that p53-deficient senescent cells 
display a significant increase in the secretion of SASP factors and exacerbation of 
the pro-tumourigenic effects of the SASP in the microenvironment (Coppé et al. 2008; 
Rodier et al. 2009; Freund et al. 2011). Future experiments aiming at characterising 
the transcriptional profile of targeted cells isolated from 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+  pituitaries are being conducted to gain 
further insight into the pathways that mediate the senescence induction in p53-
deficient β-catenin clusters and to confirm that the SASP remains unchanged in these 
structures. 
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6.5.2 Complete absence of p53 promotes cell-autonomous 
tumourigenesis postnatally and associates with higher 
malignancy phenotypes 
Chapter 5 also demonstrates that, in the absence of p53, WNT-driven pituitary 
tumours arise in cell-autonomous fashion, despite the onset of senescence and the 
SASP in embryonic p53-deficient β-catenin clusters (Fig. 5.10). Indeed, lineage 
tracing experiments demonstrated that 100% of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours were mostly formed by oncogenic 
β-catenin-targeted YFP+ cells. Conversely, the number of YFP+ tumours observed 
in p53-wild-type and p53-heterozygous mice was 35.3% and 44.4%, respectively 
(further discussed below). Notably, complete inactivation of p53 led to a significant 
increase in mortality rate and tumour size in comparison to heterozygous controls. 
(Fig. 5.9). In this regard, it is important to discuss that the Trp53fl/fl survival curve is 
very similar to that of Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice (John Apps, personal 
communication). Although this would suggest that loss of only one Trp53 allele might 
have a positive effect in survival, care must be taken as comparison between different 
genetic backgrounds might render confounding results. For example, the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Cxcr4fl/fl curve is displaced far to the left compared to 
Hesx1Cre/+;Ctnnb1lox(ex3)/+. However, it was shown that these tumours do not differ in 
their phenotype and size (data not shown), while 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours are clearly different in phenotype 
and size. In conclusion, there is a high possibility that point of death does not correlate 
well with changes in tumour size or phenotype and is possibly more related to 
hydrocephalus formation and should be considered in future experiments. 
Trp53fl/fl tumours displayed distinct histopathological features indicating a 
higher malignancy grade (Fig. 5.11) and a much higher proliferative index compared 
to tumours derived non-cell autonomously (Fig. 5.12). This increase in proliferation 
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and malignancy upon complete abrogation of p53 falls in line with previous 
experiments conducted in mouse models of WNT-driven carcinogenesis (Kuo et al. 
2015; Méniel et al. 2014). Also of note, a small proportion of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ tumours displayed a novel epithelial-
histology (Fig. 5.11d,h). Therefore, complete absence of p53 in the context of 
oncogenic β-catenin generates a full bias for the cell-autonomous formation of 
pituitary tumours with increased proliferation and enhanced malignancy phenotypes. 
Importantly, some of the features acquired by p53 KO tumours are highly reminiscent 
of human ACP, such as the presence of epithelium (completely absent from classic 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ tumours) and acellular, keratinized deposits resembling 
human ACP “wet keratin”. Together with a drastic increase in proliferative and mitotic 
indexes, p53 KO tumours could provide a model in which to study malignant ACP 
pathogenesis. Although it was attempted, such tumours are extremely rare and no 
samples could be obtained during the course of this work. However, transcriptomic 
and genomic analysis of such tumours is recommended as it could shine light into the 
role of p53 in human ACP pathogenesis. This will be particularly important in the 
improvement of current therapies, as irradiation is still a main therapeutic approach 
and it is under debate if its use underlies tumour recurrence and malignant 
transformation in human ACP (Rodriguez et al. 2007; Sofela et al. 2014) 
The molecular and mutational landscapes that distinguish tumours derived by 
cell-autonomous (YFP+) and non-cell autonomous (YFP-) mechanisms, as well as 
the identity of their respective cells-of-origin remain to be determined. Interestingly, 
some YFP+ tumours displayed high expression of E-cadherin, which in the wild-type 
postnatal pituitary gland is only expressed in the stem cell-rich marginal zone (MZ). 
E-cadherin expression is also maintained in the YFP+ epithelia of the pre-neoplastic 
regions that precede tumour formation, which also include the β-catenin clusters (Fig. 
5.14), suggesting that YFP+ tumours may arise from embryonic pituitary remnants.  
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6.5.3 Cell-autonomous tumourigenesis also occurs in the 
context of p53 haploinsufficiency and wild type p53 
Pituitary tumours developed cell-autonomously in 35.3% of mice carrying a wild 
type p53 locus (Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+) and in 44.4% of those carrying one 
intact copy of p53 (Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+) (Fig. 5.10). This 
observation is difficult to explain with current data, as YFP+ tumours of these control 
strains were not analysed due to time constraints. It will be important to increase 
sample numbers to clarify if there is a significant difference in the proportion of YFP+ 
tumours that develop in each of these backgrounds. If there is a significant increase 
in the number of YFP+ tumours in the p53 heterozygous background, this would 
suggest that p53 haploinsufficiency also gives a competitive advantage to targeted 
cells. In this case, it could be that that haploinsufficiency can promote WNT-driven 
tumour formation by itself or that targeted cells undergo loss of heterozygosity (LOH). 
In the case of lymphomas and multiple myeloma, it has been shown that expression 
of the remaining p53 allele can be further downregulated or completely silenced by 
promoter hypermethylation leading to decreased survival in mice and humans (van 
der Weyden et al. 2012; Teoh et al. 2014). Additionally, Trp53 haploinsufficiency has 
been proved to be sufficient for enhancing tumourigenesis, by cooperating with the 
expression of oncogenes such as EGFR (Rahrmann et al. 2014) and oncogenic β-
catenin (Ridgeway et al. 2006). It is also important to remark that the results 
presented in chapter 5 fall in line with thorough characterisation of tumours 
spontaneously formed in Trp53-/-, Trp53+/- and Trp53+/+ mice, where the level of p53 
inactivation also correlated positively with a drastic acceleration in tumour growth and 
decrease in survival. Intriguingly, Trp53-/-, Trp53+/- and Trp53+/+ mice developed 
distinct types of cancer with different frequencies. While Trp53-/- developed mostly 
lymphomas of T-cell origin and some soft-tissue sarcomas, Trp53+/- mice developed 
an almost equal mix of osteosarcomas, B-cell lymphomas and soft-tissue sarcomas 
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(Donehower & Lozano 2009). Interestingly, while half of the Trp53+/- tumours retained 
one functional copy of Trp53, (i.e. p53 is haploinsufficient), the rest of the tumours 
displayed LOH of the other allele (Venkatachalam et al. 1998; Venkatachalam et al. 
2001). Further transcriptomic and exome-sequencing studies will be necessary in 
order to determine the status of the Trp53 locus in Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ 
and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ tumours and to correlate it with their 
YFP expression and phenotype.   
An exciting possibility arising from the development of YFP+ tumours in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ 
mice is that the paracrine activities of the SASP could also be required for cell-
autonomous tumourigenesis. Evidence for this could be obtained by generating 
Hesx1Cre/+;Trp53fl/fl;Apcfl/fl;R26YFP/+ mice. In this model, it could be expected that 
absence of p53 in the context of WNT signalling would allow the β-catenin clusters to 
bypass or escape senescence, leading to cell-autonomous tumour formation. 
However, and as previously mentioned, Hesx1Cre/+;Apcfl/fl  β-catenin clusters display a 
dampened SASP, absence of micro-environmental alterations and do not form 
tumours. If YFP+ tumours also do not develop in Hesx1Cre/+;Trp53fl/fl;Apcfl/fl;R26YFP/+ , 
this would provide evidence for a role of the SASP also in pituitary cell-autonomous 
tumourigenesis. 
6.5.4 Non-cell autonomous and cell-autonomous mechanisms 
might coexist and compete during pituitary tumourigenesis 
Because senescence and the SASP remained unaltered in the embryonic β-
catenin clusters of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ mice and they also 
appeared to modify their microenvironment, it would be expected that there is a point 
where both YFP+ and YFP-tumourigenic populations compete before tumour 
formation. This situation might also occur during the tumourigenic process in 
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Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ 
backgrounds, albeit with different dynamics and leading to different outcomes.  
In this case, inactivation of p53 in the context of oncogenic β-catenin would be 
regarded as an advantage if it allowed a YFP+ cell to bypass (or escape) senescence, 
avoid apoptosis, accelerate their cell cycle or impair DNA damage-repair checkpoints 
(Meek 2009; Cornel et al. 2014; Frank et al. 2011; Méniel et al. 2014; Lozano 2010). 
Conversely, in the context of p53 hemizygosity or wild type loci these advantages 
would be diminished enabling YFP- tumours to arise occasionally, as observed in 
55.6% of Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+  and 64.7% of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+  tumours (Fig. 5.10). Notably, in a mouse model of 
lymphoma driven either by oncogenic β-catenin or loss of Apc, cancer cells undergo 
p53-independent OIS but require inactivation of p53 for tumourigenesis to proceed 
by evasion of apoptosis. Trp53-/- lymphomas displayed diminished latency and also a 
distinct molecular phenotype than those from a Trp53+/- background (Xu et al. 2008; 
Sharma & Sen 2013). Although end-point Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ 
YFP+ tumours indeed displayed a proliferative advantage (Fig. 5.12), further 
experiments should aim at analysing proliferation, apoptosis and senescence 
markers in targeted and non-targeted cells at intermediate stages before the onset of 
tumour growth. This will allow identification of essential biological processes that 
determine which mechanism of tumourigenesis is to prevail in this context. In this 
regard, exome-sequencing and expression profiling of tumours from each different 
genotype will provide crucial insight into additional mutations and molecular 
alterations required to shift the balance in favour of cell-autonomous or non-cell 
autonomous tumourigenesis. 
The concomitant occurrence of cell-autonomous and paracrine mechanisms of 
tumourigenesis in murine ACP are also supported by findings shown where inducible 
ablation of p53 and activation of oncogenic β-catenin occurs in adult SOX2+ cells. 
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Strikingly, both Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/fl;R26YFP/+ and 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+;Trp53fl/+;R26YFP/+ pituitaries developed pre-tumoural 
lesions in cell-autonomous and non-cell autonomous fashions (Fig. 5.16); contrary to 
Sox2CreERT2/+;Ctnnb1lox(ex3)/+ mice, which were previously reported to only develop 
YFP- tumours (Andoniadou et al. 2013).  Although thorough analysis of full-grown 
tumours was not possible in this model, it is encouraging that YFP+ tumours only 
developed in complete absence of p53, while YFP- tumours developed in Trp53fl/+ 
pituitaries. This further supports the idea that the YFP+ population expressing 
oncogenic β-catenin holds a significant advantage over paracrinally-induced cells 
only when p53 expression is completely abrogated. Further experiments conducting 
laser-capture microdissection (LCM) and expression profiling of YFP+/YFP- lesions 
and tumours will also reveal pathways involved in the selective promotion of paracrine 
versus non-paracrine mechanisms of carcinogenesis. 
The results here presented give way to a number of interesting questions of 
relevance for the study of senescence in cancer: are p53-deficient cell-autonomously-
formed tumours derived from a β-catenin cluster cell? (i.e. an already senescent cell 
escapes senescence). Are they derived from another Hesx1-lineage cell? (i.e. a non-
senescent cell bypasses senescence). The same questions can be asked for non-
cell autonomous tumourigenesis and cells not carrying the initial oncogenic hit. Also, 
is the SASP also necessary to generate a pro-tumourigenic environment necessary 
for cell-autonomous tumourigenesis? Currently, a genetic strategy allowing to both 
lineage-trace and to ablate senescent cells in vivo is being developed by the host lab. 
Application of this strategy in Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl and 
Sox2Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl mice will allow to ablate senescent β-catenin clusters 
and help dissect the mechanisms underlying both paracrine and cell-autonomously 
derived tumourigenesis.  
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Fig. 6.1 Proposed model for the role of senescence and the Senescence-
Associated Secretory Phenotype (SASP) in the non-cell autonomous formation 
of pituitary tumours.  
(Centre) Activation of oncogenic β-catenin in YFP+ embryonic pituitary progenitors 
of Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+ mice leads to WNT pathway overactivation and 
the formation of senescent β-catenin clusters. The clusters activate a SASP which 
recruit swarms of EMCN+/SOX9+ embryonic endothelial progenitors not derived from 
the Hesx1-lineage (YFP-). Throughout pituitary development, the SASP maintains 
the undifferentiated phenotype of EMCN+/SOX9+ cells, which further interact with the 
clusters by forming nests around them. EMCN+/SOX9+ express the chemokine SDF-
1 which can recruit different cell types to the microenvironment such as lymphocytes, 
macrophages, neutrophils, fibroblasts and angiogenic progenitors. Continuous pro-
tumourigenic signalling from the SASP and from recruited cells eventually lead to the 
transformation of a cell-of-origin, possibly derived from the EMCN+/SOX9+ 
population, which acquires a cancer stem cell (CSC) phenotype and forms a YFP- 
tumour. (Left) In the context of p53 loss (and possibly in a proportion of  
Hesx1Cre/+;Ctnnb1lox(ex3)/+;R26YFP/+  cases), senescent β-catenin clusters with an active 
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SASP also form and recruit cells to the microenvironment. Absence of p53 and the 
SASP provide the advantages necessary for a YFP+ cell to outcompete their YFP- 
counterpart and to give rise to a YFP+ tumour. This YFP+ CSC could derive either 
from a cluster cell that escapes senescence or a non-cluster YFP+ cell that bypasses 
senescence. (Right) Loss of tumour suppressor Apc also leads to WNT pathway 
overactivation and the formation of senescent β-catenin-accumulating clusters, albeit 
with a dampened SASP. Lower SASP levels are not sufficient to recruit and maintain 
the undifferentiated phenotype of EMCN+/SOX9+ progenitors, which eventually 
downregulate SOX9 and become part of the normal pituitary vasculature. These 
differentiated cells are unable to respond to further SASP signals and cannot be 
primed to become the cell-of-origin. The absence of an expanded EMCN+/SOX9+ 
population also leads to reduced SDF-1 levels and thus, other inflammatory and pro-
tumourigenic cell-types are not recruited into the microenvironment. Altogether, the 
absence of a primed cell-of-origin and the lack of a tumour-permissive 
microenvironment prevent tumour formation, either cell-autonomous or paracrine in 
origin.  
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6.6 Concluding remarks regarding non-cell 
autonomous tumourigenesis 
In summary, this thesis provides strong evidence arguing that the mechanism 
of tumour formation occurring in mouse models of ACP does not fall in line with the 
cancer stem cell paradigm and follows instead a paracrine model of tumourigenesis.  
Particularly, evidence is provided indicating that the β-catenin accumulating 
clusters present in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice and human ACP undergo 
senescence and accumulate DNA-damage, leading to the activation of NF-κB 
signalling and the SASP, a potent pro-tumourigenic signalling mechanism. 
Additionally, it is shown that the clusters in the mouse model and humans are similar 
structures both functionally and biologically, which makes a case for challenging the 
key pathways identified in this work to gain further insight into the mechanisms driving 
the development of ACP in humans, with the aim of identifying novel therapeutic 
targets in the future. 
Altogether, evidence obtained through experiments conducted in 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ (Chapter 3), Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl (Chapter 5) 
and Hesx1Cre/+;Apcfl/fl mice (Chapter 7) suggests that acquisition of senescence in a 
targeted cell and a robust activation of the SASP are involved in the modification of 
the pituitary microenvironment that precedes non-cell autonomous tumourigenesis 
and the transformation of a non-targeted cell of origin. Possible underlying 
mechanisms could be: 1) the modification of the microenvironment is sufficient for 
paracrine tumourigenesis to proceed; 2) the SASP itself possesses transformation 
capabilities or 3) both a modified microenvironment and a direct effect of the SASP 
are necessary for tumour development. Current understanding of the role of chronic 
inflammation in carcinogenesis argues for the third option.  
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A great number of the cytokines recognised as hallmark SASP factors are 
known to act as growth factors, which can activate oncogenic pathways that lead to 
hyper proliferation and replicative stress. This replicative stress will inevitably lead to 
genomic instability, DNA damage and the acquisition of novel mutations. Additionally, 
recent research has uncovered the ability of the SASP to promote cell 
reprogramming, particularly through IL-6, (Mosteiro et al. 2016) and to increase 
intrinsic cellular plasticity and regeneration (Ritschka et al. 2017). In both cases, the 
SASP would cause the expansion of a pool of stem cell/progenitor cells and the 
likelihood of accumulating mutations. This would certainly be aided by the well 
described generation of a proinflammatory microenvironment. In such an 
environment, abnormal amounts of reactive-oxygen and nitrogen species would be 
produced, leading to DNA-damage either directly or through the activation of 
signalling pathways that also lead to hyper proliferation, such as the NF-κB pathway, 
and reinforcing replicative stress on the cell. Finally, the SASP could also affect the 
ability of the immune system to clear these stressed cells, further promoting the 
accumulation of pro tumourigenic mutations.  
The data here collected argues that acquisition of senescence in a targeted cell 
and the robust activation of the SASP are potentially involved in the recruitment and 
paracrine transformation of a non-targeted cell-of-origin. In this sense, no studies to 
date have described this exact mechanism for the origin of tumours, although there 
is evidence indicating its applicability in other types of cancers. In a hepatocellular 
carcinoma model, the SASP was shown to remodel the immune response in order to 
induce tumours formed by non-targeted cells (Lujambio et al. 2013). Another study 
reported that expression of PDGF, a validated SASP factor (Demaria et al. 2014), 
lead to the formation of gliomas by non-targeted recruited cells, which eventually 
became transformed and formed gliomas even after transplantation (Fomchenko et 
al. 2011). Additionally, non-dividing epidermal cells carrying a MAPK transgene 
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induced non-targeted infiltrative cells to form skin papillomas upon injury. Importantly, 
this effect was mediated by the secretion of the hallmark SASP factor IL1A from 
targeted cells (Arwert et al. 2010). More recently, the SASP was shown to induce the 
emergence of cancer stem like cells in a multiple myeloma model (Cahu et al. 2012), 
while the SASP of senescent melanoma cells induced the reprogramming of naïve 
melanoma cells in order to form tumours (Ohanna et al. 2013). 
In view of the potential applicability of the paracrine model to other cancers, it 
will be particularly interesting to study the role of senescence and the SASP in models 
where the non-cell autonomous origin of tumours/cancers has been described, 
especially those driven by oncogenic β-catenin/WNT signalling (Kode et al. 2014; 
Deschene et al. 2014; Xavier et al. 2015; Kretzschmar et al. 2016). Also, the results 
obtained in this thesis warn against the idea that OIS has exclusively beneficial roles 
in tumourigenesis, which derived from the simple observation that premalignant 
cancers display high levels of senescence markers, while fully malignant cancers do 
not (Braig et al. 2005; Chen et al. 2005; Collado et al. 2005; Michaloglou et al. 2005). 
Therefore, further study of the role of OIS and the SASP in cancer development is 
encouraged in light of lineage-tracing experiments, as senescent cells carrying driver 
mutations might not be related to the cell that eventually generates a tumour. A re-
evaluation of the origin of tumours in different models of cancer by using lineage 
tracing strategies, while keeping in mind paracrine mechanisms of tumour 
development and the detrimental effects the SASP will allow the development of 
better targeted therapies for human cancers, as this study and several others 
(Campisi 2013) suggest that senescence is, indeed, a double edged-sword. 
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7. APPENDIX: THE ROLE OF SENESCENCE 
AND THE SASP IN THE CONTEXT OF WILD-
TYPE β-CATENIN 
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In the following appendix, ongoing research and preliminary data regarding 
Hesx1Cre/+;Apcfl/fl mice will be presented in order to facilitate the discussion of the 
results presented in this thesis. 
7.1 Ablation of the tumour suppressor APC leads to 
WNT pathway activation and senescence induction in  
β-catenin clusters, but not to tumour formation. 
Previously, the host lab generated Hesx1Cre/+;Apcfl/fl mice, in which expression 
of the tumour suppressor Apc is ablated in pituitary embryonic progenitors (Hesx1 
cell-lineage). These experiments aimed to answer the following research question: 
Does ACP tumorigenesis require the activation of the WNT pathway or the expression 
of oncogenic β-catenin? 
As described in the introduction chapter, APC is a crucial component of the β-
catenin destruction complex and mutations in Apc lead to stabilization and 
accumulation of β-catenin, resulting in overall activation of the WNT-signalling 
pathway. Therefore, Hesx1Cre/+;Apcfl/fl mice activate the WNT pathway, as the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice do, but this activation is caused by wild-type β-catenin 
rather than its oncogenic version (i.e. lacking the amino acids encoded by exon 3). 
 Similarly to Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice, the embryonic pituitaries of 
Hesx1Cre/+;Apcfl/fl at 18.5 dpc displayed nucleo-cytoplasmic β-catenin accumulating 
clusters (Fig. 7.2a). which also displayed WNT pathway activation as shown by 
increased expression of WNT-target gene Axin2 (Fig. 7.1b). The clusters found in 
Hesx1Cre/+;Apcfl/fl pituitaries were of smaller size relative to the 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ (i.e. composed by less cells) at all observed stages (10.5, 
12.5 and 18.5 dpc). At 18.5 dpc, there was a significant difference in cluster cell 
number (t test, p<0.0001), as Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters had in average 5.9 
cells (126 clusters counted), while Hesx1Cre/+;Apcfl/fl clusters had 1.9 cells (108 
clusters counted). 
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Litters born from Hesx1Cre/+;Apcfl/+ and Hesx1+/+;Apcfl/fl  breeding pairs displayed 
normal Mendelian ratios, indicating absence of perinatal lethality. Additionally, all 
mice displayed normal size and weight (Neda Mousavy, unpublished results), in 
contrast to the perinatal dwarfism found in Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice (Gaston-
Massuet, 2011). ISH on 12.5 dpc embryos demonstrated normal expression patterns 
between mutants and controls for pituitary fate determination factor Lhx3,  and 
pituitary lineage commitment genes Pit1 and Prop1 (Fig. 7.1d). At 18.5 dpc 
Hesx1Cre/+;Apcfl/fl  pituitaries were hyperplastic, similarly to Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
pituitaries. However, differentiation of the hormone-producing cells was normal, as 
determined by the expression of GH, PIT1, and ACTH (Fig. 7.1e). This is in contrast 
with Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries at the same stage, where the Pit1 lineage was 
severely affected (Gaston-Massuet et al. 2011).  
Intriguingly, no Hesx1Cre/+;Apcfl/fl animals developed tumours postnatally (Fig. 
7.1f,  n= 39) and were fertile and viable up to almost 2 years follow-up (n= 17) . In 
fact, the colony was maintained through Hesx1Cre/+;Apcfl/fl animals. Additionally, 
examination of the early postnatal pituitary revealed they did not contain β-catenin 
accumulating clusters (Neda Mousavy, unpublished results) nor pre-neoplastic 
regions as in the case of Hesx1Cre/+;Ctnnb1lox(ex3)/+ mice  (Fig. 7.1f).   
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Fig 7.1 Phenotypic characterisation of Hesx1Cre/+;Apcfl/fl mice and pituitaries. 
 (a) Immunofluorescence for β-catenin in wild type, Hesx1Cre/+;Ctnnb1lox(ex3)/+ and 
Hesx1Cre/+;Apcfl/fl pituitaries at 18.5 dpc. Nucleo-cytoplasmic β-catenin accumulating 
clusters are also observed in Hesx1Cre/+;Apcfl/fl mutants but in lower numbers and of 
smaller size than Hesx1Cre/+;Ctnnb1lox(ex3)/+ clusters. (b) In situ hybridisation (ISH) 
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showing overexpression of the WNT pathway target gene, Axin2, at different stages 
of development in clusters of both Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Apcfl/fl 
pituitaries. (c) Table showing normal Mendelian ratios for crosses between 
Hesx1Cre/+;Apcfl/+ and Hesx1+/+;Apcfl/fl mice (Chi-square test, P>0.05, N=73). (d) ISH 
shows normal expression of pituitary lineage determination and differentiation factors 
Lhx3, Pit1 and Prop1 in Hesx1Cre/+;Apcfl/fl pituitaries at 12.5 dpc. (e) 
Immunofluorescence for growth hormone (GH), PIT1 and Adrenocorticotropic 
(ACTH)  shows normal terminal differentiation of Hesx1Cre/+;Apcfl/fl pituitaries at 18.5 
dpc. (f) Wild type and Hesx1Cre/+;Apcfl/fl pituitaries at 45 weeks of age show normal 
morphology and histology (H&E staining shown) unlike Hesx1Cre/+;Ctnnb1lox(ex3)/+ 
specimens of the same age which already showed developing tumours. 
 
Further characterisation of the embryonic Hesx1Cre/+;Apcfl/fl clusters revealed 
they are similar to their Hesx1Cre/+;Ctnnb1lox(ex3)/+ counterparts as they were also 
negative for proliferation and apoptosis markers. Additionally, they were also found 
to contain SOX2+ cells and to not express SOX9+ (Fig. 7.2a), suggesting the clusters 
present in Hesx1Cre/+;Apcfl/fl and Hesx1Cre/+;Ctnnb1lox(ex3)/+  pituitaries share some 
features in their cellular and molecular phenotype. 
A thorough analysis for molecular markers of senescence revealed that 
Hesx1Cre/+;Apcfl/fl clusters also accumulate markers of the senescent phenotype such 
as those related to cell cycle inhibition (p21 and p16) and the DNA-Damage 
Response (phospho-DNA-PKCs and PARP-1). Moreover, Hesx1Cre/+;Apcfl/fl clusters 
displayed accumulation of phospho-Iκ-Bα, indicating activation of the NF-κB pathway 
(Fig. 7.2b). Therefore, Hesx1Cre/+;Apcfl/fl embryonic pituitaries also contain nucleo-
cytoplasmic β-catenin accumulating clusters which become senescent and activate 
the NF-κB pathway.  
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In order to explain the absence of oncogenic potential, the strength of the SASP 
induction was compared between Hesx1Cre/+;Apcfl/fl and 
Hesx1Cre/+;Ctnnb1lox(ex3)/+clusters. The expression of key senescence markers and 
secreted factors was analysed by qRT-PCR in Hesx1Cre/+;Ctnnb1lox(ex3)/+ and  
Hesx1Cre/+;Apcfl/fl pituitaries at 18.5 dpc (Fig. 7.2c). Markers analysed were Axin2, 
Trp53, Cdkn1a, Cdkn2a, Shh, Bmp4, Il1a, Il1b, Cxcl1 and Tgfb1. Although 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries displayed higher expression for all markers when 
compared to Hesx1Cre/+;Apcfl/fl, only Cdkn2a, Shh, Bmp4, Il1a and Il1b displayed 
statistically significant differences. The expression of secretory factors such as Shh 
and Bmp4 was previously shown to be upregulated in the β-catenin clusters of 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries (Andoniadou et al. 2012). In situ hybridisation in 
14.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ pituitaries showed that Axin2-overexpressing 
clusters corresponded with the overexpression of Bmp4, Fgf3 and Shh in consecutive 
sections. Conversely, Hesx1Cre/+;Apcfl/fl pituitaries also displayed Axin2 
overexpressing clusters, but Bmp4, Fgf3 and Shh signal could not be detected at the 
14.5 dpc stage (Fig. 7.2d), while they were barely expressed at 18.5 dpc (not shown). 
These results suggest that Hesx1Cre/+;Apcfl/fl clusters display a dampened SASP 
signature. Additionally, their reduced numbers and smaller individual size might result 
in an overall diminished presence of secretory factors.  
In chapter 3 it was shown that a population of EMCN+/SOX9high cells interacts 
closely with the β-catenin clusters early in development, expand profusely and occupy 
most of the pituitary stroma up to 18.5 dpc. Interestingly, triple immunostaining for 
EMCN, SOX9 and β-catenin at 14.5 and 18.5 dpc showed that Hesx1Cre/+;Apcfl/fl 
pituitaries lack this EMCN+/SOX9high population. Instead, the stroma of 
Hesx1Cre/+;Apcfl/fl pituitaries resembled more that of the wild-type pituitary, as EMCN+ 
cells were located only in the developing vasculature, did not form rings around the 
clusters and few expressed SOX9 (Fig. 7.2e). Additionally, quantification of the total 
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area occupied by EMCN+ cells (3 sections per pituitary, n=3) showed the absence of 
statistical difference in EMCN+ area between wild type and Hesx1Cre/+;Apcfl/fl 
pituitaries, while a statistically significant difference was found when compared to 
Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Ctnnb1lox(ex3)/+;Trp53fl/fl pituitaries, which 
develop tumours postnatally (Fig. 7.2f). These results further support a role for the 
SASP in the remodelling of the microenvironment, including recruiting and 
maintaining large numbers of EMCN+/SOX9high cells in early stages of 
tumourigenesis. Of note, β-catenin accumulating clusters of larger size were found 
occasionally in Hesx1Cre/+;Apcfl/fl pituitaries (2-3 clusters, n=6 pituitaries). These 
clusters resembled more their Hesx1Cre/+;Ctnnb1lox(ex3)/+ counterparts and 
interestingly, were surrounded by rings of SOX9+high cells, suggesting that cluster size 
might also determine an effect of the microenvironment (Fig. 7.2g).   
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Fig. 7.2 Characterisation of the β-catenin clusters of Hesx1Cre/+;Apcfl/fl embryos. 
(a) Double immunostaining for β-catenin together with Ki67, phosphorylated Histone 
H3 and cleaved Caspase 3, shows that the Hesx1Cre/+;Apcfl/fl clusters are also do not 
proliferate and do not undergo apoptosis. Additionally, the clusters from 
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Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Apcfl/fl share the expression of stem cell 
marker SOX2 but rarely express SOX9. (b) Double fluorescent immunostaining for β-
catenin and markers of senescence activation. Hesx1Cre/+;Apcfl/fl clusters also display 
accumulation of p21, p16, phosphorylated DNA-PKcs, PARP-1 and phosphorylated 
Iκ-Bα, indicating cell cycle arrest, an active DNA-damage-response and activation of 
the NF-κB pathway, respectively. (c) qRT-PCR comparing the expression of 
senescence and SASP markers in Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Apcfl/fl 
pituitaries at 18.5 dpc in comparison to wild types. (d) In situ hybridisation for 
secretory growth factors in 14.5 dpc Hesx1Cre/+;Ctnnb1lox(ex3)/+ and Hesx1Cre/+;Apcfl/fl 
pituitaries. Axin2 is a target of the WNT pathway and therefore is overexpressed in β-
catenin clusters. Consecutive sections are shown. (e) Triple immunostaining for 
EMCN, SOX9 and β-catenin in 14.5 and 18.5 dpc pituitaries showing the absence of 
EMCN/SOX9high swarms around the β-catenin in Hesx1Cre/+;Apcfl/fl pituitaries at both 
stages. (f) Quantification of the total area occupied by EMCN+ cells (3 different 
sections per pituitary analyses, n=3, ANOVA, *** denotes p<0.001). (g) Double 
immunostaining for β-catenin and SOX9 shows the rare presence of larger clusters 
in Hesx1Cre/+;Apcfl/fl pituitaries which were also surrounded by SOX9+high cells (~2 of 
such clusters observed in 6 pituitaries). 
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